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Abstract: 
Upon returning from the 1991 Gulf War (GW), veterans from this conflict exhibited a 
persistent multisymptomatic illness which is now defined as Gulf War Illness (GWI). There is 
ample evidence that the presentation of GWI is associated with exposure to an anti-nerve agent 
pyridostigmine bromide (PB) and pesticides, such as permethrin (PER), that were used as 
prophylactic measures by veterans during the war. The prevalence of GWI is about 30% in US 
veterans and 15% in UK veterans who were deployed during this conflict. Clinical presentation 
of GWI is heterogenous, and veterans with this condition display a wide range of symptoms such 
as memory impairment, fatigue, gastrointestinal disorder and chronic pain. Current treatment 
strategies for GWI are limited and provide only symptomatic relief. Due to the multifactorial 
nature of this illness, quest for appropriate treatment strategies is difficult and further 
complicated by the fact that many of the GW veterans are also facing age-related chronic health 
problems.  I utilized a mouse model of GWI previously developed using combined exposure to 
PB and PER (GWI mice) which exhibits neurobehavioral features that are similar to the 
symptoms reported by GWI veterans. This model displays glia activation and 
neuroinflammation, pathological features that are reported in other GWI rodent models, 
representing a common chronic outcome associated with GW chemical exposure. The main 
objectives of this thesis are to find effective therapies against GWI that target the underlying 
pathology of GWI. 
Many clinical and imaging studies have suggested a possible central nervous system 
(CNS) involvement in GWI. However, even after two decades, there is no approved medication 
for treating the CNS pathology of GWI. Much of our previous work suggests dysregulation of 
lipid homeostasis and metabolism. These results pointed to both mitochondrial and peroxisomal 
abnormalities in GWI mice as well as in veterans with GWI.  As part of my thesis work, I 
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explored whether targeting mitochondrial and peroxisomal function can reduce abnormal brain 
lipid accumulation and improve chronic neurobehavioral deficits and the accompanying 
neuropathology in a mouse model of GW chemical exposure. I examined oleoylethanolamide, 
which targets peroxisome function via activation of peroxisome proliferator-activated receptors 
(PPAR) and also decreases inflammation. I examined another strategy using two different 
treatment regimens, nicotinamide riboside and a ketogenic diet, both of which target different 
aspects of mitochondrial bioenergetics. In addition to peroxisome and mitochondria dysfunction, 
recent evidence suggests that the symptoms of GWI resemble those of patients with autoimmune 
disorders, but it is unknown how GW chemicals could have caused immune dysfunction in GWI.  
Therefore, I focused on a PER metabolite, 3-phenoxybenzoic acid (3-PBA), which is previously 
shown to form adducts with endogenous proteins. I observed the presence of 3-PBA modified 
lysine on protein peptides in GWI mice acutely post-exposure and also detected autoantibodies 
against 3-PBA-albumin conjugates in plasma of GWI mice and in veterans with GWI at chronic 
post-exposure timepoints. These studies suggest that pesticide exposure associated with GWI 
may have resulted in the activation of the peripheral and CNS adaptive immune responses, 
possibly contributing to an autoimmune-type phenotype in veterans with GWI. I hope that the 
work described in this thesis provides novel avenues for the development of objective 
biomarkers and therapies for GWI. 
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 Chapter 1: Introduction 
1.1 Background 
Gulf War Illness (GWI) is a complex and chronic, multi-symptom condition, which 
affects approximately 30% of the 700,000 US military personnel who were deployed to the 
1990-1991 Gulf War (GW)1,2. It is also believed that about 33,000 UK GW veteran are living 
with GWI3.  Almost three decades have passed since a United Nations resolution act officially 
ended this war, yet GW veterans with GWI continue to suffer from poor health and report a 
wide range of symptoms that include fatigue, muscle pain, sleep disturbance and memory 
problems. The clinical presentation of GWI resembles that of other multi-symptom conditions 
including chronic fatigue syndrome/Myalgic Encephalomyelitis (CFS/ME) and fibromyalgia, 
which affect roughly 3% and 2% of the general population in the USA, respectively.  Although 
the clinical presentations of both CFS/ME and fibromyalgia have many similarities with GWI, 
such as chronic pain, fatigue, sleep disturbance and memory problems, the causative agents of 
GWI are unique to those encountered during the 1991 GW and include overexposure to 
pesticides, insecticides and other chemicals. Veterans with GWI experience symptoms 
chronically, with no improvement over time2,4. Furthermore, the underlying pathology remains 
unknown which makes it particularly difficult to diagnose and treat GWI.  The key objectives 
of my thesis work were to identify biological targets that are downstream of GW chemical 
exposure to develop therapies and identify potential biomarkers for diagnosing GWI. 
1.2 Clinical evidence of central nervous system involvement in GWI 
 Gulf War veterans were deployed for 2 months in Gulf during 1991 Operation Desert 
Storm. It is now well-established that deployment to the GW theatre or it’s vicinities strongly 
influenced GWI symptom profiles and severity.  The chronic multi-symptom illness is more 
prevalent in deployed GW veterans than in their non-deployed counterparts1,5. Steele and 
colleagues reported that the prevalence of GWI in US veterans was directly proportional to the 
time period and location in which they served 6. Symptoms of GWI are reported more 
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frequently by veterans deployed to the combat theater compared to those deployed to other 
locations.  Of the veterans deployed to the 1991 GW, 23% continue to suffer from fatigue, 32% 
report suffering from memory problems, and 17% report chronic pain1,7,8. Among GWI 
veterans, 62% report suffering from at least two of these chronic symptoms (fatigue, mood-
cognition, and musculoskeletal)2,9.  Nearly 67% of US GW veterans report that the onset of 
these symptoms occurred with two years of their return from the conflict6,7. Among UK 
veterans diagnosed with GWI, 23% continue report suffering from fatigue, 28% from memory 
problems and 17% from chronic pain3.  Many epidemiologic studies have reported that GW 
veterans who served in the US Army and US Marines have higher rates of multi-symptom 
illness than those in the Navy and Air Force6,10,11.  The prevalence of GWI was lowest among 
GW veterans who served in the US Navy (21%) or the US Air Force (13%) and highest among 
ground troops in Iraq and/or Kuwait (42%)6,9, further supporting that deployed GW veterans 
were particularly affected by GWI.  Among GW veterans diagnosed with GWI, those who were 
deployed to Iraq and Kuwait reported a higher prevalence and severity of multiple symptoms 
compared to veterans with GWI deployed elsewhere12.  Also, several studies have reported that 
GWI prevalence differs depending on the locations where veterans served during the war.  For 
instance, GW veterans who served in some areas of theater, such as Khamisiyah, have higher 
rates of GWI than veterans who were in other locations6,10,13,14.  
Among the multitude of symptoms experienced by veterans with GWI, chronic fatigue, 
memory problems, gastrointestinal problems and musculoskeletal pain are the most commonly 
reported symptoms.  Memory impairment is a major complaint among GWI veterans, and many 
studies suggest that this may be due to damage to the brain regions involved in cognition.  
Veterans with GWI had significantly lower scores on tests of verbal memory, verbal learning, 
motor speed, and attention than non-deployed veterans15.  Janulewicz and colleagues reported 
significantly decreased performance in attention and executive function, visuospatial skills and 
learning/memory in symptomatic vs. non-symptomatic GW veterans16.  Other reports state that 
 19 
nearly 40% of GW veterans with GWI reported fatigue-related issues along with memory 
problems1,17.  These clinical findings suggest that GWI may involve central nervous system 
(CNS) dysfunction. This is supported by brain imaging studies which provide substantial 
support for a CNS component in GWI. For instance, a proton magnetic resonance spectroscopy 
(MRS) imaging study revealed a lower ratio of neuronal metabolite N-acetyl aspartate–to-
creatine (NAA/Cr) in the basal ganglia and brainstem, suggesting neuronal loss in the brains of 
veterans with GWI compared to control GW veterans 18.  Another proton MRS imaging study 
showed that NAA/Cr ratios were also significantly lower in the hippocampi of veterans with 
GWI compared to control GW veterans 19. Magnetic Resonance Imaging (MRI) using voxel-
based morphometric analysis showed reduced volume in both the gray matter and white matter 
in GWI veterans compared to GW healthy veterans 20.  Magnetic resonance imaging studies 
showed the loss of gray matter and hippocampal volume in GW veterans who were stationed at 
Khamisiyah compared to GW veterans who were stationed elsewhere 21. In a subset of GWI 
veterans, a reduction of grey matter volume was reported using functional Diffusion 
Tensor Imaging (DTI)22.  Hence, these studies show that clinical symptoms of GWI correspond 
with metabolic disturbances in the brain and support the role of CNS disturbances in GWI.  
 
1.3 Chemical exposure implicated in the pathogenesis of GWI  
While no single etiological factor has been definitively linked to GWI1, reports 
compiled by the Veterans’ Administration Research Advisory Committee (RAC) on GWI, 
based on self-reported systematic retrospective data collection from GW veterans, implicate 
exposure to GW chemicals, such as the anti-nerve agent pyridostigmine bromide (PB) and 
insecticides like permethrin (PER), in the pathogenesis of GWI.  In particular, PB is a reversible 
acetylcholinesterase (AChE) inhibitor which was taken by combat soldiers as a prophylactic 
measure against the organophosphate (OP) nerve agent sarin1.  Pyridostigmine bromide is used 
for treating myasthenia gravis23.  Comparing GW veterans who were exposed to PB to those 
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who reported not being exposed to PB, the exposed group performed significantly worse in 
motor and executive functioning21,24.  Memory impairment was greater among GW veterans 
who reported being exposed to chemical weapons along with higher intake of PB than veterans 
who did not take PB6,25.  Along with significant hippocampal dysfunction among GW veterans 
deployed to Khamisiyah, self-reported surveys revealed that GW veterans deployed to 
Khamisiyah had  higher exposure to both PB and PER6,26,27.  During the GW, the recommended 
dose of PB was 3 pills (90 mg) per day1.  However, research studies report that veterans used 6 
or more PB pills per day which was twice the recommended daily dose27.  Several 
epidemiological studies have indicated that exposure to PB was directly proportional to the 
severity of GWI 28,29.  For instance, veterans who took PB more than 3 times a day had a higher 
overall symptom severity than those who had moderately severe symptoms and reported taking 
PB pills less than 3 times a day27,30. Using a case-control design, Steele and colleagues reported 
that being stationed at Kuwait or Iraq coupled with a high intake of PB (consumption of greater 
than 3 pills per day) increased the odds of GW veterans having GWI28.  Also, memory 
impairment was greater among GW veterans who reported being exposed to chemical weapons 
along with higher intake of PB than in veterans who did not take PB25,28.  These 
epidemiological studies indicate that exposure level to PB was directly proportional to the 
severity of GWI28.  
Permethrin was also used as a pesticide by veterans deployed to the 1991 GW. It is a 
synthetic chemical that belongs to the pyrethroid family. These compounds exert their 
neurotoxic effects by prolonging the activation of voltage-gated sodium channels that are 
present on the neuronal membranes31. To protect soldiers from insect-borne illnesses, uniforms 
of the US and British soldiers were saturated with PER, using a 0.5% spray. Permethrin was 
also used far more than recommended1.  For instance, the average recommended use for PER 
on clothing was once every month. However, GW veterans reported that they used PER almost 
30 times per month 1,27.  GW veterans who sprayed their uniforms with 0.5% PER reported 
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developing multiple symptoms, such as dermatological problems, gastrointestinal complaints 
and neurological and psychiatric symptoms25,27.  Cognitive impairment was more common 
among veterans who frequently sprayed their uniforms with PER than in those who never used 
it25. Hence, exposure to PER may represent a GW exposure which was common to many 
deployed GW veterans and may have played a significant role in the pathogenesis of GWI.    
There are other chemicals which are indicated to have played a significant role in the 
pathogenesis of GWI.  Along with PER, N, N-Diethyl-meta-toluamide (DEET) was also used 
as an insect repellent, which is thought to inhibit the olfactory senses by targeting the ionotropic 
receptors of insects32.  Regular use of DEET was associated with more severe symptoms of 
GWI than infrequent use25.  Arthromyoneuropathy (joint and muscle pain and muscle fatigue) 
in GWI patients increased with higher use of insect repellents containing DEET in either a 33% 
cream or 70% liquid 25.  Collectively, these studies suggest a dose-dependent relationship 
between pesticide/insect repellent use and the clinical severity of GWI.  Organophosphates 
pesticides such as chlorpyrifos were issued for personal use to service members deployed in the 
GW33. Exposure to OP pesticides can affect the CNS, autonomic nervous system, and skeletal 
muscles; and they have neurotoxic effects through mechanisms other than acetylcholinesterase 
inhibition 34–37. Other studies have shown that repeated exposure to OP is associated with 
neurochemical and behavioral alterations that do not occur with single exposures at similar 
doses37–42.  It has been suggested that these persistent symptoms are associated with neuronal 
oxidative injury and neuronal cell death in multiple brain regions following OP exposure43.  
Acute OP poisoning usually develops within minutes to hours and persists for hours to a few 
days.  Acute exposure to OP can be toxic, producing symptoms that are similar to those seen in 
GWI44–46. Veterans were also exposed to chemicals from burning oil wells, vaccines and 
depleted uranium that may be capable of accumulating in the brain and affecting learning and 
behavior in animal studies, but the evidence does not suggest that GWI symptoms 
predominantly originated from these factors1,2. 
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1.4 A role of combined GW chemical exposure in the pathogenesis of GWI 
 It is also hypothesized that combined exposure to PB and pesticides may be a major 
contributing factor to GWI pathology.  Combined exposure to these compounds may have had a 
synergistic effect on GW veterans, resulting in the subsequent development of GWI symptoms.  
An increased risk for GWI was seen among veterans who reported taking higher than 
recommended doses of PB and used uniforms treated with pesticides1,2,5,28,47.  In many studies, 
GWI was strongly associated with the use of PB pills, exposure to PER and proximity to 
exploding missiles5,6,11,48,49.  Among GW veterans who reported using PB pills above the 
recommended dose, 62% of them reported using some form of a pesticide where nearly 44% 
used pyrethroid sprays almost 30 times per month and 26% used pesticide lotions almost 20 
times per month 27. Among the GW veterans serving on the ground, 25% reported that they had 
applied pesticides ranging from 50 to 120 times in a month and had also used an average of 15-
19 PB pills in the same month27.  As such, combined exposure to PB and multiple pesticides 
represents a key etiological factor potentially causal to the pathogenesis of GWI.  
  A causal role of combined pesticide and PB exposure in GWI comes from animal 
studies which show that exposure to these chemicals results in neurobehavioral deficits which 
resemble the symptoms reported by veterans with GWI.  There are now several GWI animal 
models available that consistently show adverse effects of GW chemicals on the brain.  Most of 
the animal models developed by different groups have focused on exposure to PB and 
pesticides such as PER and DEET. A rat model using combined exposure to PB, PER and 
DEET along with restraint stress was developed by Abdel-Rahman et al., (2004)50. In this 
model, PB was administered through oral gavage while DEET and PER were applied dermally. 
This model exhibits neurobehavioral changes such as motor function impairment and reduced 
locomotion50. In this model, Parihar et al (2013) showed mood and cognitive dysfunction at 4 
weeks post-exposure in rats using the same GW chemical exposure paradigm51. Also, in the 
same model, hippocampal-dependent and hippocampal-independent memory impairments were 
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observed, as well as mood dysfunction52.  Terry and colleagues showed that exposure to OP 
pesticides such as chlorpyrifos (CPF) every other day over 30 days resulted in impaired spatial 
learning when examined using the radial arm maze test 42. In the Roskamp Institute 
laboratories, our most commonly used mouse model of GWI was developed using combined 
exposure to PB and PER. These chemicals are administered intraperitoneally (i.p.) daily for 10 
days and characterization of these mice to 22-months post-exposure demonstrates chronic 
neurobehavioral and neuropathological changes.  Exposed mice showed learning and memory 
impairment, and disinhibition53,54. Hence, the major neurobehavioral changes associated with 
this mouse model are cognitive impairment, anxiety, motor function impairment and impaired 
spatial learning and memory.  Thus, many of these GWI rodent models exhibit neurobehavioral 
features that are similar to the symptoms reported by ill GW veterans.  However, fatigue or 
pain, which are also major symptoms of GWI, have not been examined in these rodent models.  
Nevertheless, the availability of these GWI animal models has been helpful in characterizing 
the long-term consequences of exposure to GW chemicals and provide experimental evidence 
for a potential role of these chemicals in the pathogenesis of GWI.  
In our PB and PER animal model of GWI we observed a chronic and persistent presence 
of astroglial activation ranging from 5 to 22-months post-exposure 53,54. To best model the 
current human patient population, most relevant animal models have explored the chronic 
consequences of relatively acute exposures. Collectively, these studies suggest that astroglial 
activation is a consistent feature of GWI51,53,55.  Even though microglial activation was 
observed in the rat model by Parihar and colleagues51, other studies did not observe microglia 
activation or proliferation using ionized calcium-binding adapter molecule 1 (IBA-1) staining in 
animal models at a similar time point50,53,56.  Instead, Iba12 staining of microglia was detected 
at 16-months post-exposure in PB+PER exposed mice model 54.  In addition, Iba1 is expressed 
by other myeloid cells and infiltrating monocytes57,58.  Very little is known about monocyte and 
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myeloid cell infiltration in the brain and their contribution to the neuroinflammation observed in 
GWI mouse models.  
Some degree of neuronal loss, especially in the hippocampal region, is reported in a rat 
model of GWI51,59. O’Callaghan and colleagues showed that exposure to PB and pesticides such 
as DEET in addition to corticosterone (CORT) resulted in astroglia activation, along with an 
increase in proinflammatory cytokines and chemokines, but no neurodegeneration60. This study 
also showed that di-isopropyl fluorophosphate (DFP) with and without CORT+PB/DEET does 
not cause remarkable neurodegeneration60.  Studies have shown that an increase in cytokines in 
the brain corresponds with increased macrophages in the brain. Grigoryan et al., showed that 
OP binds to tubulin which affects axonal transport61, bilaterally this model also had altered 
myelin structure along with astroglial activation62.  Exposure to an OP pesticide, individually or 
in combination with other GW chemicals (PB+PER), causes brain pathology associated with 
GWI55,60,63,64. Taken together this indicates that mild chronic neuroinflammation is predominant 
over neuronal loss or neurodegeneration in these GWI mouse models.   
 
1.5 Pathophysiology of GWI 
As can be seen from the above studies, animal models of GWI display many clinical 
features of GWI and have yielded invaluable insights.  While animal models have their 
limitations, they have advanced translational research given the complex clinical presentation of 
this illness and unknown etiological origins in humans. These mouse models have provided a 
wealth of information for understanding the molecular mechanisms behind the illness. They 
have been most useful in the search for objective biomarkers and for testing candidate therapies.  
As our previous and current work shows, these animal models have helped by providing an 
understanding of the brain pathology of GWI that would be inaccessible in humans. This aspect 
of our work is particularly valuable since human brain samples for GWI largely remain 
unavailable. Our translational studies included the use of omics technologies to examine GWI 
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rodent models and samples from GW veterans to identify biological disturbances that are 
associated with GWI in both. These studies identified the alteration of many biological 
pathways that pointed to peroxisomal dysfunction, mitochondrial dysfunction and immune and 
inflammation-related biological functions as major contributors to the pathogenesis of 
GWI54,65,66. Each of these critical areas of GWI pathogenesis will be discussed in greater detail 
below. 
 
 
 
1.6 Peroxisomal dysfunction associated with GWI 
Peroxisomes are ubiquitously distributed cellular organelles that carry out synthesis and 
metabolism of many lipids and participate in scavenging of reactive oxygen species (ROS)67–69. 
Some of these lipids include ether phospholipids (PL), sterols, and fatty acids70. Peroxisomes 
perform both catabolic and anabolic functions on lipids. b-oxidation and a-oxidation of fatty 
acids are major catabolic functions, whereas anabolic functions include ether lipid synthesis 71. 
Peroxisomes have specific enzymes that are required for performing b-oxidation of fatty acids 
with 22 or more carbons, very long chain fatty acids (VLCFA), and a-oxidation of 3-methyl 
branched FA (phytanic acid and pristanic acid).  Synthesis of ether PL, synthesis of 
docosahexaenoic acid (DHA), glyoxylate detoxification and synthesis of bile acids also occurs 
in the peroxisomes72.  For instance, peroxisomal acyl-coenzyme A oxidase 1 (ACOX1) and 
17β-hydroxysteroid dehydrogenase 4 (HSD17β4) are not present in mitochondria and, as such, 
metabolism of VLCFA initiates in the peroxisomes73. Phytanic acid, which has a branched 
methyl group on the third carbon, undergoes α-oxidation to pristanic acid (phytanoyl-CoA 
dioxygenase) that undergoes several cycles of β-oxidation in the peroxisomes after which it is 
transferred to mitochondria for its complete oxidation. Furthermore, chain shortening of these 
VLCFA results in the production of acetyl-CoA. Since, peroxisomes do not have the Krebs 
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cycle, these acetyl-CoA are transferred back to mitochondria74. An accumulation of VLCFA, as 
well as phytanic and/or pristanic acids in tissues and body fluids, is usually used as an indicator 
of peroxisomal dysfunction in genetically inherited diseases associated with peroxisome 
biogenesis dysfunction, such as Zellweger Syndrome and adrenoleukodystrophy75. 
Previous work on lipids gives a strong indication of peroxisomal dysfunction which 
coincides with abnormal lipid profiles in several GWI mouse models54,65,76.  In a previous study 
of a GWI mouse model of PB+PER exposure, immunohistochemical analyses of our PB+PER 
showed that staining of peroxisome-specific catalase was increased in the dentate gyrus (DG) of 
GWI mice65. It is possible that this increase in catalase may reflect increased proliferation of 
peroxisomes following GW chemical exposure.  However, other studies have suggested that 
such increases in catalase could be an indicator of abnormal accumulation of non-functional 
peroxisomes due to impaired recycling of these organelles through autophagy77.  There was also 
an increase in ether phosphatidylcholine (ePC) in the brains of GW chemical exposed mice65; 
other lipid changes including altered levels of omega-3 fatty acids and VLCFA-containing 
sphingomyelin (SM) species in the brains of GWI mice compared to control mice also indicate 
peroxisomal dysfunction65. As such, there is an increasing evidence connecting peroxisomal 
dysfunction to the pathogenesis of GWI in mouse models. 
Translating these studies, Emmerich and colleagues reported an increase in ether PL in 
the blood of veterans with GWI compared to healthy GW veterans as well as rodent models of 
GWI76. Additional evidence for possible impairment of peroxisome function also comes from 
same studies which showed an increase in DHA containing PL specially PC, LPC and PE76. 
More recently, my own work showed that VLCFA were increased in the plasma of veterans 
with GWI78.  Overall, these studies suggest possible peroxisomal dysfunction in both ill GW 
veterans and in mouse models of GWI.  Therefore, targeting peroxisomal lipid metabolism 
might be a possible therapeutic route to treating this illness.  
1.7 Mitochondria dysfunction in GWI 
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Mitochondria are cellular organelles that perform several complex functions including; 
1) fatty acid ß-oxidation, 2) oxidative phosphorylation (OXPHOS), 3) production and 
consumption of ROS, and 4) the generation of adenosine triphosphate (ATP). Due to their 
critical role in energy production mitochondria are commonly referred to as the “powerhouse of 
the cell”.  The substrate is provided to mitochondria in the form of pyruvate or fatty acids, 
which are metabolized to acetyl-coenzyme A (Co-A)79.  These acetyl-Co-A molecules condense 
with oxaloacetate to form citric acid, finally entering the Krebs cycle79.  During the Krebs 
cycle, 3 molecules of nicotinamide adenine dinucleotide (NAD+) are reduced to NADH.  
Along, with NAD+, the Krebs cycle reduces flavin adenine dinucleotide (FAD+) to FADH2 by 
redox reaction80. FADH2 is a reduced electron carrier of FAD+, it also donates its electron to 
the electron transport chain (ETC)80. This process also transfers protons to the inner membrane 
of mitochondria to generate a proton gradient80.  The inner membrane of mitochondria contains 
protein complexes I, II, III and IV 80; together these protein 
complexes transfer electrons from electron donors to electron acceptors via redox reaction 
and act as an electron shuttle 80.  Complex V, an ATP-synthase, uses the energy generated by 
the protons as they pass through the inner mitochondrial membrane to generate ATP from 
ADP80.  In this way the mitochondrial redox reaction helps to maintain the cellular 
NAD+/NADH ratios for normal cellular processes81. A major consequence of this event is the 
generation of unpaired electrons which interact with O2 to form ROS.  Under pathological 
conditions, or during cellular stress, high concentrations of ROS could lead to lipid peroxidation 
and damage the cellular membrane, subsequently leading to inflammation82,83.  The inner 
mitochondrial membrane also has uncoupling proteins (UCP), which act as channels to pass the 
protons from the inner mitochondrial membrane to the mitochondrial matrix80. In this way, the 
proton gradient is dissipated to the mitochondrial matrix resulting in the production of heat.  As 
such, mitochondrial membrane potential and OXPHOS is regulated by UCP. 
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The mitochondrial outer membrane is impermeable to fatty acids, so the carnitine shuttle 
system is used to transport these fatty acids inside mitochondria. The acyl group of acyl 
coenzyme A (acyl-CoA) is conjugated to carnitine by the enzyme carnitine palmitoyltransferase 
(CPT). These conjugates of fatty acids and carnitines are called fatty acid acylcarnitine.  Long 
chain fatty acid acylcarnitines are transported to the inner membrane of mitochondria for b-
oxidation.  b-oxidation results in cleavage of 2 carbons from fatty acids as acetyl-CoA and 
resynthesizes the carnitine conjugate of the chain-shortened fatty acids and the process is 
repeated for complete conversion of the fatty acids to acetyl-CoA 84,85.  Another important 
mitochondrial lipid is cardiolipin (CL), it is exclusively located in mitochondria and represents 
almost 25% of total mitochondrial lipid 86.  Cardiolipins maintain and stabilize the inner 
mitochondrial complex such as ATP synthase and UCP 87.  Mitochondrial membranes have a 
high cardiolipin content, which maintains mitochondrial membrane integrity and mitochondrial 
morphology.  As such they also play major role in regulating mitochondrial membrane 
potential87.     
Many of the GWI symptoms suggest a possible involvement of oxidative stress and 
mitochondrial dysfunction25.  Evidence of mitochondrial dysfunction is also seen in GWI 
animal models. In a rat model of GWI, transcriptomics analysis showed increased expression of 
the genes involved in mitochondrial respiration 88. These genes include NADH dehydrogenase 
1 alpha subcomplex, succinate dehydrogenase and cytochrome C oxidase, and especially 
control the function of complexes I, II, III and IV88.  This effect might be ascribed to a 
hyperactive mitochondrial electron transport chain compensating for increased ROS due to 
mitochondrial dysfunction89.  These findings are also supported by results from another study 
showing a decrease in complex I and II activity in the brains of GWI mice 66.  Also, lipid 
analysis showed lower mitochondria specific lipids such as CL and acylcarnitine in the brains 
of GWI mice54. Exposure to pesticides (dimethoate and zineb) has also been shown to lower CL 
levels in the brain of pesticide exposed mice90. 
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 The clinical presentation of GWI veterans shows many features that can be related to 
mitochondrial dysfunction. Both clinical and preclinical studies suggest targeting mitochondrial 
biogenesis and function might be a useful treatment for GWI. Recent studies found that 
mitochondrial DNA damage was 20 percent higher in GWI veterans91. Also, a study from our 
laboratories showed a change in mitochondrial specific acylcarnitine in human plasma54. 
Hokama et al., in a pilot study, showed that GW veterans had higher plasma levels of anti-CL 
antibody compared to healthy controls from the general population92.  Koslik et al. showed that 
post-exercise recovery of phosphocreatine levels in the muscle of GWI veterans is affected, as 
measured by 31P phosphorus magnetic resonance spectroscopy93.  In another study, using 1H 
MRS, veterans with GWI had increased levels of lactate in their prefrontal cortex following an 
exercise challenge94. These results suggest the inability of brain cells responsible for the 
catalytic conversions between pyruvate and lactate, which results in Krebs cycle impairment95.  
A possible cause of this might be a lower level of NAD+ substrate which is used in glycolysis 
to generate ATP in mitochondria84,96.  Additional support for mitochondrial dysfunction in GWI 
comes from our own pilot study showing increased products of lipid peroxidation in the blood 
of veterans with GWI78.  All these studies suggest mitochondrial dysfunction is involved in the 
pathobiology of GWI and should continue to be investigated. Therefore, therapies that target 
restoration of mitochondrial function and bioenergetics may prove beneficial for alleviating 
GWI pathology. 
1.8 Immune and inflammation as key pathologies of GWI 
The immune system is comprised of a network of cells, tissues, and organs that work in 
unison to defend the body against pathogens or antigens. The immune system should correctly 
identify and respond to potentially harmful organisms, and it must also differentiate between 
the non-antigenic substances and antigens that present potential harm97.  The immune system 
can be divided into two classes, the innate and the adaptive immune system.  The innate 
immune system is the body’s first line of defense and is able to respond immediately upon 
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encountering antigens; while this immune response is rapid, it does not confer specific, long 
term protection as it does not generate an immunological memory97.  The adaptive immune 
response is performed by lymphocytes which respond to pathogens via either humoral or cell-
mediated immunity. In humoral immunity, B lymphocytes secrete antibodies that mark target 
antigens or microbes for elimination.  In cell mediated immunity, T lymphocytes activate 
cytotoxic T-cells to engulf antigens or kill infected host cells97. Furthermore, T-lymphocytes 
also provide a helper function for B cells by the help of T helper (Th) cells. While the adaptive 
immune system is slower to respond to pathogens it generates an immunological memory, 
enabling it to respond more rapidly in cases of future re-infection by the same pathogen97. In 
general, Th-1 cells secrete pro-inflammatory cytokines, such as interleukin-1beta (IL-1 β), 
interferon (IFN)-g, tumor necrosis factor (TNF-a) and interleukin (IL)-2, cytokines which 
promote inflammation to fight against foreign or other pathological stimuli.  On the other hand, 
Th-2 cells release anti-inflammatory cytokines such as IL-4, IL-5, and IL-10,97 which 
essentially limit and antagonize the effects of inflammation to help restore the natural state of 
the tissue98. Th-17 cells play a role in adaptive immunity, protecting the body against pathogens 
and stimulating generation of cytokines, such as IL-17, IL-21 and IL-2399.  Recent studies have 
suggested that Th-17 cells are involved in the pathogenesis of autoimmune disorders100.  A 
homeostatic balance between pro- and anti-inflammatory cytokines is necessary to maintain 
normal physiological function in the body. Chronic inflammation involves dysregulation of pro- 
and anti-inflammatory cytokines101.  
GWI veterans were potentially exposed to many hazards such as prophylactic 
medications, multiple vaccinations and pesticides 1; it is likely that these resulted in immune 
function alterations. Previously, it was hypothesized that veterans with GWI had their immune 
response shifted towards a Th-2 cytokine pattern due to multiple vaccination 102. However, this 
is not supported by recent literature103,104. The current hypothesis is that various chemical 
exposures during the 1991 GW, together with  battle stress, may have caused a chronic 
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dysregulation of the immune system 1.  In fact, studies have shown an irregular activation of 
Th-1 and Th-17 mediated immune responses in GWI104.  Evidence for a Th1 immune response 
comes from studies showing an elevation of TNF-a and IL-2 cytokines produced by CD4+ T-
cells in GWI patients compared with healthy controls105.  Additional evidence for a Th1-like 
immune response is evident from studies showing prolonged elevation of plasma pro-
inflammatory cytokines, such as IFN-γ and TNF-a, in subjects with GWI compared to healthy 
controls104,106. Plasma cytokine profiles show a significant upregulation of IL-17A and IL-17F 
in GWI cases compared to controls, suggesting a Th-1/Th-17 immune shift104.  Veterans with 
GWI not only showed T-cell dysregulation but also an increased population of B cells and 
monocytes in their blood107,108.  Defective regulation of B- and T-cells results in a loss of the 
immune system’s ability to discriminate self- and non-self-antigens leading to autoantibody 
production109. Characterization of the immune profiles suggests a presence of autoantibodies 
against brain-specific proteins, such as glial fibrillary associated protein (GFAP), myelin basic 
protein (MBP) and tau – all produced in GWI veterans, which was absent in healthy veterans110.  
However, mechanisms behind generation of these autoantibodies following exposure to GW 
chemicals and their contribution to immune dysfunction and neuroinflammation are currently 
unknown in the literature.  Future research must focus on mechanisms that show how exposure 
to GW chemicals leads to the production of autoantibodies which then contribute to the chronic 
debilitating symptoms experienced by veterans with GWI.   
 
1.9 Currently available treatment strategies in GWI 
Currently, there are no approved treatments for GWI which target the underlying 
pathologies, and therefore there is a continual need for research into better understanding the 
pathological mechanisms associated with GWI in order to better inform the treatment 
development process. Various approaches have been utilized thus far which are focused on 
symptom management.  For instance, yoga or acupuncture clinical trials have been conducted in 
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GWI patients which provided some relief in pain reduction111,112 but benefits from these 
treatments are modest and do not change the underlining pathology of the disease.  Donta et al., 
hypothesized that GWI was caused by an systemic infection with Mycoplasma species113.  They 
tried antibiotic treatment and exercise to improve cognitive behavior, neither intervention had 
any long lasting effects113,114. Many studies conducted on GWI veterans have targeted 
mitochondrial dysfunction54,93,115. In a preliminary analysis of 46 GW veterans, treatment of 
GWI veterans with Coenzyme-Q10 (CoQ10) did show improvement in physical function and 
other symptoms related to GWI 116. CoQ10 is involved in significant metabolic pathways where 
it  receiving electron from redox enzymes and provides these electrons to ETC (specially 
Complex III)117. As such, CoQ10 was suggested to improve bioenergetics by increasing ATP 
production in the cells and also protects cells against oxidative damage118,119. 
  Others have shown that CoQ10 exerts a favorable effect on GWI-relevant symptoms such 
as fatigue120,121.  Although this study had improvements reducing commonly reported symptoms 
of fatigue, dysphoric mood, and pain, some adverse effects were observed such as 2 case of 
seizures and ischemic attacks on treatment group116.  Another study treating GWI patients with 
carnosine (a dipeptide of alanine and histidine) reported a beneficial cognitive effect but no 
improvement in other clinical symptoms such as fatigue and pain122. Although the mechanism 
of action of L-carnosine is not well understood, carnosine has been known to protect against 
ROS and improve memory in adults and children123,124.  Previous pilot studies found that use of 
carnosine supplements was effective in improving memory and neurologic function in autism 
and schizophrenia,124–126.   
 In another  GWI treatment study, the glucocorticoid receptor antagonist mifepristone 
resulted in an improvement in verbal learning, but no improvement in cognition or mental 
health was reported by veterans127. Out of 67 GWI veterans recruited in this study, 32 received 
treatment while 35 were placebo127. Treatment of chronic pain in GW veterans with repetitive 
Transcranial Magnetic Stimulation (rTMS) was terminated as it failed to meet recruitment 
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criteria. This study could only recruit 17 participant which did not meet recruitment goal 
(source: clinicaltrial.gov).  Recently, many clinical trials are recruiting GWI veterans, which are 
focused on changing the diet to treat the digestive problems associated with the illness, such as 
a low-glutamate diet or a probiotic diet (source: clinicaltrial.gov). Few other clinical trials are 
completed or are recruiting patients but very few trials look promising. As such, more research 
studies are needed that identify the underlying mechanisms associated with GWI.   As GW 
veterans are ageing, finding effective treatments for GWI is a high priority. The research in this 
thesis was directed towards identifying potential therapies that target peroxisomal and 
mitochondrial dysfunction observed in GWI. The work described in this thesis has resulted in 
identification of several therapeutic approaches that will be investigated further in veterans with 
GWI in the near future. The ultimate goal of all these interventions are to provide the patient 
with relief of symptoms, stop the progression of disease and improve the quality of life of GW 
veterans suffering from this chronic and debilitating multisymptomatic illness. 
 
1.10 Hypothesis & Synopsis of following chapters. 
My working hypothesis is therapeutic targeting of lipid remodeling pathways can reduce 
abnormal brain lipid accumulation and improve chronic neurobehavioral deficits and the 
accompanying neuropathology in a mouse model of GWI. One of my aim is to target 
peroxisomal and mitochondrial lipid metabolism in order to identify possible therapies for 
treating GWI.  I will examine several compounds such as bioactive lipids, especially 
ethanolamides, which target peroxisome function via activation of peroxisome proliferator-
activated receptors (PPAR) and also decrease inflammation. I will also examine a different 
strategy which targets mitochondrial function and/or biogenesis using nicotinamide riboside 
and ketogenic diet. 
Another main objective of this thesis is to further characterize the PB+PER mouse model for 
other key pathologies of GWI. As inflammation is major hallmark of GWI, I further wanted to 
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analyze systemic inflammation related to GW agent exposure in our GWI mouse model as well 
as in humans. I therefore hypothesize that peripheral immune cell activation and infiltration in 
the brain following GW agent exposure may be associated with brain inflammation and 
memory impairment.  
 
1.11 The aim of the thesis research 
1) To target peroxisomal lipid metabolism in order to identify possible therapies for 
treating GWI 
Using our mouse model of GWI I targeted peroxisome function via activation of 
peroxisome proliferator-activated receptors (PPAR) to determine if this approach can 
improve the behavioral phenotype and decrease the inflammation associated with 
exposure to agents known to have caused GWI. 
 
  
 
Figure 1.1: PPAR-a as a new therapeutic target for GWI (source: nature publishing group) 
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2) Mitochondrial function and/or biogenesis as a potential target for therapeutics of 
Gulf War Illness (GWI) 
The main aim of this study was to assess the efficacy of nicotinamide riboside (NR) or a 
ketogenic diet (KD) in reducing the brain pathology and mitochondrial disturbances in a 
mouse model of GWI. 
 
 
 
 Figure 1.2: Metabolic pathways involved in Nicotinamide riboside (NR) treatment 
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3) To 
examine 
peripheral and brain inflammation and immune-related changes in the PB+PER 
GWI mouse model 
The key aspect of this project was to identify the underlying immune dysfunction that 
drives the brain pathology in our GWI mouse model in order to develop appropriate 
biomarkers and therapies for treating this condition.   
 
 
Figure 1.3: Metabolic pathways involved in ketogenic diet (KD) treatment 
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Figure 1.4: PER induced immune dysfunction (source: Elsevier). 
 38 
Chapter 2: Oleoylethanolamide treatment reduces neurobehavioral deficits and brain 
pathology in a mouse model of Gulf War Illness 
2.1 Introduction 
As previously described, a common feature noted consistently across animal models and 
amongst patients affected by GWI are distinct differences in blood lipid profiles with regards to 
ether PLs, VLCFAs and BCFAs65,76,78. It has been reported in several studies that these changes 
in lipid profiles are indicative of peroxisomal dysfunction (128). Peroxisomes are small cellular 
organelles, which contain several enzymes involved in oxidative metabolism 128. Traditionally, 
their function was believed to be purely a site for the oxidation of fatty acids such as VLCFA and 
BCFA, a vital source of metabolic energy for cellular processes 128.  Furthermore, recent evidence 
suggests that in addition to their role in oxidative metabolism, peroxisomes are involved in ether 
PL and bile acid synthesis73,129,130. In GWI, peroxisomal dysfunction is believed to promote 
incomplete ß-oxidation of VLCFAs, resulting in the overproduction or inadequate detoxification 
of ROS. The dysfunctional processing of ROS has been shown to trigger oxidative stress and 
upregulate proinflammatory responses131–133. Reactive oxygen species are involved in activation 
of the signaling pathway leading to NF-κB activation and production of proinflammatory 
cytokines 134,135. 
Support for a role of inflammation in GWI has been reported in several animal models where 
exposure to GWI chemicals has been described to increase the expression of genes related to 
oxidative stress and inflammation88, potentially increasing glial cell activation and the production 
of proinflammatory cytokines in the brain136. Subsequent evidence from clinical studies reporting 
increases in pro-inflammatory cytokines, such as TNF-a, IFN-γ, IL-2 and IL-1β on immune cells 
and in the plasma of veterans with GWI compared to healthy veterans further suggest that 
disturbances in peroxisomal b-oxidation may be associated with the oxidative stress and 
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inflammation observed in GWI104,107,137,138. Together these studies suggest that targeting and 
increasing peroxisome function and thereby reducing inflammation may be a potentially viable 
therapeutic avenue in GWI research. 
One strategy to increase peroxisomal activity is by targeting peroxisome proliferator-
activated receptor alpha (PPARα), which is a nuclear hormonal receptor that stimulates 
peroxisome proliferation, thereby regulating lipid biosynthesis, b-oxidation of fatty acids and 
scavenging ROS139–143. Recent studies have shown that PPARα activation promotes normal 
cognitive function 144 and that the pharmacological stimulation of PPARα improves cognitive 
function in mice145. Furthermore, several studies have reported that PPARα agonists inhibit glial 
cell activation and enhance memory function in a rodent model of neurodegeneration146,147. 
Conversely, studies which have pharmacologically inhibited PPAR-α reported the accumulation 
of VLCFA and increases in inflammatory markers148. As such, PPARα has emerged as a 
promising molecular target for many CNS related diseases 149,150. 
With respect to lipid metabolism, PPARα activates transcription of genes encoding for the 
enzymes required in ß-oxidation. Furthermore, PPARα agonists are also shown to reduce 
inflammation through genetic regulation of NFκB in various CNS disorders151–154. One such 
natural occurring PPARα agonist is oleoylethanolamide (OEA) which is shown to have potent 
anti-inflammatory, antioxidant, neuroprotective and antidepressant-like properties. OEA ais a 
monosaturaed class of lipid compound that constitute ethanolamide of oleic acid. Therapeutic 
intervention with OEA has demonstrated considerable pre-clinical efficacy in the treatment of 
neuroinflammatory and psychological disorders150,155. We, therefore, hypothesize that GW 
chemicals disturb peroxisome function, which subsequently impair β-oxidation or aberrantly 
increases VLCFA synthesis. As such, targeting peroxisome function through OEA may be 
beneficial for treating GWI and improving disease outcomes. 
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The main goal of this study is to examine the fatty acid (FA) profiles associated with 
peroxisome function in the blood plasma of veterans with GWI compared to healthy veteran 
control samples. Furthermore, this study investigated the efficacy of the PPARα agonist OEA, to 
determine if treatment can beneficially alter peroxisomal lipid metabolism and treat the chronic 
neurobehavioral deficits and glial activation shown in our mouse model of GWI. The work 
detailed below is now published in the journal Scientific Reports78.  
Hypothesis: Lipids play a key role in neuronal survival by both supporting neuronal architecture 
and biological functions and by serving as a source of energy.  Accumulating evidence suggests 
that dysfunctional lipid metabolism is a major hallmark of GWI.  Lipid metabolism is upstream 
of many immune/inflammatory and neuroendocrine responses that are affected in GWI. Previous 
lipidomic data support a potential role of peroxisomal specific lipid metabolism dysfunction in 
GWI. We therefore hypothesize that restoring lipid homeostasis in the brain will treat the CNS 
symptoms of GWI.   
Specific aim 1: To determine if therapeutic targeting of lipid remodeling pathways can reduce 
abnormal brain lipid accumulation in a mouse model of GW agent exposure. 
Specific aim 2: To determine if PPAR agonists can decrease chronic inflammation and 
accompanying cytokine and chemokine production in a mouse model of GW agent exposure. 
Specific aim 3: To determine if supplementing PPAR agonists can treat chronic neurobehavioral 
deficits and accompanying neuropathology in a mouse model of GW agent exposure. 
 
2.2 Methods 
2.2.1 Human subjects 
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This study was approved by the Institutional Review Board (IRB) with all protocols 
conducted in accordance with relevant guidelines and regulations. Plasma samples from age- 
and gender-matched control health GW deployed veterans (n = 10) and veterans with GWI (n = 
12) were compared in this study. It is assumed that all the subject were fasting when blood was 
withdrwan, no data on Diabetes medation were avilable. A biorepository of plasma samples 
from GW veterans who previously consented to share their blood samples for future studies 
from the Boston Gulf War Illness Consortium (GWIC) and the Dynamic Modeling of GWI 
study were provided by our collaborators at the Boston University and NOVA Southeastern 
University sites. The GWI biorepository is approved by the institutional review boards (IRBs) 
at Boston University, NOVA Southeastern University and Miami Veterans Administration 
Medical Center (VAMC). All experiments were performed in accordance to the guidance from 
these oversight committees. Informed consent was obtained from all participating subjects. The 
GWI biorepository samples were all collected using the same written standard operating 
procedures for performing phlebotomy, plasma separation and aliquoting.  All samples were 
stored at -80oC and were not previously thawed and refrozen. The Kansas GWI criteria were 
used to determine cases of GWI and controls. The Kansas GWI criteria require that GW 
deployed veterans show symptoms in at least 3 of 6 symptom domains (fatigue/sleep problems, 
pain, cognitive impairment, mood symptoms, gastrointestinal symptoms, respiratory symptoms, 
and skin abnormalities). Study participants were excluded if they reported being diagnosed with 
another medical condition that could explain their chronic health symptoms. The Kansas GWI 
case definition exclusions include veterans with a history of prior CNS or major psychiatric 
disorders that could affect cognitive function (e.g., epilepsy, stroke, brain tumor, multiple 
sclerosis, Parkinson’s Disease, Alzheimer’s disease, schizophrenia).  Controls were deployed 
veterans from the 1991 GW who did not meet the Kansas GWI criteria or exclusionary criteria 
listed above. Subjects also completed demographic and health symptom questionnaires. The 
recruitment strategy for the biorepository also excludes subjects currently participating in 
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clinical trials to minimize immediate interferences from these medications at the time of the 
blood draw. Subjects are also asked if they are on any steroid treatments and, to the best of our 
knowledge, subjects have reported no. However, no other medication information is currently 
obtained. A detailed demographic table is provided in table 1. 
 
Table1. Demographics of the Gulf War veteran cohort. 
 Control (GW veteran) GWI 
 
N total 10 12 
Age (Mean ± SE) 49.3 ± 2.6 46.1 ± 1.6 SE 
Male (%) 100 100 
Ethnicity   
Caucasian 
African American 
Hispanic 
Asian 
5(50%) 
1(10%) 
2(20%) 
2(20%) 
4(28.5%) 
5(35.7%) 
2(15%) 
3(23%) 
 
 
2.2.2 In vitro study to find potent PPAR-alpha agonist which reduces LPS induced 
inflamation:  
The main aim of this experiments was to study anti-inflamatory properties of natural 
PPAR-alpha ligan and similar strutural compounds. Murine macrophage RAW 264.7 cells were 
obtained from the American Type Culture Collection (ATCC) and grown in Dulbecco's 
Modified Eagle Medium (DMEM) F12 medium (life science St. Louis, MO) containing 10% 
fetal bovine serum (FBS) and 1% mixture of antibiotics (penicillin, streptomycin sulfate) and 
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antimycotics (amphotericin B). Cells were incubated in a humidified 5% CO2 atmosphere at 
37°C and subsequently challenged with lipopolysaccharide (LPS) from E. coli (Sigma Aldrich, 
St. Louis, MO) at 10μg/ml to induce NFkB activation. Oleoylethanolamide, docosahexaenoyl 
ethanolamide (DHEA), Prostaglandin E2 ethanolamide (PGE2EA) (Cayman chemical, Ann 
Arbor, MI) at 10μM, 1μM, 100nM each were used to investigate possible inhibition of NFkB 
phosphorylation by these compounds. Cells were incubated with either DMSO alone, with LPS 
and DMSO, or with each test compound in combination with LPS and DMSO.  Conditioned 
media were collected and analyzed for the quantification of cytokines. The cells were lysed 
with mammalian protein extraction reagent (mPER) along with protease inhibitor to quantify 
pNFkB and total NFkB expression in these cells. Cytotoxicity was estimated by the presence of 
lactate dehydrogenase (LDH) using an LDH assay (Roche, Basel, Switzerland) which was 
performed according to manufacturer’s instructions.  Subsequently in another experiment, cells 
were pretreated by PPARa inhibitor (GW 6471) and PPARg inhibitor (GW 1929) at 10μm 3 
hours before LPS and OEA treatment. The main aim of this experiments was to confrom OEA 
mechanism of action was dependend on PPAR-alpha. Western blot analyses were performed as 
above to examine NFκB (Ser 536), Janus kinase  (JAK2, Tyr1008) and STAT3 (Tyr 705) 
phosphorylation as inflammation associated outcomes. JAK-STAT pathway is a signaling 
pathway that involves several tyrosine kinases  and transduce cytokine-mediated signals156. 
 
2.2.3 Animal Handling: 
All procedures on mice were approved by Roskamp Institute’s Institutional Animal Care 
and Use Committee and were in compliance with the Office of Laboratory Animal Welfare and 
Laboratory animal care guidelines as described previously 54.Eight-week-old male C57BL6 
mice(Jackson Laboratory, Bar Harbor, ME, USA) were purchased from Jackson Laboratory and 
 44 
allowed to acclimate to the new environment. All mice were placed on Standard rodent diet 
(Envigo, IN, USA) routine diet upon arrival. At 9 weeks of age (n = 48), 0.7mg/kg of 
pyridostigmine bromide (PB) (Fisher Scientific) and 200 mg/kg of PER (Sigma Aldrich) in 
50ul 100% Dimethyl sulfoxide (DMSO) was administered via intraperitoneal (i.p.) injection 
daily for 10 days, while the control group received only 100% DMSO 53,54,157. All animals were 
randomized to the various groups. Subsequently, mice were allowed to age for 5-months post-
exposure, a timepoint when we have observed cognitive impairment 53,65. Mice were again 
randomly assigned to either the OEA treatment or the control group.  Mice in the OEA group 
were fed standard rodent chow (Envigo, MD, USA) containing a daily dose of 10mg/kg OEA 
(based on the consumption of 5g daily food intake) for up to 6 months, while the control group 
mice received standard chow only (11-months post-exposure). After GW chemical exposure, 
mice underwent testing with the FST at 3- and 5-months post-exposure to establish the presence 
of GW chemical induced changes in exposed relative to control mice. Control and GWI mice 
were divided into groups which either received oral OEA treatment in diet daily or normal diet 
for a total of six months. The Barnes Maze test was used to assess learning in control and GWI 
mice after 1-month of oral OEA treatment (6-months post-exposure to GW chemicals) and 
long-term memory after 2-months of treatment (7-months post-exposure). Learning was 
assessed during the acquisition trials in which mice were allowed to freely explore the maze for 
3 min and escape into the target box through one of the holes in the platform. After 6 months of 
treatment, animals were euthanized for lipidomics, neuropathological, and biochemical studies. 
Randomization was performed in all neuro behavioural experiment, experimenter were blinded 
GW treatment but not diet.  Mice were not deprived of food before euthenesia. A timeline of the 
study procedures is provided as Figure 2.1. 
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Figure 2.1: Timeline of the study 
 
 
2.2.4 OEA Synthesis method  
A 1-L round-bottom flask was charged with a mixture of benzene and hexanes (360 mL, 
1:1, v/v) and oleic acid (25 g, 88 mmol).  The above solution was cooled on an ice-bath to which 
oxalyl chloride (20 mL, 232 mmol) was slowly added over a period of 30 minutes via an addition 
funnel. This was followed by an addition of a catalytic amount of Dimethylformamide (DMF) (1 
mL, 13 mmol). The above reaction mixture was removed from ice and then stirred at room 
temperature for 5 hrs. The solvents were then removed under reduced pressure and replaced with 
anhydrous Dichloromethane (DCM) (360 mL). To this solution, triethylamine (50 mL, 359 
mmol) and 2-aminoethanol (22 g, 360 mmol) was added. The reaction solution was stirred 
overnight at room temperature and was quenched with H2O (360 mL). Layers were separated and 
then the organic layer was washed with H2O (360 mL × 3) and brine (360 mL) and dried with 
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anhydrous MgSO4. After drying, the resulting residue was dissolved in n-hexane (500 mL) and 
was left in the refrigerator under -10°C overnight. The resulting product was filtered, washed, 
and dried in vacuo to a constant weight as a white solid (24.5 g, 86%). 1H and 13C NMR of this 
product conform to literature reports.       
2.2.5 The Barnes Maze test to access memory 
The Barnes Maze test was conducted according to previously described procedures53,54. 
Briefly, at 1-month post-treatment with OEA, the Barnes maze trial was performed for 
assessing learning. Acquisition trials were conducted over 4 days where each trial was 
conducted for 3 min, and 4 trials were conducted for each mouse per day. Briefly, each mouse 
was placed in the middle of the maze and the trial ended when the mouse entered the escape 
box through the target hole (TH) or after 3 min. Bright flood lamps were used as motivators for 
mice to enter the escape box, where they stayed for 1 min. If a mouse did not reach the TH 
within 3 min, the experimenter guided it to the escape box. A probe trial was conducted 24 hrs 
after the last training session. The escape box was removed for the probe trials. Each mouse 
was placed in the middle of the maze and allowed to explore for a fixed interval of 1.5 min. 
Another probe trial was administered at 2 months post-treatment to assess long-term memory. 
The Ethovision software was used to track mouse movement, and total distance traveled by 
each mouse on the platform was used to calculate the path length.  
2.2.6 Forced Swim Test to examine fatigue like behavior 
Forced swim test (FST) was performed to measure fatigue-like behavior, according to 
the protocol published by Can and colleagues 158 and was administered at 1- and 3-months post-
exposure to GW chemicals and then subsequently at 10-months post-exposure, corresponding 
with 5-months after OEA treatment. Furthermore, repeated exposure to FST is used to induce 
fatigue in mice 159. Mice were brought to the behavior testing room at least 30 minutes prior to 
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the initiation of the testing in order to acclimate them to the testing conditions. The FST 
apparatus was comprised of a cylindrical tank (30 cm height x 20 cm diameters) which was 
filled with warm tap water (approximately 22 °C) to a depth of 25 cm, preventing the tail and 
feet to reach the apparatus. Each animal was placed in the tank for 6 minutes, after which the 
mouse was removed to a warm and dry environment. Data were recorded and captured using 
the Ethovision XT software version 7, and latency to stop swimming and time spent being 
immobile were recorded as the outcome measures. Due to technical problems, data were lost for 
few mice(n=2/3 per group)  
2.2.7 The Elevated Plus Maze test to determine anxiety 
The elevated plus maze (EPM), used to determine anxiety, consisted of two open arms 
and two closed arms surrounded by high walls (40cm) across from each other. The middle 
section that allows the animal to transit from arm to arm consisted of a square with dimensions 
of 12 × 12 cm. Mice were allowed to move freely within the maze for 5 min. Entries to each 
arm were recorded using the Ethovision system. Only one trial per mouse was administered. 
The distance travelled in the maze, the number of entries into each arm, and the percentage of 
entries to open arms were calculated. The time spent in open and closed arms were analyzed as 
the outcome measures. 
2.2.8 Sample preparation 
Mice were euthanized via cardiac puncture under anesthesia and all animals were 
transcardially perfused with PBS.  Half brains (right hemisphere) and plasma were immediately 
frozen in liquid nitrogen and transferred to a -80˚C freezer until further use. Using a dounce 
homogenizer, each brain hemisphere was homogenized in chilled lysis buffer containing 
protease (Roche, Indianapolis IN) and phosphatase inhibitor (Pierce, Grand Island, NY) 
cocktails. 
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2.2.9 Immunohistochemistry and confocal microscopy 
The left-brain hemispheres were fixed in 4% paraformaldehyde and embedded in 
paraffin. Sagittal sections (8 μm) were prepared and rehydrated in an ethanol gradient before the 
staining procedure. Glial fibrillary acid protein (GFAP; 1: 1000, Wako, Carpinteria, CA, USA) 
and ionized calcium binding adaptor molecule 1 (Iba1) antibodies (1: 5,000; Abcam, 
Cambridge, MA, USA) were used to stain astroglia and microglia, respectively. Primary 
antibodies were localized using respective fluorescent labeled secondary antibodies. Slides were 
mounted in mounting media with DAPI (Abcam). The Image J software was used to analyze 
the stained sagittal sections. The stained areas were calculated and expressed as a percentage of 
the field of view. 
2.2.10 Enzyme-Linked Immunosorbent Assay 
Brain samples were homogenized using a dounce homogenizer, in chilled lysis buffer 
containing protease (Roche, Indianapolis IN) and phosphatase inhibitor (Pierce, Grand Island, 
NY) cocktails. Enzyme-Linked Immunosorbent Assay (ELISA) kits for mouse CCR2 and 
CCL2 protein (LifeSpan Biologicals [LSBio], Seattle, USA) were used to study levels of these 
proteins in the brain. Chemokine receptor type 2 is involved in chemotaxis of myeloid cells in 
response to CCL2 160. Brain homogenates were diluted 1:4 with the sample diluent provided 
with the kits, and all procedures were performed as per the manufacturer’s instructions. The 
total protein content of each sample was determined by the bicinchoninic acid (BCA) assay 
(ThermoFisher, Waltham, MA USA).  Results were expressed in ng/mg of protein. The 
detection limit is typically < 0.156 ng/ml and < 10000 pg/ml for both of these ELISA kits, 
respectively. Intra-Assay: CV<4.6% Inter-Assay: CV<7.6% for CCR2 and Intra-Assay: 
CV<5.6% Inter-Assay: CV<6% for CCL2. There was no reported cross reactivity with other 
proteins for the primary antibody used in these kits.  
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Brain cytokine specially IFN-γ, IL-1 β, IL-10, IL-6, and TNF-α were quantified using 
commercially available ELISA kit. LifeSpan Biologicals kit was used to quantify IFN-γ (LS-
F5065), IL-10(LS-F9770) and IL-6 (LS-F2478) according to manufacture protocol (LSBio 
Seattle, USA). IL-1 β and TNF-α (KMC0011and BMS607-3) were quantified by using 
commercial ELISA (ThermoFisher, Waltham, MA USA).  All procedures were performed as 
per the manufacturer’s instructions. Final protein concentrations were measured, which were 
then normalized to total protein content in the brain homogenate. Protein were normalized 
against total protein content determined by BCA. Results were then expressed as percentage to 
control. There was no reported cross reactivity with other proteins for the primary antibody 
used in these kits. 
2.2.11 Western blot 
Following the BCA, equal amounts of protein (20 μg) from each sample were heated 
with Laemmli buffer containing beta-mercaptoethanol (BioRad, Hercules, CA, USA) and 
separated by 4-20% PAGE using a Tris-HCL buffer system and 18-well Criterion gels (Biorad) 
and then transferred to a polyvinylidene fluoride (PVDF) membrane (Biorad) overnight at 90 
mA. The membrane was blocked for 1 hour in 5% blocking milk (BioRad, Hercules, CA, 
USA). Then, each membrane was individually immunoprobed with a primary antibody against 
total p65 (NFκB) (1:1000, cell signaling), NFκB (pNFκB) phosphorylated at Ser536 (1:1000, 
Cell Signaling),  PPARa (1:1000, cell signaling), pSTAT3 (1:1000, Cell Signaling) 
phosphorylated at Tyr 705, or tubulin (1:1000, abcam) in blocking buffer overnight. After each 
primary antibody incubation, each membrane was incubated with the recommended dilution 
(1:5000) of corresponding horseradish peroxidase-conjugated secondary antibody (cell 
signaling) in blocking buffer at room temperature for 1hr. Protein bands were visualized using 
enhanced chemiluminescence detection reagents (Thermo Scientific, MA USA). Band 
intensities were analyzed using the ChemiDoc imaging system (Bio-Rad). Results were 
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calculated using Image Lab software and normalized to the expression of tubulin protein in the 
sample.  
2.2.12 Multiplex cytokine Assay 
Selected cytokine levels in the plasma were analyzed using Meso Scale Discovery 
(MSD) 96-Well MULTI-SPOT®Ultra-Sensitive V-PLEX Proinflammatory Panel 1 mouse Kit, 
using electrochemiluminescence detection on an MSD Sector Imager™ 6000 with Discovery 
Workbench software (version 3.0.18) (MSD®, Gaitherburg, MD, USA). Cytokines were 
measured using the TH1/TH2 8-plex kit, which included 8 markers: IFN-γ, IL-1 β, IL-2, IL-4, 
IL-5, IL-10, IL-13, and TNF-α. All assays were performed according to manufacturer’s 
instructions, in duplicates. Samples were diluted 1:2 and added to the plate which contains 
capture antibody immobilized on a working electrode. Following incubation for 1 hour, 
SULFO_TAG labelled detection antibodies were added to the wells. Finally, MSD buffer was 
added which developed electrochemiluminescence and the plate was loaded into an MSD 
instrument for reading. Data were acquired using a SECTOR S 6000 plate reader (MSD). 
Results were then expressed as percentage to control 
2.2.13 Malondialdehyde assay  
Malondialdehyde (MDA) levels in brain homogenates were measured using a 
Thiobarbituric Acid Reactive Substances (TBARS) Assay Kit (Cayman Chemical, 10009055) 
according to manufacturer protocol. Malondialdehyde is an organic compound used as marker 
for lipid peroxidation, since it is a byproduct of lipid peroxidation. At boiling temperature, 
oxidized lipids produce MDA which can be measured calorimetrically at 530–540 nm. 
2.2.14 Fatty acid analysis Assay 
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Total lipid extracts were prepared from brain homogenate and plasma samples by the 
Folch et al., 161 and modified to minimize the sample volume used. Briefly, a 5 µL aliquot of 
internal standard containing C17 fatty acid was spiked into 10 µL of brain or plasma. Methanol 
(70 µL) and chloroform (120 µL) were then added. This mixture was centrifuged at 20,000 x g 
for 10 minutes to pellet proteins and other cell debris, and the supernatant was transferred to a 
clean tube. Next, 0.88% KCl was added (40 µL) at a volume of approximately 25% of the total 
reaction volume. This mixture was then vortexed for 1 minute and centrifuged as above to 
separate the phases. The upper phase was discarded, and the lower phase was dried into a clean 
tube under vacuum. Samples were cleaned using 750 µL, PVDF, 0.2 µm centrifuge filters 
(Thermo Scientific) prior to analysis. Filters were conditioned by centrifuging with 1:1 
chloroform: methanol (v/v) (200µL) at 10,000 x g for 5 minutes and discarding the flow-
through. Dried lipid extracts were resuspended in 1:1 chloroform: methanol (v/v) loaded onto 
the conditioned centrifuge filters and centrifuged as above. Flow-through was then dried 
directly into an autosampler vial under vacuum and stored at -80oC until further processing. 
Cleaned lipid extracts were resuspended in LC solvents (50 µL) at a ratio of 70% solvent A (27 
% IPA, 42 % water, 21% ACN, 0.1 % formic acid, 10mM ammonium formate), and 30% 
solvent B (90% IPA, 10% ACN, 0.1% formic acid, 10mM ammonium formate) for LCMS 
analysis of total lipids. A Thermo EASY nLC 1000 liquid chromatograph coupled with a 
Thermo LTQ/Orbitrap mass spectrometer with nanoflex ESI source was used for nano-HPLC-
MS sample analysis. Samples were injected onto an Acclaim PepMapTM 100, 75 µm X 2 cm, 
nanoViper, C18, 3 µm, 100 A trapping column using mobile phase A as the loading solvent 
with the outlet flow directed to waste. Following sample loading, the outlet flow was directed to 
the analytical column (Acclaim PepMapTM RSLC, 75 µm X 15 cm, nanoViper, C18, 2 µm, 100 
A) for chromatographic separation of lipid species. Gradient elution was carried out by the 
gradient programs shown below in Tables 1 and 2. All samples were kept at 7oC in a cooled 
autosampler tray for the duration of the analysis. Data was acquired by full scan MS in both 
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positive and negative modes with a mass range of 130-2000 m/z (13µ scans/sec, spray voltage: 
1500V, resolution: 30,000, max inject time: 200msec). TracefinderTM software (Thermo 
Scientific) was used for peak identification and integration for lipid species in each run. Target 
compound lists of expected analytes for each chosen lipid class were used to find peaks of 
interest with ion windows of 5 ppm mass accuracy for the expected ions. 
 
Table 2: Gradient Program for Positive and negative Total Lipid Runs 
Time % Solvent A % Solvent B Flow Rate (nl/min) 
00:00 70 30 250 
01:00 50 50 250 
40:00 2 98 250 
50:00 2 98 250 
50:01 70 30 250 
65:01 70 30 250 
 
2.2.15 Statistical analyses 
Data are expressed as mean ± SEM.There were total 12 mice per groups N=12. Mice were 
excluded from analysis if they were outlier. In some experiment technical error led to decreased 
in mice number. Differences between means were assessed using one-way analysis of variance 
(ANOVA) or t-tests as appropriate. Neuropathological, western blot, and ELISA data for 
protein markers described above were analyzed using ANOVA to determine statistical 
significance. For the lipidomics studies, a mixed linear model regression (MLM), Fisher’s least 
significant difference (LSD) correction, and the Benjamini–Hochberg procedure (B-H) were 
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used for multiple-test corrections and to control the false discovery rate (FDR) for hypothesis 
testing of primary outcomes and as applicable. Barnes Maze data were analyzed using MLM for 
the acquisition trials and ANOVA for the probe trials.  All other behavior tests were analyzed 
using ANOVA. All data were analyzed using SPSS version 22.0.0 (IBM Corporation, Armonk, 
NY). B-H (α = 0.05) was calculated using excel. P < 0.05 was considered to be significant. 
 
2.3 Results: 
2.3.1 Peroxisome-associated VLCFA and BCFA are altered in plasma from veterans with 
GWI  
In a pilot cross-sectional study of age- and gender-matched healthy GW veterans and 
those with GWI, we examined pristanic acid (a BCFA), VLCFAs, and several other free fatty 
acids (FFA). Figure 2.2A shows that levels of VLCFA were significantly increased (F(5,18) = 
2.64, p  = 0.034) in plasma from veterans with GWI compared to control GW veterans. Plasma 
TBARS levels were used as surrogate for MDA measurements since TBARS are formed 
following MDA’s reaction with thiobarbituric acid. Levels of TBARS were two-fold higher in 
GWI compared to control GW veterans (t-test (df= 7) = 2.7, p = 0.004, Figure 2.2B).  Pristanic 
acid levels were decreased in GWI compared to controls (F(2,10) =3.4, p = 0.053, Figure 2.2C). 
An increase in several omega-3 (FA18:3, FA20:5n3, FA 22:5n3) and omega-6 (FA18:2, 
FA20:4, FA22:4 and FA 22:5) FFA was observed in plasma from GWI compared to control 
subjects (Figure 2.2C).  Absolute concentration of these human plasma free fatty acid is 
provided in appendix. 
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Figure 2.2. Plasma free fatty acid profiles in veterans with GWI compared to GW control veterans. Plasma free 
fatty acid were measured using LC/MS. Mean ± SEM (n = 10 for controls and n = 12 for GWI). (A) When all VLCFA 
(≥ C22 fatty acids), were combined as one category, there was an overall increase in GWI compared to control GW 
veterans T-test*p ≤ 0.05. (B) Quantification of lipid peroxidation product TBARS (n = 8 per group for these analyses 
only) showed that levels were significantly elevated in GWI plasma compared to control veterans. T-test*p ≤ 0.05. (C)  
Profiling of FFA showed that while several saturated (no double-bonds) and monounsaturated fatty acids (one double-
bond) were decreased in blood of veterans with GWI compared to controls.  Pristianic acid was decreased in GWI 
compared to controls. The remaining long-chain fatty acids (14-21 carbons) and VLCFA species particularly omega-3 
and omega-6 species, were significantly elevated in veterans with GWI compared to controls. MLM along with BH 
correction *p ≤ 0.05. 
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2.3.2 OEA treatment improves neurobehavioral deficits in a GWI mouse model 
Based on the suggestion of possible peroxisomal b-oxidation dysfunction shown in blood 
samples from GWI subjects described above, I tested whether targeting peroxisomal b-
oxidation with OEA (administered orally in chow at 10mg/kg daily dose) can improve the 
chronic learning and memory deficits observed in a well-characterized mouse model of GWI.  
After GW chemical exposure, mice underwent testing with the FST at 3- and 5-months post-
exposure to establish the presence of GW chemical induced changes in exposed relative to 
control mice. Control and GWI mice were divided into groups which either received oral OEA 
treatment in diet daily or normal diet for a total of six months. Average food intake was 5.75 ± 
0.07 g/day/mouse, and the average consumption of diets was not affect by OEA treatment(p=). 
There was no significant change in body weight among all four groups(Figure 2.4 C). The 
Barnes Maze test was used to assess learning in control and GWI mice after 1-month of oral 
OEA treatment (6-months post-exposure to GW chemicals) and long-term memory after 2-
months of treatment (7-months post-exposure). Learning was assessed during the acquisition 
trials in which mice were allowed to freely explore the maze for 3 min and escape into the 
target box through one of the holes in the platform.  On days 1 and 2, GWI mice travelled a 
longer distance to reach the TH than control mice. However, GWI mice treated with OEA had 
the best performance compared to all other groups (F(1,10) = 12, p = 0.03, Figure 2.3A), having 
the shortest travel time when compared to controls treated with OEA (p < 0.05) as well as 
compared to controls (p < 0.05) and GWI mice on the normal chow diet (p < 0.05). During the 
probe trial at 2-months post-treatment, GWI mice had lowest frequency of visit to the TH 
compared to all other groups (F(1,16)= 11.1, p = 0.02, Figure 2.3B). Oleoylethanolamide treated 
GWI mice had a higher frequency of visiting the TH compared to GWI mice on a normal diet 
(p < 0.05, Figure 2.3B).   
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To test whether OEA corrected fatigue-like behavior in GWI mice, I performed the FST at 
5-months post-treatment. While this test can be used for assessing depression, it is also helpful 
in quantifying fatigue by examining immobility, particularly when mice are repeatedly assessed 
with the FST apparatus 162,163, as is the case here, where all mice were subjected to the FST at 1- 
and 3-months post-exposure (figure 2.4). I also observed at 3-months post-exposure, immobility 
was similar between control and GWI mice for the first 2 min, but the immobility increased in 
GWI mice with time, further suggesting that fatigue emerges with some time delay.  At 5-
months post-treatment (10-months post-exposure), GWI mice treated with OEA were less 
immobile compared to all other groups (F(1,6) = 10.2, p = 0.018; 2.3C), while post-hoc analysis 
showed that OEA treated GWI mice had less fatigue type presentation than GWI mice on the 
control diet (p < 0.05) but mean velocity did not differ between the groups (F(2,6) = 5.2, p = 
0.318, Figure 2.3C).  However, OEA treated control mice were more immobile than control 
mice on normal diet (p < 0.05; Figure 2.3C). Anxiety/disinhibition was tested at 6-months post-
treatment using the elevated plus maze (EPM) test, in which the amount of time spent in the 
closed arm indicates increased anxiety, whereas time spent in the open arms is indicative of 
disinhibition. Relative to all other groups, GWI mice spent more time in the open arms (F(2,6) = 
9.2, p = 0.018, Figure 2.3E); and an influence of OEA treatment was observed whereby the 
time spent in the open arms was reduced in OEA-treated GWI mice (p < 0.001, Figure 2.3E  
and 2.3F ). Control mice on the OEA diet exhibited disinhibition when compared to control 
mice on the normal diet, but no anxiety-like behavior was observed. There was no significant 
change in weight across all 4 groups. 
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Figure 2.3: OEA treatment improves cognitive function, reduces fatigue and disinhibition type behavior 
in GWI mice. Mean ± SEM of control (n = 12), GWI mice (n = 11), control+OEA (n=12) and GWI+OEA 
(n=12). (A) One month after OEA treatment (6-months post-exposure to GW chemicals), acquisition trials were 
conducted to train mice to escape into the TH. In GWI mice treated with OEA, total distance to the TH was 
smallest, particularly on days 1 and 2, indicative of learning.  As expected GWI mice on normal chow had the 
worst performance having the largest total distance to the TH. Control mice treated with OEA had a higher 
latency to find the TH compared to control mice on normal diet on day 2 only. (B) For the probe trials, 
conducted at 2-months post-treatment (7-months post-exposure), OEA treated GWI mice had similar frequency 
of the visits to the TH as control mice on normal chow and on OEA but higher frequency of visits than GWI 
mice.  (C) The immobile time was significantly increased in GWI mice compared to controls which was reduced 
in OEA treated GWI mice. (D) There was no change in average speed among all the different group. (E) An 
examination of the time in open arms of the EPM showed an increase of disinhibition in GWI mice on normal 
chow compared to both control groups and OEA treated GWI mice. (F) Time in closed arm was decreased in 
GWI mice compared with control groups and OEA treated GWI mice. ANOVA with post-hoc tukey *p ≤ 0.05. 
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2.3.3 Elevated levels of VLCFA in the brains of GWI mice were reduced by OEA 
treatment 
         Levels of VLCFA were significantly elevated in the brains of GWI compared to all other 
groups (F(1,13) = 4.4, p = 0.045; Figure 2.5). Compared to GWI mice on normal chow, those 
treated with OEA had lower levels of VLCFA (p < 0.05) and were similar to control mice on 
normal chow (Figure 2.5B, p < 0.05for VLCFA). Level of TBARS were also different between 
0 2 4 6 8 10
0
10
20
30
40
50
                                                                                          months
w
ei
gh
t m
g 
(m
ea
n 
 ±
 S
EM
)
Control + V PB+PER+V 
Control + OEA PB + PER+ OEA 
GW agent 
exposure OEA treatment
C
Figure 2.4 Fatigue-like presentation is observed in GWI-exposed mice. (A) FST data expressed as percent control 
of immobile time ± SEM (n = 24 per group). Total immobile time was significantly decreased in GWI mice at 3-
months post-exposure, but no effect was seen at 1-month post-exposure. (B) At 3-months post-exposure, immobility 
was similar between control and GWI mice for the first 2 min, but the immobility increased in GWI mice with 
time.(C) Body weight showed no change across all 4 hroups. ANOVA with post-hoc tukey *p ≤ 0.05.  
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all experimental groups (F(1,11) =12.4, p = 0.015; Figure 2.5). Post-hoc analysis showed a 
statistically significant increase in TBARS in the brains of GWI mice compared to controls (p < 
0.05) and these levels were lower in GWI mice treated with OEA (Figure 2.5C, p < 0.05). 
Several omega-3 and omega-6 FFA were altered in GWI compared to control mice on normal 
chow (Figure 2.5). OEA-treated GWI mice had levels similar to those observed in control mice 
on a normal diet, whereas levels of these FFA were elevated in control mice treated with OEA 
(Figure 2.5A). Individual species are shown in heatmap below. 
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2.3.4 OEA reduces astroglia and microglia activation in GWI mice 
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Figure 2.5: Brain lipid profiles show OEA improves fatty acids profile in the brain of GW agent exposed 
mice relative to controls. Mean ± SEM expressed as percent control of mice on normal chow (n = 4/5 per group).  
(A) Compared to controls, GWI mice had higher levels of several major omega-6 and omega-3 FA (FA20:4, 
FA22:4. FA22:5, FA24:5 and FA24:6). Treatment with OEA decreased the levels of these FA in GWI mice (B) 
Levels of VLCFA were increased in the brains of GWI mice compared to control mice. OEA treated GWI mice 
had similar levels as in control mice. However, control mice treated with OEA had significantly higher levels of 
VLCFA compared to control mice which received normal diet). (C) Quantification of lipid peroxidation product 
TBARS showed that levels were significantly elevated in GWI compared to control mice on normal chow but were 
lower in OEA treated GWI mice compared to all other groups. ANOVA with post-hoc tukey *p ≤ 0.05 
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Astroglia and microglia, which participate in protecting the brain and modulating 
inflammation 164–167, were upregulated in the brains of GWI mice at long-term post-exposure 
timepoints. Using immunohistochemistry followed by confocal microscopy, an increase in the 
GFAP staining of astroglia was observed in the cerebral cortex (F(1,8) = 4.8, p = 0.034) and the 
dentate gyrus (DG) (F(1,8) = 6.3, p = 0.021) of GW chemical exposed mice compared to all other 
group. Post-hoc analysis showed significant decreased in GFAP staining in OEA-treated GWI 
mice compared to GWI mice on a normal diet (p < 0.05, Figure 2.6, p< 0.05 for the 
hippocampus and p < 0.001 for the cortex). Immunohistochemistry staining with ionized 
calcium binding adaptor molecule 1 (Iba1) staining followed by light microscopy was used to 
examine microglia proliferation and activation, respectively. There was an elevation of 
microglia staining with Iba1 in the dentate gyrus (DG) of GWI mice compared to all other 
groups (F(1,6) = 10.2, p = 0.018; Figure 2.7), whereas OEA-treated GWI mice had much lower 
staining with Iba1 compared to GWI mice on control diet (Figure 2.7, p < 0.05).  
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Figure 2.6: OEA treatment reduced elevated astroglia activation in GWI mice. Confocal microscopy 
images showing staining of astroglia with GFAP (n = 4 per group, 4 serial sections for each animal). Scale bar 
50μm. (A) Images show 20x GFAP staining (red) and DAPI (blue) in the cortex and the DG of mice from all 4 
treatment groups. (B) Images show 100x magnification of GFAP stained astroglia in the cortex of each study 
treatment group. (C) Quantification of GFAP staining from 20x images. There significant increases in GFAP 
staining for both the cortex and the DG within the hippocampus of GWI compared to control mice. GWI mice 
treated with OEA had similar levels as control mice on normal chow. Control mice treated with OEA had 
higher levels than control mice on normal diet. ANOVA with post-hoc tukey * p ≤ 0.05 
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2.3.5 OEA treatment reduces chronic brain inflammation in GWI mice 
In order to determine if NFκB-mediated pro-inflammatory pathways could be inhibited by 
OEA in the brains of GWI mice, I examined the ratios of pNFκB at the p65 subunit to total 
NFκB, pSTAT3, and several pro-inflammatory cytokines. At 11-months post-exposure to GW 
chemicals, corresponding to 6-months of OEA treatment, there was a significant increase in the 
Figure 2.7: OEA treatment reduced microglia proliferation in GWI mice 
Light microscopy images showing staining of microglia with IBA-1 (n = 4 per group, 4 serial section for each 
brain). Scale bar 50μm.  (A) Images show 20x Iba1 staining in the cortex and DG of mice from all 4 treatment 
groups. (B) Images show 100x magnification of Iba1 stained astroglia in the cortex of each study treatment 
group. (C) Quantification of Iba1 staining from 20x images. Levels of Iba1 staining within the DG was lower in 
OEA treated GWI mice compared to GWI mice on normal chow.  Levels of Iba1 in GWI mice were higher in 
the DG compared to control mice. There were no differences in the cortices of GWI mice compared to control 
or OEA treated GWI mice. ANOVA with post-hoc tukey * p ≤ 0.05. 
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ratio pNFκB/NFκB in the brains of GWI compared to all other groups F(1,6) = 8.2, p = 0.012; 
Figure 2.8A), whereas OEA-treated GWI mice had lower ratios compared to GWI mice on 
normal chow (p < 0.001, Figure 2.8 A and B). Since pSTAT3 is thought to enhance the 
activation of NFκB, I examined this protein and found it to be increased in the brains of GWI 
mice across all 4 experimental groups (F(2,10) = 12.42, p = 0.033), and reduced in OEA-treated 
GWI mice compared to GWI mice on normal diet following post-hoc (p < 0.05, Figure 2.8 C 
and D) analysis. Furthermore, several pro-inflammatory cytokines, including IL-1β (F(3,9) = 7.2, 
p = 0.011), IL-6 (F(2,8) = 8.31, p = 0.032), and IFN-g (F(1,7) = 6.12, p = 0.028), were affected by 
GWI status and OEA treatment, where post-hoc analyses showed that these cytokines were 
elevated in GWI mice compared to all other groups and were significantly lower in GWI mice 
treated with OEA (p < 0.05, Figure 2.8E). We also observed significant effect of the GWI status 
and OEA treatment was observed for CCR2 (F(2,8) = 11.32, p = 0.031) and CCL2 (F(2,10) = 
11.14, p = 0.03) at 11-months post-exposure to GW chemicals (Figure 2.8) with post-hoc 
analyses showing increases in the brains of GWI mice compared to control mice and lower 
levels in OEA treated GWI mice (Figure 2.8F, p = 0.049 for CCL2 and p = 0.056 for CCR2). 
Also, Figure 2.9 shows an effect of OEA treatment on PPARα (F(4,10) = 4.12, p = 0.041) and 
PPARγ co-activator 1α (PGC-1α)( F(2,8) = 16.11, p = 0.039) expression, irrespective of GWI 
status. Post-hoc analysis showed that OEA treatment increases PPARα (p<0.05) and PGC-1α 
(p<0.05) in control and GWI mice. 
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Figure 2.8: Levels of phosphorylated NFκB and STAT3 were reduced by OEA treatment in GWI mice. 
Mean ± SEM (shown as densitometric arbitrary units, n = 4 per group). (A-B) Ratio of p-P65)/P65 was 
elevated in GWI mice at 11-months post-exposure. At this time-point, which corresponded with 6-months of 
OEA treatment, GWI mice having OEA treatment had a significantly lower ratio compared to GWI mice on 
normal chow. Control mice treated with OEA had non-significantly lower ratios compared to control mice on 
regular diet. (C-D) Similarly, p-STAT3/Actin levels were significantly elevated in GWI compared to control 
mice and were also lower in OEA treated GWI mice compared to those on normal chow. Levels of STAT3 
were also elevated in control mice treated with OEA compared control mice on normal diet. (E) Among the 
cytokines examined in the brain, IFN-g, IL-6, and IL-1β were lower in OEA treated GWI mice compared to 
GWI mice on normal chow. Mice with GWI had elevated levels of these pro-inflammatory cytokines compared 
to control mice. These cytokines did not differ between control mice treated with OEA compared to control 
mice on normal diet. (F) Treatment with OEA decreased the levels of CCR2 and CCL2 in the brain of GWI 
mice compared to GWI mice on normal chow. ANOVA with post-hoc tukey *p ≤ 0.05.  
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2.3.6 In vitro screening of the drug that reduces Lipopolysaccharides induced NFkB 
activation 
I used OEA, DHEA and PGE2EA at 10μM, 1μM and 100nM along with LPS (10μg/ml) 
to determine if these compounds were able to decrease NFκB phosphorylation induced by LPS.   
There were no significant differences in LDH release from cells treated with vehicle (DMSO), 
LPS and all three tested ethanolamides (p > 0.05). I observed that LPS treated cells had a 
significant increase in pNFκB relative to total NFκB levels when compared to DMSO treated 
cells (F (5,18) =13, p=0.012, Figure 2.10). Compared to LPS alone, LPS with OEA, PGE2EA 
and DHEA treatment had a lower ratio of pNFκB to total NFκB protein levels at 10μM and 
1μM ( p < 0.001). Also, OEA at all dose decreased NFκB phosphorylation relative to LPS 
treatment (p < 0.05, Figure 2.10). However, 100nM PEA along with LPS had a decreasing trend 
in NFκB phosphorylation (p > 0.056, Figure 2.10) when compared to LPS treated cells. (Figure 
2.10).  In this study the most potent drug was OEA and IC 50 of OEA was determined as shown 
in figure 2.11 
Figure 2.9 Western blot analysis of PPAR-a and PGC-1 a protein expression in the brain. Mean ± SEM 
(shown as densitometric arbitrary units, n = 4 per group). There was significant increase in PPAR-a and PGC-1 
a level in the mice feed with OEA compared to non OEA controls. Histogram showing relative levels of each 
of the PPAR-a and PGC-1 a protein in all four groups. ANOVA with post-hoc tukey *p ≤ 0.05 
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2.3.7 Modulation of NFκB and STAT 3 activation by ethanolamides is depended on 
PPARa 
Above, I used OEA at 100nM along with LPS to determine if OEA is able to decrease 
NFκB phosphorylation induced by LPS.   I next tested whether NFkB inhibition by OEA is 
PPARa dependent. As expected, LPS treament significantly increased NFκB phosphorylation 
when compared to all other groups (F(3,16) = 16.14, p = 0.003, Figure 2.11).  Post-hoc analysis 
showed that normalization of OEA effect on NFκB phosphorylation were depended on PPARa 
but not on PPARg (p < 0.05, Figure 2.11) since only the pretreatment of cells with PPARa 
antagonist blocked the anti-inflammatory effects of OEA. Similarly, LPS treated cells had a 
Figure 2.10: Effects of OEA on the NFκB inflammatory signaling pathway in LPS-induced RAW cells. 
Modulation of NFκB activation by ethanolamides. Activation of NFκB, induced by LPS, was reduced by 
different ethanolamides in vitro. Compared to LPS alone, LPS along with OEA, PGE2EA, and DHEA 
significantly decreased this ratio of p-NFκB to NFκB. Cytotoxicity results showed no significant toxicity 
associated with ethanolamide compounds at all doses tested. ANOVA with post-hoc tukey *p ≤ 0.05 
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significant increase in STAT3 (F(3,12) = 18.31, p = 0.012, Figure 2.11) and JAK2 
phosphorylation (F(3,14) = 21.23, p = 0.002, Figure 2.11) across all four groups. Post-hoc 
analyses showed that these effects were similar to those observed for NFκB where only 
pretreatment with PPARa antagonist was able to abolish phosphorylation of STAT3 and JAK2 
(Figure 2.11). 
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Figure 2.11: Anti-inflammatory effect of OEA is depended on PPAR-alpha. OEA shows more potent than 
commercially available PPARα agonist at similar concentration. PPARα blockade showed no anti-
inflammatory effect of OEA and fenofibrate in LPS induced murine macrophage cell. No such effect was seen 
in PPAR-gamma blockade cell line. Cells were pretreated with PPAR-alpha inhibitor (GW 6471) and PPAR- 
gamma inhibitor (GW 1929) for 3 hours and then treated with LPS and OEA. ANOVA with post-hoc tukey *p 
≤ 0.05 
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2.4: Discussion 
Our studies showed that lipids which are specially metabolized in peroxisomes, including 
VLCFA, pristanic acid, and DHA, were altered in plasma from veterans with GWI. These 
findings were supported by our previous studies showing that omega-3 DHA and ether-
containing PL were disturbed in veterans with GWI 76. Our preclinical mouse model studies 
also showed that VLCFA were also elevated in the brains of GWI mice compared to control 
mice. Further supporting possible relevance of impaired peroxisomal β-oxidation or aberrantly 
active biosynthesis of these fatty acids to the pathogenesis of GWI.  Currently, there are no 
approved therapies that can treat the underlying pathology of GWI. The present treatment 
strategies mostly focus on pain management with non-steroidal anti-inflammatory drugs or 
opioids, reducing fatigue with vitamins/antioxidants and targeting mood/cognitive issues with 
antidepressants.  These symptom management approaches do not modify the underlying disease 
process associated with GWI. Hence, there remains a need for developing treatments which 
target the underlying pathobiology of GWI. I used OEA as a stimulator of peroxisomal b-
oxidation and showed that abnormal increases in brain VLCFA, tetracosahexaenoic (a precursor 
of DHA) and DHA levels in GWI mice were normalized after OEA treatment. It is well-known 
that OEA is a potent PPARα ligand, which in itself has various health benefits which include 
weight loss and reduced fatigue 168. These post-treatment changes in GWI mice corresponded 
with reduced brain glia activation and inflammation and improvement in neurobehavioral 
deficits relevant to the clinical symptom presentation of GWI.  
Memory impairment is one of the major complaints among veterans with GWI, and a recent 
meta-analysis comparing results of neuropsychological functioning in veterans with GWI 
across 14 studies has shown that veterans with GWI consistently report cognitive deficits in 
both learning and memory 47,169–175. This is further supported by imaging studies showing 
damage to the brain hippocampal regions in veterans with GWI which may possibly contribute 
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to memory problem observed in ill GW veterans 176–178. Another recent study of 
neuropsychological functioning in military pesticide applicators from the GW reported worse 
memory functioning in veterans exposed to pesticides and personal repellents during the war 
compared to healthy GW veterans 179. Animal studies have consistently shown chronic 
impairment in learning and memory in several rodent models of GWI 44,51,53,54,157,180. Our 
current studies show that even after a couple of months of OEA treatment, GWI mice 
performed far better on both learning and memory-related tasks compared to all other groups, 
which is consistent with the currently known effects of OEA on cognition 145,149,181 and may be 
of therapeutic value in GWI.  
Other non-cognitive behavioral features were examined in this study with a particular 
emphasis on fatigue since clinical studies show that fatigue is one of the major symptoms of 
GWI, reported by nearly 79% of veterans with GWI 1,154,172,173. This is supported by an imaging 
study showing altered axial diffusion patterns within brain areas which link cortical regions 
involved in pain, fatigue, and cognition in a subset of veterans with GWI 22.  At 1-month post-
exposure, there was no difference between GWI and control mice on immobility during the 
FST, indicating no change in fatigue parameters. Interestingly, I detected increased immobility 
in GWI mice with repeated exposure to the FST apparatus at 3-months and a further increase at 
10-months post-exposure. Interesting, such effects were alleviated in GWI mice after 5-months 
of OEA supplementation.  At this 10-month post-exposure timepoint, there were no indications 
of anxiety on the EPM and no locomotor problems or increased perimeter activity on the OFT 
in GWI mice. Instead, our findings on the EPM indicate disinhibition in GWI mice, evident by 
the fact that GWI mice were spending more time in the open arms of the EPM, which is 
consistent with a previous study reporting disinhibited behavior in the same model at 13-
months post-exposure to GW chemicals 53. Disinhibition is suggested to be a consequence of 
lesions in the hippocampus and inhibition of dorsal hippocampal functioning182,183. Collectively, 
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these behavior studies suggest that OEA treatment may help with reducing cognitive deficits 
and fatigue in veterans with GWI.  
Consistent with previous studies 51,53,157, I observed astroglia activation in both the cortex 
and hippocampus of GWI mice which were reduced by OEA treatment. As before, Iba1 
staining was increased in the hippocampus of GWI mice when it was examined at 16-months 
post-exposure 54. This increase was also normalized after OEA treatment in GWI mice.  As can 
be seen, astroglia to be key pathologies in GWI along with microglia proliferation with age. 
These finding are  replicated in several rodent models of GWI 51,53,54,157. We do observe, 
astroglial activation was observed at 5-, 16- and 22-months post-exposure 54,184, whilst increased 
Iba1 staining, generally associated with microglia proliferation can only be seen at 11-months 
post exposure but not at any earlier timepoints, despite the presence of robust 
neuroinflammation. In fact, a role of astroglia involvement in GWI was suggested by an 
imaging study showing abnormal lactate utilization in subsets of GWI veterans 22,110. While 
previously thought to serve in a supportive capacity within the CNS, recent studies have shown 
that astroglia also play a prominent role in regulating the innate immune responses in the brain 
by releasing chemokines which facilitate activation, migration, and proliferation of microglia 
185,186.  Given that astroglia activation in this GWI model precedes changes in microglia, it is 
possible that the observed increase of microglia cells in the hippocampus may be a result of 
increased migration to control ongoing immune and inflammatory responses, which warrant 
further investigation. However, it is unclear why microglia activation is undetectable in this 
model until very late stages.  
While both astroglia and microglia can release monocyte chemoattractant protein-1 (MCP-
1/CCL2), in conditions with an active immune component and an absence of obvious neuronal 
damage, astroglia appears to be the major producers of CCL2 187. Our current study shows that 
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CCL2 levels are chronically elevated in GWI compared to the control which is consistent with 
findings of increased mRNA of this protein in another mouse model of GWI that was exposed 
to an organophosphate pesticide179. Release of CCL2 helps recruit brain macrophage/microglia 
to the damaged area and attracts CCR2 expressing monocytes from the periphery in response to 
injury or chemical exposure 188,189, contributing to inflammation via CCR2 activation through 
NFkB and STAT3 pathways 190,191. Given that myself and my colleagues do not observe an 
overt neuronal death in our GWI mice at any of the chronic post-exposure timepoints 53,54,157, the 
increase in CCL2 is likely due to inflammation rather than cell death. Consistent with these 
studies, I also observed increases in phosphorylation of NFkB and STAT3 in the brains of GWI 
mice, which corresponded with an increase in several pro-inflammatory cytokines, such as IL-
1b, IL-6, and IFN-g. Increases in serum levels of these cytokines are also observed in veterans 
with GWI compared to control veterans 103,104,192. 
Treatment with OEA can potentially alleviate the inflammatory aspects of GWI described 
above. This can be supported by our studies showing that OEA exerts anti-inflammatory effects 
in GWI by inhibiting NFkB activity and downregulating many pro-inflammatory cytokines. 
However, metabolism of OEA by fatty acid amide hydrolase (FAAH) may target the brain 
cannabinoid receptors and, as such, some of the observed effects of OEA could be mediated by 
these alternative pathways and warrant further evaluation 193.  Furthermore, given this impact of 
OEA on the endocannabinoid system, translation of OEA treatment into humans in the context 
of cannabinoid use may produce adverse effects and will require close monitoring. One 
limitation of this study is that OEA also affected the lipid homeostasis in control mice treated 
with OEA which corresponded with the lowered anxiolytic response and higher immobility in 
the FST.  Despite that, I did not observe any adverse effect on memory or increase in lipid 
peroxidation and inflammation in these mice. However, given the role of OEA in lipid 
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metabolism and reducing inflammation, increasing its level in the absence of underlying 
inflammation or metabolic dysfunction warrants further examination. Our work into the 
mechanism of these effects suggests that PPARα and PGC-1α elevation could have contributed 
to possible increases in peroxisome proliferation and mitochondria biogenesis and that increases 
in lipids could be a reflection of these changes 194–196. I do expect that additional 
pharmacokinetics and pharmacodynamic studies will help identify a safe and effective dose for 
chronic administration in veterans with GWI. 
The recent study in Roskamp institute support that activation of astroglia along with lipid 
dysfunction corresponds with peroxisomal dysfunction. As I already know peroxisome is a very 
important site for metabolism of VLCFA. I also see some evidence of peroxisome dysfunction 
in our study from the total fatty acid. As I observe the change in branched chain fatty acid 
(pristanic acid) which suggests peroxisomal dysfunctions.  Phytanic acid in the human body is 
mainly derived from diet is still unknown how they are translocated in the peroxisome 197,198. 
Once inside the peroxisome, phytanoyl-CoA is metabolized by phytanoyl-CoA hydroxylase and 
is converted into 2-hydroxyphytanoyl-CoA, which again metabolized by aldehyde 
dehydrogenase to form pristanic acid 198. Decrease in pristanic acid suggest decrease in 
expression or activity of these enzyme which are specific to peroxisome. 
I also investigated other ethanolamides which act as PPARα agonist to improve 
peroxisomal functions 199. PPARα activation leads to NFkB inhibition so, I also checked this in 
vitro to select an appropriate bioactive compound 200. I used OEA, AEA, PGE2EA at 10μm, 
1μm, and 100nM concentration to investigate their anti-inflammatory properties, evident by 
reduced NFkB activation. Our study suggests that most of these compounds reduce LPS 
induced activation of NFkB phosphorylation. Among all of them OEA was the most potent in 
reducing  LPS induced NFkB activation via PPAR-α 199.  
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As reported by other studies, I also observed that OEA ability to reduced inflammation was 
depended on PPARα. This was confirmed because since our in vitro studies showed that 
PPARα inhibition prior to OEA administration did not reduce NFkB phosphorylation after LPS 
treatment. But I do not see a similar effect of OEA if PPAR-g was inhibited. Peroxisomes and 
mitochondria are related with each other in term of function specially metabolizing fatty acid. 
They both interact with each other and play a major role in cell metabolism of the different 
metabolite. As mentioned above, mitochondria and peroxisomes are small organelles 
ubiquitously present in every cell and are functionally coupled, despite differences in their 
general physiological roles.  The interaction of these two organelles is necessary for optimal 
cell function and maintain lipid homeostasis. Also, I observed this in our study that PGC1α 
increased with targeting PPAR-α. It is well known that PGC1α is master regulator of 
mitochondrial function and biogenesis 201. Taken together, our finding supports the idea that 
peroxisomal and mitochondrial activity are co-regulated at the transcriptional level in a PPARα 
and PGC1α-dependent manner. Since preclinical and clinical studies have suggested an 
imbalance of lipid homeostasis and lipid metabolism dysfunction. So, another strategy to treat 
this disease to target mitochondrial function and biogenesis. 
2.5 Conclusion: 
This study provides support for restoration of lipid profiles associated with improved 
peroxisome function following OEA treatment, which corresponds with improvements in 
neurobehavioral symptoms relevant to GWI. These studies also show that OEA treatment leads 
to a reduction of brain inflammation in our well-characterized mouse model of GWI, a 
pathology that is highly relevant to the etiology of GWI. These data provide critical support for 
future translational studies to find an optimal and safe dose of OEA for treating subjects with 
GWI. 
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2.6 Graphical summary of our working hypothesis
 
Figure 2.12. OEA reduces brain inflammation in GWI mice. We propose that targeting peroxisome 
with OEA reduces astroglia activation which corresponds with normalization of peroxisomal lipid 
metabolism. 
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Chapter 3: Mitochondrial function and/or biogenesis as a potential target for therapeutics 
of Gulf War Illness (GWI) 
 
3.1 Introduction     
Mitochondria are responsible for the maintenance of cellular bioenergetics and 
reduction oxidation (redox) balance and also play a critical role in lipid metabolism. 
Impairment of mitochondrial function can cause homeostatic dysfunction, impeding the normal 
physiological processes of the cell.  Mitochondrial dysfunction can lead to chronic activation of 
the proinflammatory cellular cascades 202.  As discussed in Chapter I, mitochondrial 
dysfunction is a consistent feature of GWI and has been suggested in multiple studies as an 
explanation for the most common symptoms of GWI, which include memory and learning 
impairments and chronic fatigue 1.  These findings are in line with our previous studies showing 
a persistent presence of cognitive deficits and fatigue-like behavior over several chronic post-
exposure timepoints in our well-characterized mouse model of GWI 78. Therefore, development 
of interventions that restore a healthy physiological bioenergetic profile represents a promising 
and potentially beneficial strategy for altering GWI associated lipid dysfunction and cognitive 
and behavioral deficits.  
 
Mitochondrial disturbances in patients with GWI are characterized by changes in plasma 
acylcarnitine levels indicative of disturbances in fatty acid transport or metabolism and 
bioenergetic processing, such as the inability to recover phosphocreatine levels in muscle after 
exercise as well as impaired lactate utilization in the brain22,54,91,203. Additional evidence for the 
CNS bioenergetic disturbances in GWI comes from animal studies showing decreases in the 
Krebs cycle intermediary compounds54, and downregulation of pathways related to the 
conversion of pyruvate to lactate and gluconeogenesis. Collectively, these studies suggest that 
mitochondrial bioenergetic disturbances following exposure to GW chemicals is a critical 
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aspect of GWI pathogenesis104–107,204,205. Mitochondrial bioenergetic disturbances lead to an 
accumulation of ROS via a decline in complex I activity, which coincides with increased lipid 
peroxidation followed by increased production of inflammatory cytokine via activation of 
NFkB 206–208.  We hypothesize that GW chemicals disturb CNS bioenergetics performed by 
mitochondria which may impair cellular redox balance and promote chronic 
neuroinflammation. As such, the focus of this current work is to identify interventions that can 
target the brain bioenergetics and determine the efficacy of such therapies in treating the CNS 
symptoms and pathology of GWI in a mouse model.  
 
One of the treatment strategies that I tested as part of my thesis work was to supplement 
mouse diet with the NAD+ precursors, nicotinamide riboside (NR). In the cell, NR is converted 
to NAD+ by an enzyme nicotinamide riboside kinase (NRK) 209. Treatment with NR may be a 
valuable therapeutic approach due to its high bioavailability, minimal toxicity, and evidence of 
its ability to cross the BBB 210. In a pilot human study, level of NAD+ rose by 3-fold after a 
single oral dose of 300mg of NR 210. NAD+ is a critical component in a plethora of cellular 
functions performed within mitochondria. NAD+ and its reduced forms, including NADH are 
crucial in cellular metabolism and energy production 211,212. NAD+ is used in energy-generating 
catabolic reactions such as the Krebs cycle, where it is initially reduced to NADH which then 
serves as an electron rich molecule that take part in OXPHOS ultimately contributing to ATP 
generation.  During OXPHOS, NAD+/NADH only shuttle electrons and they are not consumed 
during this process. However, NAD+ is actively consumed during the enzymatic processes that 
are carried out by sirtuins (Sir T), which are deacetylase enzymes that catalyze protein 
deacylation reactions. Sirtuins are able to bind NAD+, and deacetylation of acetyllysine in 
cellular protein occurs by nucleophiles reaction via deacetylase 213.  In this deacetylation 
reaction, nicotinamide and 2’-O-acetyl-ADP-ribose are generated 214.  Sirtuins undergo 
alternative pathway where NAD + is also used as a substrate to generate ADP-ribosylated 
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products and nicotinamide via mono-ADP-ribosyl transferase 215. Nicotinamide can be recycled 
back to NAD+ by first being converted to nicotinamide mononucleotide  by nicotinamide 
phosphorybosyltransferase (NAMPT) and then eventually to NAD+ by nicotinamide 
mononucleotide adenylyltransferase (NMNAT)216. As NAD+ and NADH are required for 
Krebs cycle and ETC respectively, an ideal NAD+/NADH ratio is needed for proficient 
mitochondrial metabolism. Many studies have shown that metabolic disease are influenced by 
mitochondrial NAD+/NADH ratio 217,218. Intervention with NR is able to restore NAD+ 
availability and improve oxidative metabolism, resuting in a significant enhancement of 
mitochondrial NAD+/NADH ratios 219,220 
 
Literature suggests that NAD+ increases the expression of the sirtuin protein family 
(SirT1 and SirT3)219. The increased expression of these proteins has the potential to reduce 
inflammation via NFkB mediated pathways and increase mitochondrial health and biogenesis 
by PGC-1a dependent pathway220–222. Supplementation with NR reduces inflammation and 
attenuates neuropathological phenotypes through SirT1-mediated deacetylation of the NFκB 
pathway in animal models of neurological disorders such as alzheimer's Disease220,223. 
Administration of NR decreases oxidative stress via the NAD+/ SirT1 signaling or via 
increasing autophagy 224,225.  Hence NAD+ is critical for mitochondrial function, health, and 
biogenesis, as well as in the ETC 226. As described above, GWI is associated not only with 
mitochondrial dysfunction but also neuroinflammation and glia activation is a common feature 
of the chronic CNS pathology of GWI. Others have shown that NR treatment enhances 
cognitive functioning and reduces neurotoxicity and glial cell activation220,227. As such, I 
believe that by targeting mitochondrial dysfunction with NR, I may be able mitigate 
neuroinflammation and improve mitochondrial functioning in GWI mice.   
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While glucose is the primary energy source which fuels the Krebs cycle in the brain, 
availability of free fatty acids in neurons and their subsequent metabolism fulfills bioenergetic 
requirements when glucose supply is low or during high neuronal activity 228. β-oxidation of 
FFA yields acetyl-CoA molecules for the Krebs cycle to generate ATP 228. Lipid peroxidation 
often follows lipid accumulation due to reduced fat oxidation capacity 229. As a consequence, 
lipid metabolites may become unavailable to meet neuronal energy demands.  As lipid 
accumulation and peroxidation was observed in our GWI mouse model as well as reduced 
levels of several compounds from the Krebs cycle54,65,78, we opted to explore ketogenic diet 
(KD) as another approach for targeting mitochondrial bioenergetics.  This type of diet mimics 
the metabolic profile of fasting and has provided some promising results when tested as an 
intervention in animal models of neurological disorders 230,231. Ketogenic diets generally 
contain high fat and low carbohydrate content232. Prolonged feeding with KD leads to ketosis 
which increases the ketone bodies specially β-hydroxybutyrate (βHB) in the liver233–235, which 
are subsequently used as the source of acetyl-CoA to fuel the Krebs cycle, thereby replacing the 
need for glycolysis of glucose to generate acetyl-CoA236. We therefore also investigated if KD 
can reduce the CNS pathology in our mouse model of GWI.   
Work described below examines how the NAD+ and βHB levels were affected in 
veterans with GWI and in GWI mice. We also show an impact of NR and KD interventions on 
these metabolites, markers of mitochondria function and biogenesis as well as glia activation 
and neuroinflammation in a GWI mouse model.  
Hypothesis: Mitochondrial dysfunction is associated with numerous CNS illnesses 
including GWI. Mitochondria dysfunction in GWI is associated with decreased in bioenergetics 
specially NAD+ and BHB which in turns effects lipid metabolism. Since there is sufficient data 
to suggest that certain aspects of mitochondrial specific lipid metabolism are altered in our GWI 
mouse model and in GWI patients, we hypothesized intervention that increases NAD+ and 
BHB may lead to potential therapies for this complex and chronic disease. 
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Specific Aim 1: To determine if therapeutic intervention that increase NAD+ such as NR is 
beneficial for GWI 
Aim 1A: To determine if NR treatment increases bioenergetic along with improves lipid 
metabolism in mice model. 
Aim 1B: To determine if NR treatment increases decreases chronic inflammation as well as 
neuropathology associated with GWI. 
Aim 1C: To identify possible mechanism of action associated to NR treatment in GWI mice 
model. 
Specific Aim 2: To determine if therapeutic intervention that increase BHB such as ketogenic 
diet is beneficial for GWI 
Aim 1A: To determine if KD treatment increases bioenergetic in mice model. 
Aim 1B: To determine if NR treatment increases decreases chronic inflammation as well as 
neuropathology associated with GWI. 
Aim 1C: To identify possible mechanism of action associated to NR treatment in GWI mice 
model. 
 
3.2 Methods: 
3.2.1 Human subject: 
Recruitment process is previously described in chapter 2. The study was approved by 
the Institutional Review Board (IRB) at Roskamp Institute. The  protocol and procedures were 
carried out in accordance with the Declaration of Helsink 237. An IRB-approved informed 
consent was provided to each potential participant, and a signed consent was obtained from all 
participants. Six healthy GW-deployed veterans and 12 GWI veterans volunteered in this study. 
The Kansas GWI criteria were used to diagnose GWI 6. It is assumed that all the subject were 
fasting when blood was withdrwan, no data on Diabetes medation were avilable. Diagnostic and 
recruitment criteria is also explained previously in chapter 1.  The Kansas GWI criteria require 
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that GW veterans show symptoms in at least 3 out of 6 symptom domains (fatigue/sleep 
problems, somatic pain, neurological/cognitive/mood symptoms, gastrointestinal symptoms, 
respiratory symptoms, and skin abnormalities). Study participants were excluded if they 
reported being diagnosed with another medical condition that could explain their chronic health 
symptoms. Veterans who volunteered for the study were interviewed in person. After the 
interview blood samples were obtained as described previously. Detailed demographics of the 
study are provided below in table 3. 
 
Table 3. Demographics of the Gulf War veteran cohort. 
 
 Control (GW veteran) GWI 
 
N total 6 12 
Age (Mean ± SEM) 59.3 ± 2.6 56.1 ± 1.6  
Male (%) 100 100 
Ethnicity   
Caucasian 
African American 
Hispanic 
Asian 
5(50%) 
1(10%) 
0(0%) 
0(0%) 
8(66.6%) 
2(16.7%) 
2(16.7%) 
0(0%) 
 
 
3.2.2: Animal Handling:  
All procedures on mice were approved by the Roskamp Institute’s Institutional Animal 
Care and Use Committee and were conducted in compliance with the Office of Laboratory 
Animal Welfare and Laboratory Animal Care guidelines performed as previously described 
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53,157. Mice were maintained with a 12h light/dark cycle in a temperature-controlled 
environment (21± 2 ℃). Male C57BL/6 mice (3 months of age, weight 25 g ± 0.7 SD) were co-
administered 0.7 mg/kg of PB (Fisher Scientific, Hanover Park, IL) with 200 mg/kg of PER 
(Sigma Aldrich, St. Louis, MO) in a single 50μl intraperitoneal injection in dimethyl sulfoxide 
(DMSO) (Sigma Adrich, St. Louis, MO) or DMSO alone (as control) daily for 10 consecutive 
days. 
After 6 months post-exposure to GW chemicals, a treatment regimine was initiated 
where mice were either on normal chow diet (Teklad rodent diet , Envigo, Madison, # 2018) 
that comprised of 58.2% carbohydrate, 10.6% fat and 19% protein by calorie was used as 
regular chowfed with NR (100μg/kg) in their diet (MedKoo Biosciences, Research Triangle 
Park, North Carolina # 329479 ) or fed with NR in the same diet. Mice were separated into 4 
groups; one cohort receive NR treatment in their diet for two months. Mice were divided into 4 
groups: control mice +regular diet, control mice+NR, GWI mice+regular diet and GWI+NR. 
Mice were euthanized 2 months after the NR treatment; a timeline of the study procedures is 
provided as Figure 3.1A. All animals were randomized to the various groups and were not 
deprived of food before eutheneisa. Average food intake was 5.32 ± 0.09 g/day/mouse, and the 
average consumption of diets was 0.09 ± 0.015 g/day/mouse. Randomization was performed in 
all neuro behavioural experiment, experimenter were blinded GW treatment but not diet. Mice 
were not deprived of food before euthenesia. 
For another cohort, 6 months after GW chemical exposure, mice were fed with either 
the KD or normal chow diet listed above. Mice were divided into 4 groups: control mice + 
normal diet, control mice +KD, GWI mice+ normal diet and GWI mice+KD. The Ketogenic 
Diet (Envigo, Madison, # TD.96355) was comprised of 0.5% carbohydrate, 67% fat and 13.4% 
protein by calorie. Mice were euthanized approximately 1.5 months after the KD treatment; a 
timeline of the study procedures is provided as Figure 3.1B. All animals were randomized to the 
various groups and were not deprived of food before eutheneisa.  
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Figure 3.1A: Timeline of NR study design 
 
  
 
 
Figure 3.1B: Timeline of KD study design 
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Forced swim test 
We performed FST as described in chapter 2 and as described elsewhere78,  Since our 
previous work showed that fatigue-type behavior emerges after a few minutes of swimming 
during the FST, we split the entire duration of FST into two halves, first half (2-4min) and 
second half (4-6min). The difference between the two halves is denoted as delta immobile time 
(Δ).  Δ immobile time = immobile time[second half-first half].  
 
3.2.3 Sample preparation 
Mice were exsanguinated via cardiac puncture using an 18-gauge wide-bore needle to 
prevent hemolysis of RBC during blood collection. Blood samples were collected into 1.5ml 
Eppendorf tubes containing 10 units of EDTA to a final concentration of 1x. Samples were 
immediately centrifuged at 3000 x g for 5 min, and the plasma was transferred to a new 1.5 ml 
Eppendorf tube and snap frozen in liquid nitrogen. Plasma samples were stored at -80˚C until 
further biochemical studies were performed. Subsequently, all animals were perfused with PBS, 
and right hemispheres were immediately frozen in liquid nitrogen and transferred to a -80˚C 
freezer until further use. Using a dounce homogenizer, brains were homogenized in chilled lysis 
buffer containing a protease inhibitor cocktail (Roche, Indianapolis, IN) and phosphatase 
inhibitor (Pierce, Grand Island, NY) cocktails. The total protein content of each sample was 
determined by the bicinchoninic acid assay (BCA assay, Pierce, Grand Island, NY). 
 
3.2.4 Western Blot 
Western blotting was performed as described in previous chapter. List of primary 
antibodies used is provided in the table below. Horseradish peroxidase–conjugated appropriate 
secondary antibodies and loading control anti–β-actin antibody was obtained from Cell 
Signaling, Danvers, MA. The blots were analyzed as described previously. 
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Table 4A: List of Antibodies used for Western Blot analysis: 
Antibody used Dilution Company 
SirT1 1:1000 Cell Signaling 
Sir T3 1:1000 Cell signaling 
Phospho p65 (NF-κB subunit) 1:1000 Cell signaling 
Total p65(NF-κB subunit) 1:1000 Cell signaling 
Phospho STAT3(Signal 
transducer and activator of 
transcription 3 ) 
1:1000 Cell signaling 
Total STAT3 1:1000 Cell signaling 
Uncoupling protein 2(UCP-2) 1:800 Cell signaling 
PGC-1 alpha 1:800 Cell signaling 
Cytochrome C 1:1000 Cell signaling 
Acetylated lysine 1:500 Cell signaling 
Actin 1:5000 Cell signaling 
 
 
3.2.5 Mitochondrial isolation and protein analysis 
Mitochondria were isolated by a commercially available kit from Miltenyl Biotech 
(Gladbach, Germany). After tissue lysis mitochondria was isolated according to manufacture 
protocol. Briefly, mitochondria was magnetically labelled with translocase of the outer 
membrane (anti-TOM-2) antibody; this antibody recognizes mitochondrial surface proteins. 
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These samples were then allowed to pass through a column under the magnetic field of 
MidiMACS (Miltenyl Biotech, Gladbach, Germany). After several washes, only magnetically 
labelled mitochondria remain in the column which was finally eluted to obtain functional 
mitochondria. These mitochondrial preps were used in Western Blots against different 
mitochondrial proteins involved in mitochondria biogenesis, such as PGC-1α (1:1000, Cell 
Signaling, Danvers, MA) and uncoupling protein 2 (UPC-2) (1:1000, Cell signaling, Danvers, 
MA ), whereas cytochrome C (1:1000, Cell Signaling, Danvers, MA) was used for 
normalization. Mitochondrial biogenesis was measured by expression of PGC-1α in 
mitochondrial fraction238. 
 
 
3.2.6 Immunoprecipitation of SirT1, PGC-1α and p65 
Sirtuin 1 is an NAD+ dependent deacetylase which regulates metabolism and 
inflammation239. To determine if SirT1 interacts and deacetylates PGC-1α and p65 (NFκB 
subunit), we performed pull down experiments. Briefly, using a dounce homogenizer, left 
hemisphere was homogenized in 1ml of mPER (Thermo Fisher Scientific, Waltham, MA) 
containing a protease inhibitor cocktail (Thermo Fisher Scientific, Waltham, MA). 200μl of 
PBS was added in 100μl brain homogenate and then centrifuged at 21 x g, 4°C, 15 min. 
Supernatant was collected and combined with 500μl methanol and again centrifuged at 21 x g 
4°C, 15 min. 200μl Triethylammonium bicarbonate (TEAB) buffer was added to pellet 
(cytosolic fraction). Primary antibody (p65 or Sir T1) was added at 1:100 to the cytosolic 
fraction and incubated with gentle rocking overnight at 4°C. This antibody complex was 
incubated for 20 min at room temperature with pre-washed magnetic bead pellet (Cell 
Signaling, Danvers, MA). Beads were pelleted with a magnetic separation rack (Cell Signaling, 
Danvers, MA). Pellet was washed several times before adding 30μl of 3X SDS sample buffer. 
Samples were then boiled for 5 minutes, beads were pelleted and the collected supernatant 
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underwent SDS-PAGE analysis.  Proteins were transfer on a PVDF membrane and probed with 
primary antibody. HRP-conjugatef secondary antibody was used to detect protein of interest. 
List of antibodies used is provided in the table below 
Table 4B: List of Antibodies used for Western Blot analysis: 
 
Antibody used Dilution Company 
SirT1 1:1000 Cell Signaling 
Acetylated p65 (K310) 1:1000 Cell signaling 
p65 (NF-κB subunit) 1:1000 Cell signaling 
Acetylated-Lysine Antibody 1:500 Cell signaling 
PGC-1 alpha 1:1000 Cell signaling 
 
 
 
 
3.2.7 Enzyme-Linked Immunosorbent Assay 
To assess the impact of NR diet on inflammatory pathways, we also examined C-C 
chemokine receptor type 2 (CCR2) and its ligand, CCL2, as well as fractalkine receptor 
(CX3CR1). Mouse CX3CR1, CCL2 and CCR2 Enzyme-Linked Immunosorbent Assay 
(ELISA) kits from Lifespan Biosciences were used for the detection of these proteins in the 
samples. The total protein content of each sample was determined by the bicinchoninic acid 
assay (BCA assay, Thermo Fisher Scientific, Waltham, MA). These procedures were performed 
following the manufacturer’s instructions. Approximately 1ml of sample diluent was added to 
the lyophilized protein provided by the manufacturer and allowed to incubate for 10 min with 
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gentle agitation, and then serial dilutions were performed following the manufacturer’s 
instructions. Sample at 1:4 dilution and standard were added to the capture antibody-coated 96-
well plate and then incubated for 90 min at 37°C. Subsequently, biotinylated detection antibody 
was added to each well and gently agitated to ensure thorough mixing. The ELISA plate was 
incubated again for 1 hour at 37°C followed by washing, and then HRP-conjugated antibody 
was added to each well followed by a 30-min incubation at 37°C. Tetramethylbenzidine (TMB) 
Substrate solution was added to each well and incubated for 15 min, and the reaction was 
stopped by adding the stop solution. The optical density (OD 450 nm) of each well was then 
immediately determined using a microplate reader. This procedure was followed for all 
CX3CR1, CCL2 and CCR2 ELISAs. Intra-Assay: CV<10.6% Inter-Assay: CV<12.6% for all 
the ELISA. There was no reported cross reactivity with other proteins for the primary antibody 
used in these kits. 
 
3.2.8 Cytokine Assay 
We examined pro-inflammatory cytokine levels, which included IFN-γ, IL-1 β, IL-10, 
IL-6, and TNF-α, were quantified using commercially available ELISA kits. Lifspan 
Biosciences (Seattle, WA) ELISA kits were used to quantify IFN-γ (LS-F5065), IL-10 (LS-
F9770) and IL-6 (LS-F2478) (Lifspan Biosciences, Seattle, WA). IL-1β and TNF-α (KMC0011 
and BMS607-3) were quantified by using commercial ELISA kits (Thermo Fisher Scientific, 
Waltham, MA). All procedures were performed as per the manufacturer’s instructions. 
Cytokine concentrations were normalized against the total protein content determined by BCA. 
Results were then expressed as a percentage to control. There was no reported cross-reactivity 
with other proteins for the primary antibody used in these kits. Intra-Assay: CV<10.6% Inter-
Assay: CV<12.6% for all the ELISAs. There was no reported cross-reactivity with other 
proteins for the primary antibody used in these kits. 
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3.2.9 Multiplex Cytokine assay 
Selected cytokine levels in the plasma and brain were analyzed using Meso Scale 
Discovery (MSD) 96-Well MULTI-SPOT®Ultra-Sensitive V-PLEX Proinflammatory Panel 1 
Mouse Kit, using electrochemiluminescence detection on an MSD Sector Imager™ 6000 with 
Discovery Workbench software (version 3.0.18) (MSD®, Gaithersburg). Cytokines were 
measured using the TH1/TH2 8-plex kit, which included 8 markers: IFN-γ, IL-1β, IL-2, IL-4, 
IL-5, IL-10, IL-13 and TNF-α. All assays were performed according to manufacturer’s 
instructions in duplicates. Plasma samples were diluted 1:2 and added to the plate which 
contained the capture antibody immobilized on a working electrode. Following incubation for 1 
hour, SULFO_TAG labeled detection antibodies were added to the wells. Finally, MSD buffer 
was added which developed electrochemiluminescence, and the plate was loaded into an MSD 
instrument for reading. Data were acquired using a SECTOR S 6000 plate reader (MSD). 
Results were then expressed as the percentage to control. 
 
3.2.10 Thiobarbituric Acid Reactive Substance assay 
Plasma and brain levels of malondialdehyde (MDA) were measured using a 
Thiobarbituric Acid Reactive Substance (TBARS) formed during the reaction of MDA with 
thiobarbituric acid. Oxidative stress in the cellular environment results in the formation of 
highly reactive and unstable lipid hydroperoxides. TBARS are formed as a byproduct of lipid 
peroxidation (i.e. as degradation products of fats) which can be detected by the TBARS assay. 
Levels of MDA in brain homogenates were measured using a TBARS Assay Kit (Cayman 
Chemical, Ann Arbor #10009055) as per the manufacturer’s protocol. At boiling temperature, 
oxidized lipids produce MDA which can be measured calorimetrically at 530–540 nm. 
 
 
3.2.11 β-Hydroxybutyrate (β-HB) assay 
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β-Hydroxybutyrate are ketone bodies generated following complete beta-oxidation of 
fat and, they are expected to be generated following ketogenic diet given the high fat content. 
We examined β-HB levels in the brain, liver and plasma were determined by using 
commercially available kits as per manufacture’s instruction (BioVision, San Francisco#K632). 
Brain and liver concentrations were normalized to total protein content determined by BCA.  
 
3.2.12 Nicotinamide adenine dinucleotide (NAD+) assay 
Nicotinamide adenine dinucleotide (NAD+) is a co-enzyme and is involved in redox 
reactions. As a result of electron transfer, NAD+ is reduced to NADH, and NADH is oxidized 
to NAD+ forms. NAD+ levels were measured using a commercially available quantitation kit 
(Cloud Clone, Houston# CEG409Ge). Briefly, NAD+ were extracted by using extraction buffer 
supplied with the kit. The amount of NAD+ present in the samples were determined by NAD 
cycling enzyme. Brain NAD+ levels were normalized against total protein content determined 
by BCA. 
 
3.2.13 Acylcarnitine analyses 
Acylcarnitine profiling was performed for the biochemical screening of disorders of 
fatty acid oxidation (FAO) and in some metabolic disorders. Acylcarnitine analysis is also a 
process that is dependent on positive identification of biomarkers through mass spectrometry. 
Aclycarnitine was extracted as described previously54. Briefly, 5 μl of labeled internal standard 
mix (Nsk-b-1, Cambridge isotope laboratories, MA, USA) were spiked into 100μl of brain 
homogenate. Carnitine was extracted by adding 1000μl of 25% methanol in acetonitrile (ACN) 
followed by centrifugation at 20,000 x g for 20 min at 4 °C. Extracts were dried and then 
resuspended in 100μl of mobile phase A and centrifuged for 5 min at 10,000 x g. Supernatants 
were subjected to LC/MS using a 2.1mm ID x 50mm Kinetex HILIC column containing 1.7 μm 
particles (Phenomenex, Torrance, CA, USA). A gradient was run from 95% solvent A (ACN: 
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water:100mM ammonium formate,90:5:5 v/v) in 5% solvent B (ACN: water:100mM 
ammonium formate,50:45:5 v/v) to 70% B in 10 min with a 10 min hold at the final conditions. 
The flow rate was 250μl/min with the column temperature at 40°C. Data was acquired by full 
scan MS in positive and negative modes with a mass range of 130-2000 m/z (13 uscans/sec, 
spray voltage: 1500V, resolution: 17,500, max inject time: 200msec). 
TracefinderTM software (Thermo Fisher Scientific, Waltham, MA) was used for peak 
identification and integration for acylacrnitine species in each run. Target compound lists of 
expected analytes for each chosen acylcarnitine class were used to find peaks of interest with 
ion windows of 5 ppm mass accuracy for the expected ions.  
 
Table 5: Gradient Program for acylcarnitine 
Time % Solvent A % Solvent B Flow Rate 
(ml/min) 
0.10 80 20 0.250 
5.00 88 22 0.250 
10.00 60 40 0.250 
13.00 40 60 0.250 
15.00 20 80 0.250 
15.01 1 99 0.250 
20.00 1 99 0.250 
20.01 80 20 0.250 
25.00 80 20 0.250 
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3.2.13 Statistical analyses 
 For the human study, the Student’s t-test was used to examine the group differences 
between GWI case and control. Neuropathological, Western Blot and ELISA data for protein 
markers described above were analyzed using ANOVA to determine statistical significance. 
Normally distributed data were analyzed using parametric tests; otherwise non-parametric tests 
were used. For multiple groups, we used one-way analysis of variance (ANOVA) followed by 
the Tukey post-hoc test. A p value < 0.05 was considered statistically significant. These 
analyses were performed using GraphPad Prism7 (San Diego, CA, USA), and data were 
expressed as means ± standard errors. All graphs were generated using GraphPad Prism7 (San 
Diego, CA,). For lipidomics study after data analysis using MLM, Fisher’s least significant 
difference (LSD) correction and the Benjamini–Hochberg procedure (B-H) were used for 
multiple-test correction and control of false discovery rate (FDR) for all species between all 
groups. All data were analyzed using SPSS version 22.0.0 (IBM Corporation, Armonk, NY). B-
H (α = 0.05) was calculated using Excel. Since human NAD+ data were not normally 
distributed, Kolmogorov-Smirnov test (K-S test) were performed on them to check if they were 
statically significant. 
 
3.3 Result 
3.3.1 GWI is associated with low NAD+ and β-HB levels in the plasma 
We examined blood levels of mitochondria specific metabolties NAD+ and β-HB in a 
pilot cross-sectional study of age- and gender-matched healthy GW veterans (n = 6) and those 
with GWI (n = 12).  These studies showed that levels of NAD+ (K-S test, p = 0.002, Figure 
3.2A) and β-HB (t-test (df= 16) = 2.75, p = 0.013, Figure 3.2B) were significantly decreased in 
veterans with GWI compared to controls.  
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3.3.2 Nicotinamide riboside improves fatigue like behavior in GWI mice 
To determine whether NR corrected fatigue-like behavior in GWI mice, we performed 
the FST at 2-months post-treatment with NR. At 2-months post-treatment (8-months post-
exposure), there was no change in total immobile time (F (3,26) = 1.32, p = 0.28, Figure 3.3A) 
and frequency of immobility (F (3,22) = 3.62, p = 0.98, Figure 3.3A) between all experimental 
groups. Also, the mean velocity did not differ between groups (Figure 3.3A).  There were 
signficiant differences between the groups when Δ immobile time between first and second half 
of the FST was analyzed (F(3,22) = 4.2, p = 0.01;Figure 3.3B). Post-hoc analysis showed a 
significant difference between GWI and control mice as well GWI mice treated with NR 
compared to GWI treated with control diet (p =	0.05). NR treatment has no effect on memory 
and learning as measured by Barnes Maze(Figure 3.3). 
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Figure 3.2. Plasma NAD+ and β-HB levels in veterans with GWI compared to GW control veterans. 
Mean ± SEM (n=6 for controls and n=12 for GWI). (A) NAD+ and (B) β-HB are altered in plasma from 
veterans with GWI. * p ≤ 0.05,**<0.001. 
 96 
  
  
0
2
4
6
8
Fr
eq
ue
nc
y 
to
 im
m
ob
ile
± 
 S
EM
Immobile frequency
0
20
40
60
80
100
Im
m
ob
ile
 ti
m
e (
se
c)
 ±
  S
EM
Immobile time
Control(DMSO) Control+NR GWI(PB+PER) GWI+NR
0
20
40
60
Im
m
ob
ile
 ti
m
e (
se
c)
 ±
  S
EM
First half
Second Half
0
5
10
15
20
m
ea
n 
ve
lo
ci
ty
(c
m
/se
c)
 ±
 S
EM
Control(DMSO)
Control+NR
GWI(PB+PER)
GWI+NR
FST Speed
Control Control+NR GWI GWI+NR
0
10
20
30
40
Δ 
im
m
ob
ile
 ti
m
e ±
 S
EM
Control
Control+NR
GWI
GWI+NR
*
*
A 
B 
C 
Figure 3.3: Forced swim test data showed NR treatment reduces fatigue-like behavior in GWI mice. 
Mean ± SEM of control (n = 8), GWI mice (n = 8), control+NR (n = 7) and GWI+NR (n = 8). (A) two 
months after NR treatment (7-months post-exposure to GW chemicals), the frequency and immobile time 
had increasing trend in GWI mice compared to controls and was reduced in NR treated GWI. (B) 
Comparing two halves showed GWI performed worst among all group in second half which was improved 
by NR treatment. (C) Δ immobile time representing difference between two halves across all groups where 
GWI had elevated Δ immobile time than control mice and lower in GWI treated with NR diet compare to 
GWI mice. ANOVA with post-hoc tukey * p ≤ 0.05. 
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3.3.3 Nicotinamide riboside treatment helps recover normal NAD+ levels in GWI mice 
There was a significant effect of GWI status and NR treatment on NAD+ levels in the 
brain (F (3,12) = 7.33, p = 0.004) and plasma (F (3,12) = 12.33, p = 0.0005).  In brain, post-hoc 
analyses showed no differences in NAD+ levels between control and GWI mice on regular diet 
(p > 0.05), whereas NR treatment increased NAD+ levels in both control (P < 0.05) and GWI 
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Figure 3.4: NR treatment showed no effect on learning and memory behavior in GWI mice. Mean ± 
SEM of control (n = 8), GWI mice (n = 8), control+NR (n=8) and GWI+NR (n=8). (A) Two months after 
NR treatment (8-months post-exposure to GW chemicals), acquisition trials were conducted to train mice to 
escape into the Target hole (TH). There was no significant difference between any group on total distance to 
target hole indicative of learning.  (B) For the probe trials, conducted at 5-day of BM (8-months post-
exposure), there was no significant difference in the frequency of the visits to the TH across all groups. ANOVA 
with post-hoc tukey * p ≤ 0.05. 
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mice (p < 0.05). In plasma, post-hoc analysis showed that NAD+ levels were significantly 
decreased in GWI mice compared to control mice (p < 0.05) and NR treatment significantly 
increased NAD+ levels in GWI mice (p < 0.01; Figure 3.4). There was no change in the brain 
β-HB levels between all four groups (F (3,12) = 1.83, p = 0.4). However, we do observe 
significant differences in the liver β-HB levels across all four study groups (F (3,12) = 7.83, p = 
0.004) with post-hoc analysis showing that statistical significance was limited to GWI 
compared to control mice, and there was no affect of NR treatment on these levels (p > 0.05; 
Figure 3.4). NR treated mice showed decresing trends for weight in both GWI and control mice 
(Figure 3.5C). 
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3.3.4 Nicotinamide riboside increases PGC-1α, UCP-2 and SirT3 activity associated with 
mitochondrial biogenesis in control and GWI mice 
PGC-1α is not just a master regulator of mitochondrial biogenesis but also regulates 
UCP-2 240. Uncoupling protein 2 is a mitochondrial inner membrane protein that reduces 
mitochondria-derived ROS generated by mitochondrial respiration. There was a significant 
elevation of UCP-2 in the brain across GWI and NR treatment groups (F (3,8) = 13.068, p = 0.01; 
Figure 3.5A), while post-hoc analysis showed no change in UCP 2 expression between control 
and GWI mice on regular diet (p > 0.05), NR treatment increased UCP-2 expression in both 
control (p < 0.05) and GWI mice (p < 0.05; Figure 3.5). Levels of PGC-1α were elevated in the 
brain following NR treatment (F (3,9) = 0.14, p = 0.009; Figure 3.5B) and while post-hoc analysis 
Figure 3.5: Effects of NR supplementation on the NAD+ and β-HB concentration. Mean ± SEM (n = 6 per 
group). (A)Brain and plasma NAD+ levels across all 4 groups.NAD+ level was decreased in both brain and 
plasma of GWI. Intervention with NR increases increases NAD+ level in GWI and control. (B) Liver β-HB 
levels were decreased in GWI mice compared to and NR treatment failed to recover β-HB level in the liver. 
There were no differences between the experimental groups for brain β-HB levels. Weight change across all 4 
groups(C). ANOVA with post-hoc tukey * p ≤ 0.05. 
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showed no change in PGC-1α expression in GWI compared to control (p > 0.05), PGC-1α 
protein levels were increased by NR treatment in both control (p < 0.01) and GWI mice (p < 
0.01; Figure 3.5B). We further examined acetylated lysine residue of PGC-1α, which was used 
as a surrogate for SirT3 activity. Immunoprecipitated PGC-1α from mitochondrial fraction were 
examined for lysine acetylation. I observed a significant impact of NR and GWI status on 
acetylated PGC-1α  levels across all groups (F(3,9) = 7.14, p = 0.001; Figure 3.5C).The post-hoc 
analyses showed a significant increase in acetylated PGC-1α  levels in GWI compared to 
control mice (p < 0.05) which was significantly decreased in GWI mice treated with NR (p < 
0.05,Figure 3.5C). 
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3.3.5 Nicotinamide riboside treatment elevates SirT1 and SirT3 expression  
Sirtuins are a family of proteins that use NAD+ for deacetylation reactions241. I 
observed a significant impact of NR and GWI status on SirT1 protein levels across all groups 
(F(3,20) = 37.48, p = 0.001; Figure 3.6) and post-hoc analyses showed significant decreases in 
SirT1 levels in GWI compared to control mice (p < 0.05) which was significantly increased in 
GWI mice treated with NR (p < 0.05; Figure 3.6). We also observed change in SirT3 levels 
across all groups (F(3,12) = 5.48, p = 0.001) with post-hoc analyses showing that while there were 
no differences between GWI and control mice for SirT3 levels (p > 0.05), NR treatment 
increased SirT3 levels by 4-fold in both control (p < 0.001) and GWI mice (p < 0.001; Figure 
3.6). 
Figure 3.6: Representative images of UCP 2 and PGC-1alpha Western blot of whole brain mitochondria. 
Mean ± SEM (shown as arbitrary units, n = 6 per group). (A) NR treatment increased UPC-2 levels in both 
GWI and control mice compared to those on regular diet within respective groups. (B) Levels of PGC-1α were 
elevated in NR-treated GWI and control mice compared to their respective groups on normal diet. (C) 
Acetylation assays were performed, PGC-1α immunoprecipitation showed increased acetylated PGC-1α  in 
GWI mice, NR treatment increased deacetylated PGC-1α in GWI mice. (D) Regulation of PGC-1α  by 
acetylation. ANOVA with post-hoc tukey * p ≤ 0.01. 
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3.3.6 SirT1 directly interacts with p65 and deacetylated p65 
Increased expression of SirT1 reduces acetylation of p65 (NFkB subunit). Acetylation 
of p65 leads to phosphorylation of p65, subsequently leads to activation NF-kB. Following 
immunoprecipitation of SirT1, immunoblotting of this percipipate showed significant group 
differences in SirT1 interactions with p65 across GWI and NR treatment groups (F (3,12) = 8.068, 
p = 0.0026; Figure 3.7A).  Post-hoc analyses showed that this interaction was significantly 
decreased in GWI mice as compared to control mice (p < 0.05) and this interaction was 
partially restored by NR treatment in GWI mice compared to GWI mice on normal diet (p < 
0.05). This interaction of Sir T1 and p65 can lead to deacetylation of p65. Examination of 
acetylated lysine at residue 310 of p65 subunit showed that significant group differences (F (3,12) 
= 5.068, p = 0.01; Figure 3.7B) and post-hoc analyses showed that GWI mice had a significant 
increase in acetylated lysine compared to control mice (p < 0.05). In addition, NR treatment 
Figure 3.7: Sirtuin 1 and 3 (targets of NR) changes in GWI mice. Mean ± SEM (arbitrary value n = 6 per 
group) (A-B)Western blot analysis demonstrates decline in Sir T1 in GWI and no change in SirT3 levels 
between control and GWI. The expression of SirT1 and SirT3 were upregulated by NR treatment on both 
control and GWI. ANOVA with post-hoc tukey * p ≤ 0.001 
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significantly reduced p65 acetylation at this lysine residue in GWI mice compared to nontreated 
GWI mice (p < 0.05) and in NR treated control mice compared to control mice on normal diet 
(p < 0.05). 
 
 
  
 
 
 
3.3.7 Nicotinamide riboside treatment reduces chronic brain inflammation in GWI mice. 
To assess an impact of NR on NFκB activation, we examined p65 protein levels and 
found significant group differences (F (3,8) = 8.68, p = 0.001; Figure 3.8) with post-hoc analyses 
Figure 3.8: SirT1 deacetylates p65 and inactivates NFkB. Mean ± SEM (shown as arbitrary units n = 6 
per group). (A)p65 immunoblotting analysis on SirT1 immunoprecipitation demonstrates the NR treatment 
increases interaction of SirT1 and p65. (B)Acetylation assays were performed, and p65 immunoprecipitation 
showed increased in acetylated lysine in GWI mice and NR deacetylated p65 at k 310 in treated GWI mice. 
ANOVA with post-hoc tukey * p ≤ 0.05.  
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showing higher phosphorylated p65 to total p65 ratios in GWI compared to control mice (p < 
0.05), whereas NR-treated GWI mice had lower ratios of phosphorylated p65 over total p65 
protein levels compared to GWI mice on control diet (p = 0.034; Figure 3.8). Cytokines, 
especially IL-1β (F (4,16) = 8.68, p = 0.001; Figure 3.9), IFN-γ (F (3,12) = 5.16, p = 0.003; Figure 
3.9) and IL-6 ( F (2,8) = 7.86, p = 0.03; Figure 3.9) were significantly different across all four 
groups.  Post-hoc analyses showed that the brains of GWI mice had increased expression of 
these pro-inflammatory cytokines compared to controls (p < 0.05), whereas the brains of NR-
treated GWI mice had significantly lower levels compared to GWI mice on normal diet (p < 
0.05; Figure 3.9). Since chronic upregulation of IL-6 leads to activation and phosphorylation of 
STAT3, we examined p-STAT3 levels in the brains of GWI and control mice with or without 
NR treatment. We observed significant changes in p-STAT3 with respect to GWI and NR 
treatment (F (3,8) = 19.068, p = 0.01; Figure 3.8) with its levels being elevated in the brains of 
GWI mice which were normalized in NR-treated GWI mice (p=0.034). 
We also observed significant effects of NR and GWI status on the brain CCL2 (F (1,4) = 
7.46, p = 0.041, Figure 3.9) CCR2 (F (3,9) = 7.068, p = 0.01, Figure 3.9) levels with post-hoc 
analyses showing their levels to be increased in the brains of GWI mice compared to control 
and NR-treated GWI mice (p<0.05; Figure 3.9). The TBARS levels, indicative of lipid 
peroxidation, was altered in the brains of GWI and NR treated mice (F (3,8) = 65.068, p = 0.0001; 
Figure 3.9). Post-hoc analyses showed high TBARS levels in the brains of GWI mice compared 
to control mice (p < 0.05) and these levels were lower in the brains of NR treated GWI mice 
compared to GWI mice on regular diet (p < 0.05).  
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Figure 3.9: Representative images of P65 and STAT 3 western blot of whole brain homogenate. Mean ± 
SEM (shown as arbitrary units n = 6 per group). (A)The ratio of p-p65/p65 as well as p-STAT3/STAT3 was 
significantly increased in GWI mice. NR treatment normalizes both P65 and STAT3 phosphorylation in GWI 
mice. ANOVA with post-hoc tukey * p ≤ 0.05. 
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3.3.8 Brain acylcarnitine alterations in GWI mice were normalized by NR treatment 
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Figure 3.10: NR-normalized inflammatory cytokine, chemokine and lipid peroxidation in the brain 
of GWI mice. Mean ± SEM (n = 6 per group). MSD cytokine assay showed significant increased in the 
the brain, IFN-γ, IL-6, and IL-1β level. Among these cytokines examined in the brain, IFN-γ, IL-6, and 
IL-1β were lower in NR-treated GWI mice compared to GWI mice on normal chow. Similarly, CCR2 
and CX3CR2 chemokine levels were elevated in GWI mice compared to control mice, but these levels 
were reduced in mice treated with NR. Lipid peroxidation measured by TBARS showed GWI mice 
higher TBARS level compared all other groups. ANOVA with post-hoc tukey * p ≤ 0.05. 
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We examined acylcarnitines, which are mitochondria-specific lipids that transport 
LCFA for b-oxidation in mitochondria and shuttle short- and medium-chain fatty acid between 
peroxisomes and mitochondria. Short-chain acylcarnitine (SCAC)  species were affected across 
all groups (F (3,8) = 22.068, p = 0.01; Figure 3.10). Post-hoc analyses showed that SCAC were 
significantly upregulated in the brains of GWI mice compared to conrols (p = 0.01; Figure 
3.10). This effect in GWI mice was normalized to similar levels in control mice after 2 months 
of NR treatment in GWI mice (p=0.03). However, there were no significant differences 
between the study groups for medium-chain acylcarnitine (MCAC; 6–14 carbons)(F (2,11) = 4.14, 
p = 0.61; Figure 3.10) or long-chain acylcarnitine species (LCAC; (14–20 carbons) (F (4,12) = 
2.84, p = 0.041; Figure 3.10). Very Long chain acylcarnitine species (VLCAC;  >22 carbons) 
were changed across all four experimental groups (F(3,12) = 10.29, p = 0.002) and post-hoc 
analysis showed a significant increased in these acylcarnitine species in the brains of GWI mice 
compared to control mice (p = 0.009), and these levels were reduced to control levels in NR-
treated GWI mice (p = 0.03). Indiviual species along with fold change to control is shown in the 
heatmap below. After BH correction these events were either partially or fully normalized in 
GWI mice by treating them with NR for 2 months. Gamma-butyrobetaine hydroxylase (GBBH) 
is a key enzyme in the biosynthesis of carnitine which catalyzes L-carnitine formation from 
GBB. We observed a signficanst effect of GWI status and NR treatment on free L-carnitine 
(F(3,8) = 12.22, p = 0.002) and carnitine/gamma-butyrobetaine (GBB) ratio (F(3,12) = 7.29, p = 
0.02) with post-hoc analysis showing that L-carnitine and carnitine to GBB ratios were elevated 
in GWI mice, but these levels were lower in GWI mice treated with NR diet (p  < 0.05). 
Trimethylamine N-oxide (TMAO) is an organic compound, and its concentrations are increased 
after consuming foods containing carnitine (i.e. red meat and fish). There were significant 
group differences for brain TMAO levels (F(3,8) = 11.32, p = 0.001; Figure 3.10) with post-hoc 
analysis showing increases in GWI mice compare to control and lower levels in NR-treated 
GWI mice (p=0.032).  
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Figure 3.11 NR treatment normalizes increased Acylcarnitine in the brain of GWI mice. Mean ± SE (n = 
4 per group).(A) Several short-, medium- and long-chain FA containing acylcarnitine species were elevated in 
the brains of vehicle-treated GWI mice and were reduced in GWI mice treated with NR. (B)Compared to 
vehicle-treated GWI mice, NR-treated GWI mice had lower GBBH activity in the brain.(C)Heatmap showing 
foldchange to control for individual acetylcarnitine species. Mixed linear model with BH correction * p ≤ 
0.05. 
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3.3.9 Nicotinamide riboside reduced astroglia proliferation in GWI mice 
Astroglia and microglia participate in protecting the brain and modulating inflammation. In 
our mouse models using immunohistochemistry, we observed differences in GFAP staining in 
GWI and NR-treated mice within the DG (F(3,12) = 15.29.48, p = 0.002, Figure 3.11) and post-
hoc analysis showed a significant increase in GFAP staining within the DG of GWI mice 
compared to control mice (p < 0.05). Treatment with NR reduced brain GFAP staining in GWI 
mice as compared to GWI mice on a normal diet (p < 0.05, Figure 3.11). Levels of GFAP 
staining in the cortex also showed significant change across all groups (F(3,12) = 4.19.48, p = 
0.42; Figure 3.11B), and post-hoc analysis showed a significant difference between GWI and 
control as well as GWI mice treated with NR compared to GWI treated with control diet (p < 
0.05). There were no differences across any of the experimental groups for microglia staining 
with Iba1in the DG (F(3,8) = 6.98, p = 1.72;Figure 3.12) or cortex ( F(3,10) = 4.19, p = 3.42;Figure 
3.12).  
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Figure 3.12: Representative images of GFAP staining in the DG and Cortex regions. Sagittal sections of 
the mouse brain at 0.8 mm lateral to midline in the brainstem. 20x images of astroglia GFAP staining in the 
hippocampus showed a significant increase in GFAP within the DG of GWI mice compared to controls and 
NR-treated GWI mice. Quantitative analysis of GFAP staining intensity indicated an increased area of GFAP 
immunoreactivity in the DG(A) and cortex (B)of GWI mice. Mean ± SEM (n = 4 per group) ANOVA with 
post-hoc tukey * p ≤ 0.05. scale bar 100µm 
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Figure 3.13: Representative images of IBA-1 staining of DG and cortex regions. Sagittal sections of the 
mouse brain at 0.8 mm lateral to midline in the brainstem. 20x images of microglia marker Iba1 staining within 
the DG showed no significant change among all four groups. Quantitative analysis of IBA-1 staining intensity 
indicated no change in the IBA-1immunoreactivity in the DG(A) and cortex(B) of GWI mice. Mean ± SE (n = 
4 per group). ANOVA with post-hoc tukey * p ≤ 0.05. Scale bar 100µm 
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3.3.10 Ketogenic Diet restores decreased NAD+ and β-HB levels in GWI mice 
We also tested whether targeting mitochondrial dysfunction with a ketogenic diet can 
restore β-HB and NAD+ levels. Administration of KD significantly increased liver β-HB levels 
across all groups (F (2,6) = 6.14, p = 0.023, Figure 3.13) with post-hoc analyses showing that 
liver β-HB levels were significantly decreased in GWI mice compared to control mice but 
restored to normal levels in GWI mice with KD treatment (p < 0.05). Brain β-HB level did not 
differ between the 4 experimental groups (F(2,8)  = 30.88, p > 0.05). There was a significant 
decrease in plasma NAD+ levels in GWI mice compare to all other groups (F (4,8) = 14.13, p = 
0.01; Figure 3.13). Post-hoc analysis showed that NAD+ levels in plasma were significantly 
decreased in GWI mice compared to control mice and KD treatment significantly increased 
plasma NAD+ levels in GWI mice (p < 0.05). Brain NAD+ level were unchanged in all 4 
groups (F (4,8) = 10.11, p = 1.01; Figure 3.14). There was no significant change in weight across 
all 4 groups. 
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3.3.11 Ketogenic diet increases marker of mitochondrial function and reduces 
mitochondria-derived reactive oxygen species 
There were significant differences in UCP-2 levels across all experimental groups (F (2,6) 
= 6.14, p = 0.023, Figure 3.14) with post-hoc analyses showing that 2 months of KD treatment 
increased its levels in GWI and control mice (p < 0.05), despite there being no differences 
between untreated GWI and controls mice (p > 0.05). Levels of PGC-1α in the brain were 
different across all 4 group treatment groups (F (3,8) = 6.14, p = 0.023, Figure 3.14), and post-
hoc analyses showed that while its brain levels in GWI and control mice did not differ 
significantly, treatment with KD increases protein levels of PGC-1α in the brains of GWI and 
control mice (p < 0.05).  
  
 
Figure 3.14: Effects of KD treatment on the NAD+ and β-HB concentration. Mean ± SEM (n = 3/4 per 
group). (A)Brain and plasma NAD+ levels on all 4 groups showed decreased in plasma NAD+ level in GWI. 
Treatment with KD increases NAD+ in both plasma and brain among control and HWI(B)Liver and brain β-
HB level on all 4 groups. There was no change in brain β-HB among all groups. Liver β-HB levels were 
decreased in GWI mice, which was significantly increased after KD treatment. Chronic KD treatment had an 
increasing trend for β-HB in the liver * p ≤ 0.05. 
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3.3.12 Ketogenic Diet treatment had no effect on SirT1 and SirT3 expression 
To determine if KD treatment also affects the SirT levels since NAD+ levels were 
increased with this treatment, we analyzed the expression of SirT1 and SirT3. There were group 
differences for SirT1 protein levels in the brain (F (3,8) = 3.08, p = 0.05, Figure 3.15), and post-
hoc analyses showed that while SirT1 levels differed between control and GWI mice (p < 0.05), 
there was no significant effect of KD on SirT1 levels (p > 0.05). There were no differences in 
SirT3 protein levels between the experimental groups (F (3,9) = 0.8, p = 0.49, Figure 3.15).  
 
 
3.3.13 Ketogenic Diet treatment reduces chronic brain inflammation in GWI mice. 
Figure 3.15: Representative images of UCP-2 and PGC-1alpha Western blot of whole brain 
mitochondria. Mean ± SEM (shown as arbitrary units, n = 3/4 per group). KD treatment increased UPC-2 
levels in both GWI and control mice compared to those on regular diet within each respective group. Similarly, 
levels of PGC-1α were elevated in KD-treated GWI and control mice compared to their respective groups on 
normal diet. ANOVA with post-hoc tukey * p ≤ 0.05 
Figure 3.16: Sirtuin 1 and 3 changes in GWI mice. Mean ± SEM (arbitrary value n =3 per group) Western 
blot analysis demonstrates the expression of SirT1 and Sir T3 were not changed by KD treatment. SirT1 levels 
were decreased in GWI mice compared to control. Sir T3 levels were unchanged across all the experimental 
groups. ANOVA with post-hoc tukey * p ≤ 0.05 
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We examined if NFkB activity was affected following KD diet and observed an overall 
effect of KD and GWI status on p65 phosphorylation (F (2,7) = 4.08, p = 0.032, Figure 3.16) with 
post-hoc analysis showing that p65 phosphorylation was significantly increased in GWI mice, 
(p < 0.05) and KD treatment partially normalized p65 phosphorylation in the brain of GWI 
mice (p < 0.05). We also observe that chronic KD treatment and GWI status affected STAT3 
activation/phosphorylation across all groups (F (2,8) = 10.08, p = 0.02, Figure 3.16). Post-hoc 
analysis showed that KD treatment reduces STAT3 phosphorylation in the brains of GWI mice 
(p < 0.05) which were elevated in the brains of GWI mice compared to control mice (p < 0.05). 
Cytokines, specially IL-1β (F (2,7) = 4.08, p = 0.032, Figure 3.17), IFN-γ (F (2,7) = 4.08, p 
= 0.032, Figure 3.18) and IL-6 (F (2,7) = 4.08, p = 0.032, Figure 3.17) were affected in the brain 
across all groups (Figure 3.17). Post-hoc analysis showed that IL-1β (p < 0.01), IFN-γ (p <0.05) 
and IL-6 (p <0.05) were significantly upregulated in the brains of GWI mice compared to 
controls. These cytokines levels were also partially normalized by KD treatment in the brain of 
GWI mice (p<0.05). Along with cytokine levels, KD treatment also affected chemokine and 
chemokine receptors such as CCR2 (F (2,8) = 7.08, p = 0.02, Figure 3.17) and CX3CR1(F (2,8) = 
6.86, p = 0.03, Figure 3.17) in the brain across all 4 groups. Chronic treatment of KD 
normalized levels of CCR2 (p < 0.05) and CX3CR1 (p < 0.05) in the brain of GWI mice which 
were elevated in the brains of GWI mice compared to control mice ( p < 0.05). Lipid 
peroxidation measured by TBARS were also changed across all 4 groups ( F (4,10) = 14.08, p = 
0.033;Figure 3.17). Post hoc analysis showed significant increased in GWI compared to all 
other groups and KD diet decreased TBARS levels in GWI mice compared to GWI mice on 
normal diet (p < 0.05, Figure 3.17). 
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Figure 3.17: Representative images of p65 and STAT3 Western blot of whole brain homogenate. Mean ± 
SEM (shown as arbitrary units n = 3/4 per group).  The ratio of p-p65/p65 is higher in the GWI mice compared 
to all 4 groups. The ratio of p-STAT3/STAT3 is higher in GWI mice compred to all 4 groups. ANOVA with 
post-hoc tukey * p ≤ 0.05 
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3.3.14 Ketogenic Diet reduces astroglia activation in GWI mice 
Similar to my previous result, we do see a change in astroglia proliferation in DG across 
all groups (F (3,8) = 8.18, p = 0.001, Figure 3.18A). Post-hoc analysis showed significant 
increases in astroglia proliferation in GWI mice compared to control mice (p < 0.05) that were 
normalized by KD treated GWI compared to GWI mice on control diet (p < 0.05). GFAP 
staining in cortex did not affect all experimental groups (F (3,8) = 6.31, p = 0.71, Figure 3.18B). 
Also consistent with our previous result, we did not observe any microglia activation or 
proliferation in GWI mice at 7-months post exposure time point in DG (F (2,9) = 4.11, p = 0.87, 
Figure 3.19A) and cortex (F (3,8) = 10.31, p = 1.54, Figure 3.19B). 
 
Figure 3.18: KD normalized inflammatory cytokine and chemokine levels in the brain of GWI mice. 
Mean ± SEM (n = 6 per group). Among the cytokines examined in the brain, IFN-γ, IL-6 and IL-1β were 
lhigher in  GWI mice compared to control, KD treatment reduced these cytokines levels in GWI mice 
compared to GWI mice on normal chow. Similarly, CCR2 and CX3CR2 chemokine levels were elevated in 
GWI mice compared to control mice, but these levels were reduced in mice treated with KD. Lipid 
peroxidation measured by TBARS. Increased TBARS levels in GWI brain were normalized in after KD 
treatment. ANOVA with post-hoc tukey * p ≤ 0.05. 
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Figure 3.19: Representative images of GFAP staining of DG and Cortex regions. Sagittal sections of the 
mouse brain at 0.8 mm lateral to midline in the brainstem. 20x images of astroglia GFAP staining in the DG(A) 
and Cortex (B) showed a significant increase in GFAP immunoreactivity within the DG, observed in GWI 
compared to controls and KD treated GWI mice. ANOVA with post-hoc tukey*=p<0.05.Scale bar 100µm  
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3.4 Discussion 
 Previous proteomic and metabolomic investigations in our labs suggested that exposure 
to GW chemicals similar to those utilized in this research to generate a GWI mouse model have 
the potential to disrupt multiple mitochondrial pathways, including; the Krebs cycle, glycerol-3 
phosphate shuttling and gluconeogenesis I 54. The work described in this chapter mechanistically 
explores whether targeting cellular bioenergetics using NR and KD can restore mitochondrial 
function and furthermore, whether these bioenergetic changes may also help attenuate 
neuroinflammation, reduced fatigue like behavior, and improve mitochondrial specific lipid 
metabolism. In this current study, we demonstrate that treatment with NR rescues mitochondrial 
bioenergetics, the data in this study are supported by several other studies in the literature which 
show efficacy of NR in enhancing mitochondrial oxidative phosphorylation 242 and increasing 
mitochondrial biogenesis 226. We also demonstrated that the effects of NR and KD are associated 
with an increase in UPC-2 and PGC-1α protein, supporting mitochondria biogenesis and 
ultimaltey improving OXPHOS.  
I observed a decrease in fatigue-like behavior in GWI mice after NR treatment. Chronic 
fatigue is one of the primary symptoms of GWI 6, among veterans deployed to the 1991 GW, 
23% continue to suffer from fatigue 6. Decreased levels of NAD+ (indicative of lower 
bioenergetics capacity) in veterans with GWI may be one of the reasons why chronic fatigue has 
persisted in ill veterans. Although the underlining mechanism is not well understood, study links 
CFS to reduced NAD+ level 243. There are now several clinical studies which have shown that 
chronic oral treatment with NR has an excellent safety profile and is generally well tolerated 
244,245, and furthermore, chronic treatment with NR is associated with decreased fatigue intensity 
Figure 3.20: Representative images of IBA-1 staining of DG and Cortex regions. Sagittal sections of the 
mouse brain at 0.8 mm lateral to midline in the brainstem. Quantitative analysis of IBA-1 staining intensity 
indicated no change in IBA-1 immunoreactivity in the DG(A) and Cortex(B) of GWI mice. Mean ± SE (n = 3/4 
per group). ANOVA with post-hoc tukey * p ≤ 0.05. Scale bar 100µm 
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and improved quality of life 210,246. Therefore, an intervention that increases NAD+ levels in GWI 
patients may decrease fatigue intensity.  
I did not observed any change in memory and learning as measured by Barnes Maze in 
this cohort. While other cohort showed significant decline in both learning and memory in GWI 
mice as measured by BM at similar time point. Although exact reason is  not well understood but 
it could be due to order of neuro behaviour experimnets. I did FST a week before BM, FST 
increases stress and might have affect memory in these mice. 
 Along with the critical role of oxidized and reduced forms of NAD in ATP generation, 
NAD+ activates sirtuins, which are critical regulators of mitochondrial function and biogenesis.  
Among the seven mammalian sirtuins that have been identified, SirT1 is localized to the nucleus, 
whereas SirT3 is found explicitly in mitochondria 247. SirT1 is also ubiquitously expressed in the 
rodent prefrontal cortex, hippocampus, and basal ganglia. Recent evidence has supported the 
concept that sirtuin expression is regulated by the availability of free NAD+ and NADH 248. We, 
therefore, examined SirT1 and SirT3 protein levels after GW chemical exposure and after NR 
treatment. We found that SirT1 levels were significantly decreased in the brains of GWI mice 
and were increased in the brains of GWI mice treated with NR. While SirT3 levels did not differ 
between GWI and control mice, NR treatment significantly increased SirT3 expression in the 
brains of both control and GWI mice. It is, therefore, possible that increased protein levels of 
sirtuins along with increased availability of NAD+ could result in improved mitochondrial 
function, mitochondrial biogenesis, and reduced inflammation.   
More recently, sirtuins have been shown to influence inflammatory processes via the 
deacetylation of cellular p65 protein and inhibition of NFκB activation 249,250. SirT1 deacetylates 
p65 subunit of NFκB, in an NAD+ dependent manner, resulting in suppression of NFκB 
transcription which subsequently leads to a decreased production of pro-inflammatory cytokines 
249,251. Consistent with these findings, in our immunoprecipitation studies, we observed lower 
levels of p65 bound to SirT1 in the brains of GWI mice compared to control mice and these levels 
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are similar to control in GWI mice treated with NR.  These results suggest regular interaction 
between SirT1 and p65 interaction is reduced and therefore reduced deacetylation of p65 resulting 
in increased phosphorylation and translocation to the nucleus. 
Furthermore, NR treatment seems to increase the interaction between p65 and SirT1, 
corresponding with reduced acetylation of p65.  Given the well-known effects of NF-kB 
activation in inflammation and observations of increased downstream effects of inhibiting NFkB 
were examined by measuring cytokines and chemokines that are involved in promoting 
inflammation.  Treatment with NR was able to reduce several cytokines, IL-1β, IFN-g and IL-6, 
levels and STAT3 phosphorylation in the brains of GWI mice. In addition to cytokines, we also 
observed decreases in chemokine CCL2 levels as well as its receptor CCR2 along with CX3CR1 
after NR treatment in the brains of GWI mice. These findings suggest that NR treatment can 
target multiple aspects of GWI pathology, including lipid and mitochondrial dysfunction along 
with reducing inflammation.  Increases in cytokine and chemokine levels lead to reactive 
astroglial activation and proliferation252,253. Consistent with other studies, we observed a 
noticeable decrease in reactive astrocytes and astroglial proliferation following NR treatment220. 
Furthermore, changes in sirtuin levels after NR treatment are consistent with the well-known 
effects of NAD on sirtuin activity and; therefore, some of these positive effects on mitochondria 
function are likely facilitated through sirtuin mediated pathways.  
While glucose is the primary molecule supporting CNS bioenergetics, under certain 
conditions or in some diseases, b-oxidation of fatty acids can serve as an alternative energy source 
for the CNS 254. Since carnitine and acylcarnitines contribute to fatty acid metabolism and 
maintain appropriate ratios of acyl-CoA to free CoA, changes in their levels could provide some 
insight into brain bioenergetics, particularly in disorders with metabolic disturbances. 
Furthermore, carnitine/acylcarnitine transporter (CACT) can be deacetylated by SirT3, resulting 
in increased CACT activity 255. Since our previous studies have found an alteration in blood and 
brain acylcarnitine levels in GWI mice and veterans with GWI 54, we, therefore, evaluated 
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acylcarnitine levels following NR or sham treatment to obtain an indirect measure of CNS 
bioenergetics. We observed that VLCAC and SCAC were particularly affected and their levels 
were restored to that of control mice following NR treatment. Furthermore, an increase in C14:0 
acylcarnitine was detected in the brains of GWI mice, which is generally associated with very 
long-chain acyl-CoA dehydrogenase deficiency. After NR treatment, levels of this acylcarnitine 
were reduced in the brains of GWI mice.  
Interestingly, the final product of fatty acid b-oxidation, bHB, was unaffected by NR 
treatment, suggesting that changes in acylcarnitine profiles may not directly translate into 
metabolites that support Krebs cycle processes. However, it is possible that acetyl-CoA that is 
generated from chain shortening may enter the Krebs cycle, which would prove a useful 
mechanism for monitoring NR mediated mitochondrial bioenergetics.  While the exact 
mechanism of how NR diet improves acylcarnitine profiles requires further investigation, the 
effects of NR shown in this research could be due to improved mitochondrial metabolic function 
256. Therefore, these results suggest that the restoration of acylcarnitine profiles in GWI mice 
following NR treatment may be indicative of improved fatty acid transport and metabolism. 
Further examination of this acylcarnitine transport and metabolism, as well as other bioenergetics 
related compounds, is needed to better understand the effects of NR on the brain mitochondria 
function and bioenergetics recovery in GWI mice. 
 
In recent years, many studies have suggested that sirtuins are critical regulators of 
mitochondrial biogenesis, a process that is regulated by PGC-1α and UCP-2 257.  Uncoupling 
proteins play an essential role in the regulation of fatty acid metabolism and ROS elimination 
and have also been reported to maintain mitochondrial membrane potential 258. PGC-1α 
increases mitochondrial biogenesis by increasing gene transcription of factors, such as AMPK 
(adenosine monophosphate-activated protein kinase),  that activate mitochondrial transcription 
factor A257. Both SirT1 and SirT3 have been shown to deacetylate PGC-1α, promoting 
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increased mitochondrial biogenesis 259,260.  In our study, while levels of PGC-1α and UCP2 did 
not differ between GWI and control mice, NR treatment increased PGC-1α and UCP2 protein 
levels in both control and GWI mice, suggesting that some of the beneficial effects of NR 
treatment may be mediated through this mechanism 226,239,242. PGC-1α is also deacetylated by 
SirT3261. We observed that the acetylated form of PGC-1α in the mitochondrial fraction was 
elevated in GWI compared to control mice and that NR treated GWI mice had lower levels, 
generally similar to those observed in control mice. Since SirT3 is mitochondria specific 
deacetylase, it might be possible that the observed effects on PGC-1α are due to the changes in 
SirT3 acitivty after exposure to GW chemicals.  In addition, PGC-1α deacetylation by SirT3 
increases PGC-1α activity contributing to increased mitochondria biogenesis and mitochondrial 
and peroxisomal lipid metabolism201,261–263. As such SirT3-mediated deacetylation and 
activation of PGC-1α is an important cellular response to restore cellular metabolic function, 
particularly in conditions like GWI, where there might be energy deprivation or low 
bioenergetics function. Together, these studies suggest that activation of sirtuins in combination 
with increases in PGC-1α and UCP2 may help recover impaired mitochondria function seen in 
veterans with GWI by increasing mitochondrial function after NR treatment may be a useful 
therapeutic approach for improving the general well-being of veterans with GWI.    
Mitochondria are the primary source of ROS production within the cell, excess 
accumulation or dysfunctional clearance of ROS has been shown to result in the impairment of 
mitochondrial bioenergetics and metabolic function206–208. Our previous works have identified 
the importance of lipid peroxidation and oxidative stress in our GWI model78. Oxidative stress in 
the cellular environment results in the formation of highly reactive and unstable lipid 
peroxides264. Because reactive oxygen species (ROS) have extremely short half-lives, they are 
difficult to measure directly. Instead, what can be measured are several products of the damage 
produced by oxidative stress, such as TBARS. Thiobarbituric acid reactive substances - TBARS 
- are formed as a byproduct of lipid peroxidation (i.e., as degradation products of fats) which can 
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be detected by the TBARS assay 265. In the current study, we observed the levels of TBARS were 
partially normalized by NR treatment in GWI mice, supporting the anti-inflammatory potential 
of this compound.  
Trimethylamine N-oxide is an amine metabolite generated from choline and carnitine 
oxidation by gut microbes 266. Although the mechanism is not clearly understood, recently TMAO 
been identified as a novel risk factor for promoting atherosclerosis and vascular inflammation 267. 
More recently, TMAO has been found to induce phosphorylation of the NFκB resulting in 
increased inflammatory cytokine production such as Il-6 and IL‐1β 268. Increased in TMAO 
induces inflammation leading to mitochondrial ROS via inhibition of SirT3 activity 267. In our 
study, we do see increased in TMAO and L-carnitine in GWI brain. Studies have shown that 
TMAO and L-carnitine level are accumulated and correlated in metabolic disorder 269. Chronic 
NR treatment decreases both L-Carnitine and TMAO. As such, further investigation is required 
to confirm our finding, especially in the human population. The final step of L-carnitine synthesis 
involves the conversion of GBB to L-carnitine by GBB hydroxylase (GBBH). In this study, we 
showed that NR treatment reduces GBBH activity in GWI mice.  
    
  As with the studies above, an examination of NAD+ and βHB showed a decreasing trend 
in the brains of GWI mice. This allowed me to investigate KD as a potential therapeutic approach 
since it is know that both NAD+ and βHB levels are increased after KD222. In this treatment 
strategy we performed long term treatment with KD.  However, NAD+ in plasma were increased 
following KD. Levels of βHB were low in the liver of GWI mice but increased following 
treatment with KD in GWI mice. These studies suggest that KD produces peripheral effects on 
molecules that support bioenergetics.  Since there are transporters are present at the BBB and 
transport βHB to the brain, it is possible that βHB generated by the liver is transported to the brain 
to support bioenergetics 270. Ketone body specially βHB can cross BBB by two mechanism (1) 
lipid-mediated free diffusion through the BBB or (2) carrier- or receptor-mediated transport 
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through the BBB While the exact mechanism behind NAD+ increase following KD is currently 
being investigated, the literature suggests that calorie restriction and KD increase NAD+ levels 
by possibly stimulating ATP production 271,272. 
  Since NAD+ levels were elevated in the blood of GWI mice after KD, we explored 
whether sirtuin levels were also increased as with the NR diet. We observed the expected decrease 
of  SirT1 in the brains of GWI mice, neither SirT1 nor SirT3 were affected by KD.  We examined 
PCG-1a and UCP2 because studies have shown that KD or fasting increases these proteins222. 
We observed increases in their levels in the brains of GWI mice after KD. While the molecular 
mechanism behind this remains poorly understood,  one possible mechanism might be that KD 
may increase βHB which may increases expression of PGC-1a, a master regulator of 
mitochondrial biogenesis and function273. β-Hydroxybutyric acid not only provides energy but 
also attenuates neuroinflammation via the inhibition of NFκB activation, bilaterally reducing 
cytokine such as IL-1β 274,275.  Increased NFκB correlates with increasing in astroglia activation 
and pro-inflammatory cytokines and chemokines in GWI mice 78. However, 2-months of KD 
intervention was able to decrease the activation of astroglia and pro-inflammatory cytokines such 
as IL-1β, IL-6, IFN-γ in the brain of GWI.  
One key limitation of these studies is small sample size and lack of neurobehavioral data. 
This study needs to be repeated with a larger sample size, along with memory and anxiety 
evaluation. Overall, these preclinical findings suggest that chronic oral NR and KD treatments 
restore GWI pathology. In conclusion, this study suggests that NR can target several aspects of 
GWI, including mitochondrial biogenesis, fatigue, lipid peroxidation, and inflammation. This 
current study supports that βHB regulates inflammation and stimulates mitochondrial 
functioning. Once confirmed using larger studies, we propose that strategies to increase βHB 
levels via KD and NAD+ levels via NR intervention will likely be therapeutically beneficial in 
GWI. 
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Chapter 4: A permethrin metabolite is associated with adaptive immune responses in Gulf 
War Illness 
4.1 Introduction: 
 As discussed in previous chapters, several clinical studies suggest that immune 
dysfunction and chronic inflammation are among the key causes of the symptoms experienced 
by ill GW veterans 2.  Studies using the rodent models of GWI implicate both the CNS and 
peripheral immune systems in contributing to the pathogenesis of this illness 179. However, a 
better understanding of these immune responses in GWI would further contribute towards the 
development of biomarkers and therapies for the CNS symptoms and pathology of GWI.  
 As discussed in chapter 1, it is now well established that pesticide exposure played a 
significant role in the manifestation of GWI 1,276.  Statistics reported by the DoD have suggested 
that a large proportion of the ground troops deployed to the GW reported using any kind of 
pesticides 33.  Among these, 44% were pesticide sprays that contained pyrethroids, such as PER 
1. Recently emerging evidence suggests that exposure to pesticides in humans can be associated 
with autoimmune disorders 277. In particular, several case reports documented that acute 
pyrethroid intoxication in humans is associated with autoimmune clinical phenotype, including 
disorders like scleroderma and myasthenia-like syndromes 278–280. The most compelling 
evidence for autoimmune abnormalities in GWI comes from studies showing increases in 
immunoglobulin G (IgG) and T- and B-cells in the blood of veterans with GWI compared to 
healthy GW veterans 107 and is supported by a study showing elevated autoantibodies against 
brain-specific proteins, such as GFAP and tau in blood from veterans with GWI 110.  
 Low molecular weight chemicals can form adducts with endogenous proteins, and these 
chemically modified proteins can elicit an adaptive immune response 281. Studies have shown 
that a 3-phenoxybenzoic acid (3-PBA) is a common metabolite of PER, which is generated by 
esterase cleavage followed by enzymatic oxidation 282. It is shown that 3-PBA can undergo 
glucuronidation in the liver for excretion in urine to form 1-O-(3-phenoxybenzoyl)-ß-D-
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glucopyranuronate (Glu-3-PBA) 282. This Glu-3-PBA has been shown to further react to form 
an amide with lysine in proteins 282. Others have shown that chemically-haptenated proteins can 
reach the lymphatic system, where they encounter immune cells that are involved in antigen 
presentation to T- and B-cells 283. These studies suggest a role of haptenated proteins in 
promoting autoimmune responses. As such, an activation of autoimmune responses in GWI 
could be downstream of PER exposure that occurred during the GW conflict.   
 Autoantibodies against brain proteins are a part of a continuum of many autoimmune 
disorders 284. For example, in Sydenham’s chorea, a neurological manifestation of rheumatic 
fever where peripheral autoantibodies against Group A β-hemolytic streptococcus cross-reacts 
with neuronal proteins 284. In systemic lupus erythematosus (SLE), peripherally generated anti-
DNA antibodies enter the brain and cross-react with N-methyl-D-aspartate (NMDA) receptors 
285. In other autoimmune disorders, such as multiple sclerosis (MS), studies suggest that a 
breach in the BBB allows CNS proteins to leak into the periphery where immune cells first 
encounter them. Alternatively, these immune cells can gain antigen experience within the 
cervical lymph nodes where CNS antigens drain 286.  While the exact mechanisms behind brain 
and peripheral immune cross-talk remain unknown in GWI, the presence of autoantibodies 
against brain proteins and evidence of glia activation in GWI mouse models do suggest an 
involvement of adaptive immune system in promoting the CNS pathology of GWI 54,78,110. 
  
Previous studies including my own work shows increases in astroglia activation, NFkB 
phosphorylation and proinflammatory cytokines are commonly observed in the brains of GWI 
rodent models 51,53,54,78,157,180, also supporting a role of adaptive immune cells in the CNS 
pathology of GWI. Elevated proinflammatory cytokines can increase matrix metalloproteinase 
9 (MMP9) activity at the BBB and enhance the transmigration process, potentially promoting 
the infiltration of peripheral immune cells into the CNS 287. Among these, Ly6C+ monocytes 
are capable of converting to macrophages upon CNS infiltration 288,289. As mentioned in 
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chapters 2 and 3, I observed increases in C-C chemokine receptor type 2 (CCR2) and its 
ligand, CCL2,  in the brains of GWI mice 78. In neuroinflammatory conditions, CCL2 released 
by astroglia recruits CCR2-expressing peripheral monocytes into the parenchyma, leading to 
the activation of NFkB-mediated inflammatory pathways 188,191,290–292. These studies suggest 
that peripheral adaptive immune responses could be involved in promoting neuroinflammation 
in GWI.   
I hypothesize that exposure to PER results in 3-PBA haptenation of proteins and that 
haptenated proteins presented by antigen-presenting cells (APC) could activate T- and B-cells, 
resulting in autoantibody production. The presence of haptenated proteins in the CNS may 
promote infiltration of peripheral immune cells, which would further contribute to 
neuroinflammation. In this study, I determined the presence of 3-PBA-Lys in proteins and 3-
PBA recovered from protein hydrolysis in the brains and livers of a GWI mouse model 
developed using combined PB and PER exposure. I examined the presence of autoantibodies 
against 3-PBA-haptenated albumin in plasma from GWI mice and in veterans with GWI.  I 
investigated the ability of 3-PBA-haptenated albumin to activate peripheral T- and B-cells and 
determined that these immune cells are elevated in the blood of GWI mice and in veterans with 
GWI. I determined that proinflammatory monocytes capable of tissue infiltration are present in 
the blood of GWI mice.  I also examined infiltrating monocytes and macrophages derived from 
these monocytes in the brains of GWI mice. Collectively, these studies will help determine the 
role of PER metabolites in activating adaptive immune responses in GWI. This work is 
published in the journal brain behavior and immunity293. 
We hypothesize that peripheral 3-PBA-haptenated proteins activate adaptive immune 
responses resulting in the production of autoantibodies against them. These autoantibodies 
promote antigen presentation by perivascular macrophages and promote brain entry of T-cells 
perviously primed by 3-PBA haptenated proteins. We propose that these T-cells encounter 3-
PBA-haptanted protein primed memory B-cells in the cervical lymph nodes or in the periphery 
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which promotes the expansion of plasma B-cells that now produce autoantibodies against brain 
proteins that are similar to the peripheral 3-PBA-haptenated proteins and contribute to aberrant 
brain autoimmune responses in GWI.  
Specific Aim 1: To identify peripheral autoantibodies against peripheral 3-PBA-haptenated 
proteins that also cross-react with normal proteins. To identify peripheral 3-PBA-haptenated 
proteins and autoantibodies against them in human and GWI mice 
 Specific aim 2: To identify 3-PBA-haptenated protein reactive B- and T-cells in the blood 
of GWI mice and in veterans with GWI.    
 Specific aim 3: To identify B- and T-cells which cross-react with normal brain proteins that 
are similar to 3-PBA-haptenated proteins.    
4.2 Material and methods 
4.2.1 Human subjects 
 Plasma and/or peripheral blood mononuclear cells (PBMC) were utilized from 3 
different cohorts: (1) GWI and GW control veterans recruited at the Roskamp Institute Clinics 
(2) GWI cases and GW controls from the Boston Gulf War Illness Consortium (GWIC) and (3) 
subjects from Thailand who were farm workers or consumed pyrethroid-infested fruits and 
vegetables and either had positive or negative urine 3-PBA measurements. Plasma from age- 
and gender-matched GWI and control GW veterans were used for this study. Sample collection 
at the Roskamp Institute Clinics was approved by the WIRB, and all protocols were conducted 
in accordance with relevant guidelines and regulations. Recruitment of study subjects and blood 
collection to obtain plasma and PBMC has been described previously in chapter 1 76,78,294. 
Plasma and PBMC collection at the Boston GWIC were approved by the Boston University 
IRB. The Kansas GWI criteria 6 were used to diagnose GWI. The Kansas GWI criteria require 
that GW veterans show symptoms in at least 3 of 6 symptom domains (fatigue/sleep problems, 
somatic pain, neurological/cognitive/mood symptoms, gastrointestinal symptoms, respiratory 
symptoms, and skin abnormalities). Study participants were excluded if they reported being 
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diagnosed with another medical condition that could explain their chronic health symptoms. A 
detailed demographic table is provided in Table 5A and 5B. Subjects were also excluded from 
the study if they were currently on any steroid medication, to minimize interferences from the 
effects of these medications at the time of the blood draw. Controls were veterans deployed to 
the 1991 GW who did not meet the Kansas GWI criteria or any of the exclusionary criteria 
listed above. Self-report of pesticide exposure was based on questions which inquired whether 
they had worn a uniform saturated with pesticide and/or used pesticide cream/spray. Using 
these data, a summary variable was generated which assigned yes/no to pesticide exposure. 
Since the exposure status of GW veterans is based on self-report, we also examined plasma 
from samples obtained from farm and non-farm workers with documented exposure to 
pyrethroids and measurements of 3-PBA in urine. These were occupational health worker who 
were expose to different pesticides during their occupation. These were used as positive and 
negative controls for a 3-PBA-albumin autoantibody detection assay. All the participants gave 
their written consent, and the study was approved by their respective IRBs. A detailed 
demographic table is provided in Table 6. Many of these age- and gender-matched people had 
been exposed to pyrethroids during their occupation, and half of them had 3-PBA detected in 
their urine (n = 5 positive and n = 5 negative). 
 
 
 
 
 
 
 
 
Table 5A. Demographics of the Gulf War veteran autoantibody cohort 
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 Controls (GW veteran) GWI cases 
 
N total 
 
10 14 
Age (Mean ± SEM) 54.3 ± 7.6 52.4 ±7.5  
Male (%) 79.7% 86% 
Self-report of pesticide 
exposure during war 
 
Self-report of PB exposure 
during war 
5(50%) 
 
 
60% (6) 
95% (12) 
 
 
100% (14) 
Ethnicity 
Caucasian 
African American 
Other/Multiracial 
 
8 (70%) 
2 (3%) 
 - 
 
11 (78.4%) 
2 (14.2%) 
1 (7.13%) 
 
 
 
 
 
 
 
 
 
 
 
Table 5B. Demographics of the Gulf War veteran Boston consortium cohort 
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 Controls (GW veteran) GWI cases 
 
N total 12 12 
Age (Mean ± SEM) 51.23 ± 8.56 54.3 ±7.4  
Male (%) 83.33% 100% 
Self-report of pesticide 
exposure during war 
Self-report of PB exposure 
25% (3) 
 
83.33%(10) 
83.33% (10) 
 
100%(12) 
Ethnicity 
Caucasian 
African American 
Other/Multiracial 
 
9 (75%) 
2 (16.67%) 
1 (8.33%) 
 
10 (83.4%) 
1 (8.3%) 
1 (8.3%) 
 
Table 6. Demographics of the subjects from Thailand. 
 Negative Controls (no urine 
3PBA detected) 
Positive cases (urine3-PBA 
detected)  
N total 5 5 
Age (Mean ± SEM) 57.3 ± 7.6 61.4 ± 6.33  
Male (%) 80% 80% 
Pesticide exposure  
PB exposure 
20% (1) 
0 
66.6%(3) 
0 
Occupation 
Farm worker 
Non-farm worker 
 
60%(3) 
40%(2) 
 
60%(3) 
40%(2) 
 
There was no significant difference in age among two groups in all 3 tables above 
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4.2.2 Animals:  
 All procedures on mice were approved by the Roskamp Institute’s Institutional Animal 
Care and Use Committee (IACUC) and were conducted in compliance with the Office of 
Laboratory Animal Welfare and laboratory animal care guidelines as previously described 53,157. 
Mice were maintained with a 12h light/dark cycle in a temperature-controlled environment (21± 
2 °C). Male C57BL/6 mice (3 months of age, weight 25 g ± 0.7 SD) were co-administered 0.7 
mg/kg of pyridostigmine bromide (PB) (Fisher Scientific Hanover Park, IL) and 200 mg/kg of 
PER (Sigma Aldrich, St. Louis, MO, USA) in a single 50μl i.p. injection in dimethyl sulfoxide 
(DMSO) (Sigma Aldrich, St. Louis, MO,USA) or DMSO alone (control) daily for 10 
consecutive days. Mice were divided in two groups, with the control group receiving vehicle 
only (DMSO) and the GWI group receiving vehicle along with PB and PER.  
 
 
4.2.3 Detection and quantification of 3-PBA using LC/MS reverse phase analysis  
 Levels of 3-PBA in plasma, brain and liver were quantified as described by Ahn et al 
295. Briefly, 400mg of liver and 100mg of brain from both control and GWI mice were 
homogenized in 1mL of PBS, and a protein crash was then performed via the addition of 4mL 
of acetone. Samples were then subjected to acid hydrolysis by 1mL 6N HCL at 100°C for 2 hrs 
to hydrolyze covalent bonds between 3-PBA and proteins 295. These samples were subjected to 
solid-phase extraction (SPE) using 8B-S100-UBJ Strata™-X 33µm polymeric reversed phase, 
60mg/3mL spin columns (Phenomenex, Torrance, CA, USA) for clean-up and spiked with 
10µM phenoxy-13C6-3-PBA (Cambridge Isotope, Tewksbury, MA, USA) internal standard (IS). 
Samples were analyzed by reverse-phase liquid-chromatography/mass spectrometry (LC/MS) 
using a Shimadzu LC-20AT HPLC system, with a 2.6µm EVO C18 100A 100 x 2.1mm 
Kinetex column (Phenomenex, Torrance, CA, USA). The mobile phases used were as follows: 
A (10 mM ammonium formate in water); B (100% Acetonitrile. A gradient was run from 90% 
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solvent A in 10% solvent B to 50% B in 6 min with a 4 min hold at 100% solvent B. with a 
flow rate of 100µL/min and column temperature at 40°C. Mass spectrometry analyses were 
conducted with high mass accuracy and parallel reaction monitoring (PRM) using a Q-Exactive 
(QE) hybrid quadrupole-Orbitrap mass spectrometer (Thermo Fisher Scientific, Waltham, MA, 
USA). Negative ion electrospray spectra were acquired at 17,500 resolution with a scan range 
from m/z 150 to 600. All spectra were obtained with a 100ms maximum ion injection time and 
5 microscans. The 3-PBA IS (Cambridge Isotope Laboratories, Tewksbury, MA, USA) was 
monitored with m/z 219.1 as the precursor mass and product ions at m/z 99.053 and 175.084. 
For 3-PBA, I used m/z 213.1 as the precursor ion and m/z 93.033 and 169.065 as product ions.  
 
 
4.2.4 Quantification of 3-PBA peptide using LC/MS reverse phase analysis  
Levels of 3-PBA bound lysine in plasma, brain and liver were quantified as described by 
Noort et al 282. Briefly, 400mg of liver and 100mg of brain from both control and GWI mice 
were homogenized in 1mL of PBS, and protein was precipitated by the adding 4mL of acetone 
at -20°C for 3 hrs. Precipitated protein was digested with 100µL of pronase solution (10mg/mL, 
50mM NH4HCO3) for 1 hr at 37°C, then analysis with LC-tandem MS as explained above. In-
house synthesis of 3-PBA-albumin (described below) was as standard. The 3-PBA-lysine was 
monitored with m/z 343.12 as the precursor mass and product ions at m/z 197.06. 
 
4.2.5 Detection of 3-phenoxybenzoic in urine using GC-ECD 
The first urine samples of the morning were collected and frozen at -20°C until they 
were analyzed for 3-PBA in urine samples and was detected as described by Pakvilai et al. 
(2014)296. Briefly, 50µL of 3-PBA (1µg/mL), as internal standard, was added to 2mL of urine 
sample, then mixed for 30 s. The urine samples were subjected to acid hydrolysis by adding 
500µL of concentrated hydrochloric acid (37%) at 100°C for 2 hrs. Each sample was extracted 
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twice with 2mL of ethyl acetate (EA), followed by centrifugation at 2,500rpm for 5 min. The 
organic phase was separated, and sample cleanup was then performed on pre-conditioned C18– 
cartridges. The resulting solution was dried and dissolved in acetonitrile. The 3-PBA was 
analyzed by using a Hewlett-Packard 7890B-electron capture detector (GC-ECD) and 
Autosampler G4513A (Agilent Technology, CA, USA) equipped with HP-5 (5% phenylmethyl 
polysiloxane with 30m × 0.25mm, 0.25µm film thickness) after derivatization by 1,1,1,3,3,3-
Hexafluoroisopropanol (HFIP) and N,N’-Diisopropylcarbodiim (DIC). 
 
4.2.6 Preparation of 3-PBA-albumin conjugate 
 It has been shown that the 3-PBA metabolite of PER forms covalent adducts with 
albumin, and, due to its high abundance, albumin is often the major target of drug haptenation 
56,297. I chose albumin to test our hypothesis that 3-PBA can also haptenate albumin (3-PBA-
albumin) and stimulate immune responses. I prepared a 3-PBA-albumin conjugate as described 
by Ahn et al, 298. Briefly, 65mg of 3-PBA (Sigma Aldrich, St. Louis, MO, USA) and 92mg 1,3-
dicyclohexylcarbodiimide (DCC) (Sigma Aldrich, St. Louis, MO, USA) was dissolved in 4mL 
of N,N-Dimethylformamide (DMF)(Sigma Aldrich, St. Louis, MO,USA). The active ester in 3-
PBA was formed by adding 52mg of N-hydroxysuccinimide (NHS) (Thermo Fisher Scientific, 
Waltham, MA USA) and allowed to react for 5 hrs at room temperature after which, 10mL of 
50mM bovine or human serum albumin in pH 8 borate buffer was added to the solution and 
allowed to react overnight. The resulting precipitate containing 3-PBA-albumin was collected 
and dialyzed (12,000 Da) against PBS for 3 days to remove low molecular weight 
contaminates. For mouse studies (including blood culture studies), bovine albumin was used as 
previous studies have shown that mouse and bovine serum albumin (BSA) share 72% amino 
acid homology, and BSA is immunologically inactive in mice 299. For human studies, human 
albumin was used.  
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4.2.7 3-PBA-albumin autoantibody detection in GWI plasma:  
 Both free albumin and 3-PBA-albumin were subjected to sodium dodecyl sulfate (SDS) 
polyacrylamide gel electrophoresis in 4-20% Criterion™ TGX Stain-Free™ Precast Gels (Bio-
Rad, Hercules, CA, USA). These proteins were then transferred to a polyvinylidene difluoride 
(PVDF) membrane for 4 hrs at 60mA. After blocking in 5% milk for 1 hr, GWI mouse plasma 
and control mouse plasma was used as a source of antibody. The membrane was incubated in 
GWI mice or control mice plasma (1:300) overnight at 4°C.  Membranes were then incubated in 
HRP-linked mouse secondary anit-IgG antibody, and the blot was developed using 
SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Fisher Scientific Waltham, 
MA USA) and visualized using a chemiluminescence imager (Bio-Rad, Hercules, CA, USA) as 
described previously 78. 
  
4.2.8 Ex vivo whole blood flowcytometry studies 
 To test our hypothesis that 3-PBA albumin can stimulate immune response and activate 
T and B lymphocytes, blood from control mice was collected following a cardiac 
puncture. Blood was then combined with 2% EDTA and cultured in RPMI media (Gibco, 
Carlsbad, CA, USA) at 37°C in a humidified atmosphere containing 5% CO2 supplemented 
with 1% of penicillin-streptomycin solution and 10% FBS. Cultured blood was then treated 
with 5µm 3-PBA-albumin, 5µm 3-PBA and 5µm albumin for 12 hrs followed by red blood cell 
(RBC) lysis and stained with antibodies against the cell surface markers: CD4 (Thermo Fisher 
Scientific, Waltham, MA, USA), CD8 (Thermo Fisher Scientific, Waltham, MA USA), CD3 
(Thermo Fisher Scientific, Waltham, MA USA), CD19 (Thermo Fisher Scientific, Waltham, 
MA USA), CD27 (Thermo Fisher Scientific, Waltham, MA USA) and CD45R (B220) (Thermo 
Fisher Scientific, Waltham, MA, USA). These cells were analyzed using Attune® NxT 
Acoustic Focusing Flow Cytometer (Thermo Fisher Scientific, Waltham, MA USA). Flow 
cytometry analyses were done using Attune® NxT software version 2.7 (Thermo Fisher 
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Scientific, Waltham, MA, USA). Flow cytometry data were presented as total percentage 
change, and graphs were generated using GraphPad Prism7. CD4+CD3+ staining was used to 
identify T-helper cells while CD3+CD8+ staining was used to identify cytotoxic T-cells 73. 
CD19+ and CD27+ were used to distinguish memory and naïve B-cell population 300.  
 
4.2.9 Detection of mouse blood monocytes and lymphocyte (B- and T-cells) using flow 
cytometry 
 Whole blood was drawn from mice and 100µL was subjected to red blood cell (RBC) 
lysis using 1mL of RBC lysis buffer (Thermo Fisher Scientific, Waltham, MA USA), washed 
twice with PBS-containing 5mM EDTA and 0.5% FBS and stained with CD45 (Thermo Fisher, 
Waltham, MA USA), CD115 (BD bioscience, NJ, USA), Ly6C (BioLegend, San Diego, USA) 
and CD11b (BD Bioscience NJ, USA) antibodies for flow cytometry analysis. Monocytes were 
identified by gating cells that were positive for both CD11b and CD115 57,301. Patrolling and 
infiltrating monocyte populations were identified by CD11b+ CD115+ with Ly6C- and 
CD11b+ CD115+ with Ly6C+ respectively 302. Ly6C+ monocytes are defined as 
proinflammatory and tissue-infiltrating while Ly6C++ are phagocytic monocytes301. Flow 
cytometry analysis was conducted using combinations of these monoclonal antibody using 
Attune® NxT Acoustic Focusing Flow Cytometer (Thermo Fisher Scientific, Waltham, MA 
USA).  
 In another experiment, 150μL of whole blood from the same mice was lysed via 
addition of 1500μL of RBC lysis buffer (Thermo Fisher Scientific, Waltham, MA, USA). The 
monocytes and lymphocytes were pelleted by centrifugation at 700 x g for 10min and 
resuspended in 500μL of FACS buffer (PBS, 0.5-1% BSA or 5-10% FBS, 0.1%), to which 
10µL of CD4/CD8 antibody cocktail (Thermo Fisher Scientific, Waltham, MA USA) was 
added. Cells were incubated with the cocktail for 20min at room temperature. Lymphocyte 
populations were gated, and CD4+ and CD8+ cells were analyzed using Attune® NxT Acoustic 
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Focusing Flow Cytometer (Thermo Fisher Scientific, Waltham, MA USA). CD3+CD4+ are 
used to identify T-helper cells while CD3+CD8+ cells are used to identify cytotoxic T-cells. 
These cells were analyzed as described above. For B lymphocytes, a combination of CD27, 
CD19 and CD45R (B220) stains were used as described previously; detail on antibodies used is 
provided above. As described previously, these were used to distinguish memory and naïve B-
cell population 300. 
 
4.2.10 Labeling of human PBMC for T- and B- lymphocytes: 
 The peripheral mononuclear cells provided by GWIC(Boston) were treated with 
monoclonal antibodies conjugated to different fluorophores. To find the T-cell population, cells 
were incubated with Anti-human CD3/CD4/CD8 Cocktail (Biolegend, San Diego, CA USA). 
To find memory B-cell population, a combination of CD19 (Thermo Fisher Scientific, 
Waltham, MA, USA) and CD27 (Thermo Fisher Scientific, Waltham, MA, USA) antibodies 
were used and analyzed using Attune® NxT Flow Cytometer as described above.  
 
4.2.11 Flowcytometry studies of the brain myeloid and microglia cells 
 A single cell suspension was generated from adult mouse brains, using the Adult brain 
dissociation kit from Miltenyi Biotec (Cologne, Germany) and closely following the 
manufacturer instructions. Briefly, mouse brains were collected in serum-free media and 
chopped finely with a sterile scalpel blade. The brains were subjected to a combination of 
enzymatic Papain (1 ug/uL) mechanical digestion (pipetting up and down 20 times) to yield a 
single cell suspension, the brain homogenate was then passed through a 70μm strainer, and the 
cell suspension was centrifuged for 10min at 1000xG and 4°C.  Cell pellets were then 
resuspended in debris removal solution and carefully overlaid with 4ml D-PBS as per 
manufacturer instructions; the samples were then centrifuged at 3000xG for 10 minutes at 4°C 
in a swinging bucket rotor with minimal brake. Following centrifugation four phases were 
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formed in the tube, the upper 2 phases were aspirated, the remaining (glial cell containing) 
fraction was then resuspended in D-PBS, inverted multiple times and centrifuged at 1000xG for 
10 minutes to generate a pellet containing a mixed glial cell population. The microglia 
population was then isolated by magnetically activated cell sorting (MACS), using anti-CD11b 
conjugated magnetic microbeads (Miltenyi Biotec, Cologne, Germany) according to the 
manufacturer's protocol. Briefly, cells were incubated with 10μL CD11b microbeads for 15min 
at 4 °C. Cells were then washed and placed on a new LS magnetic column (Miltenyi Biotec, 
Cologne, Germany) in a magnetic holder. The CD11b-ve fraction was washed through the 
column, and the CD11b+ve cell fraction was eluted from the column by removing the column 
from the magnetic field, adding buffer and emptying the column with a plunger. Cells were 
incubated with Rat anti-mouse Fc-block (1:100 BD bioscience) for 5min at room temperature. 
These cells were then stained with monoclonal antibodies for desired surface markers. The 
antibodies used were CD11b (BioLegend San Diego, USA), CX3CR1(BioLegend, San Diego, 
USA), Ly6c (BioLegend San Diego, USA) and CD206 (BioLegend San Diego, USA). Details 
on the antibodies used are provided in the supplementary table S6. These cells were analyzed as 
described above using an Attune® NxT Acoustic Focusing Flow Cytometer (Thermo Fisher 
Scientific, Waltham, MA USA). A combination of CD11b+, CX3CR1+, CD206+, and Ly6C+ 
staining was used to analyze brain macrophages, and cells stained with CD11b+, CX3CR1+, 
and CD206- were classified as microglia 303–306  
4.2.12 Immunostaining for microglia and astrocytes: 
 The left-brain hemispheres were fixed in 4% paraformaldehyde (PFA), dehydrated and 
embedded in paraffin. Sagittal sections (8μm) were prepared using Leica RM2235 microtome 
(Leica, Buffalo grove, IL). Approximately 8 to 10 slices of each mouse brain were incubated in 
blocking buffer (10% donkey serum and 0.3% Triton X-100 in PBS) for 60min at room 
temperature. Samples were then incubated overnight with the primary antibody Rabbit anti-
IBA-1 (Wako, Osaka, Japan) and Chicken anti-GFAP (Aves Lab, Tigard, Oregon) at 4°C. The 
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following day, slices were incubated with the appropriate fluorescent probe-conjugated 
secondary antibodies for 1 hr at room temperature. Nuclei were counterstained with DAPI. The 
entire DG was scanned using an Axiovert 200M Zeiss microscope (Zeiss) equipped with 
AxioVision 4.8.3.0 software. ImageJ software was used to analyze the stained sagittal sections. 
The stained areas were calculated and expressed as a percentage of the field.  
 
4.2.13 Enzyme-Linked Immunosorbent Assay 
 Using a Dounce homogenizer, brains were homogenized in ice cold mPER, which 
contained protease (Roche, Indianapolis, IN, USA) and phosphatase inhibitor (Pierce, Grand 
Island, NY, USA) cocktails. The total protein content of each sample was determined by the 
bicinchoninic acid (BCA) assay (Pierce, Grand Island, NY, USA). Enzyme-Linked 
Immunosorbent Assay (ELISA) kits for mouse CCR2 (Lifspan Biosciences, Seattle, WA,USA), 
CCL2 (Lifspan Biosciences, Seattle, WA, USA), Matrix Metalloproteinase-9 (MMP-9) 
(Bosterbio, Pleasanton, CA, USA) and fractalkine (CX3CL1) protein (MyBiosource, San 
Diego, CA,USA) were used to study levels of these proteins in the brain using the 
manufacturer’s protocol. Soluble CX3CL1(Thermo Fisher Scientific, Waltham, MA USA) in 
human plasma were quantified using commercial ELISA kit. The level of IgG protein in blood 
was quantified by IgG ELISA (Cayman Chemical, Ann Arbor, MI, USA) according to the 
manufacturer’s instruction. MMP-9 is proteolytic protein capable of degrading tight junction 
protein leading to BBB impairment 307,308. Results were normalized to total protein 
quantification obtained from BCA. Intra-Assay: CV<10.6% Inter-Assay: CV<12.6% for all the 
ELISAs. There was no reported cross-reactivity with other proteins for the primary antibody 
used in these kits. 
 
4.2.13 Western Blot analyses 
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 CX3CR1 (Abcam, Cambridge, MA, USA), p- NFkB phosphorylated at Ser536 (Cell 
Signaling, Danvers, MA, USA), total p65 NFκB (Cell Signaling, Danvers, MA, USA), tubulin 
(Abcam, Cambridge, MA, USA), major histocompatibility complex-II (MHC-II) (Abcam 
Cambridge, MA, USA), actin (Cell signaling, Danvers, MA, USA) and occludin (Santa Cruz 
biotechnology, Santa Cruz, CA, USA) were analyzed using Western Blotting. MHC-II are 
markers of antigen-presenting cells 309,310. In the brain, microglia and macrophages are the main 
cells expressing MHC-II 309. Occludin is a tight junction protein used to analyzed BBB 
impairment 311,312. Western Blotting was performed as described previously 78. Horseradish 
peroxidase–conjugated appropriate secondary antibodies and loading control anti–β-actin or 
tubulin antibody was obtained from Cell Signaling. The blots were analyzed as described 
previously in chapter 278. 
 
4.2.14 Multiplex cytokine assay 
 Selected cytokine levels in the plasma were analyzed using Meso Scale Discovery 
(MSD) 96-Well MULTI-SPOT® Ultra-Sensitive V-PLEX Proinflammatory cytokine Panel 1 
mouse Kit (MSD, Rockville, MD, USA), using electrochemiluminescence detection on an 
MSD Sector Imager™ 6000 with Discovery Workbench software (version 3.0.18) (MSD®, 
Gaithersburg, MD, USA). Cytokines were measured using the TH1/TH2 8-plex kit which 
included interleukin-1β (IL-1β), IL-6, interferon-g (IFN-g) and tumor necrosis factor-α (TNF- 
α).  All assays were performed according to the manufacturer’s instructions, in duplicates as 
described previously 78. Human plasma were analyzed using V-PLEX Proinflammatory 
cytokine Panel 1 Human Kit (MSD, Rockville, MD, USA) according to manufacturer protocol. 
 
4.2.15 Statistical analyses 
 Normally distributed data were analyzed using parametric tests; otherwise non-
parametric tests were used. As applicable, the Student’s t-test was used to examine the group 
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differences between GWI and control mice for cytokines, chemokines and percentage of 
specific cells identified using flow cytometry and protein levels of p-NFkB, occludin, MMP9, 
IgG and MHC-II. Murine cytokine data were analyzed by using the Student’s t-test. Human 
cytokine data were not normally distributed, so Kolmogorov-Smirnov test (K-S test) was 
performed on them to check if they were statistically significant. For autoantibody analysis in 
the GW veteran cohort, the Chi-square test was performed to determine statistical significance. 
For multiple groups in blood culture studies, I used one-way analysis of variance (ANOVA) 
followed by the Tukey post-hoc test. A p value < 0.05 was considered statistically significant. 
These analyses were performed using GraphPad Prism7 (San Diego, CA, USA), and data were 
expressed as means ± standard errors. All graphs were generated using GraphPad Prism7 (San 
Diego, CA, USA). 
 
4.3 Results 
4.3.1 Detection of 3-PBA released following protein hydrolysis and 3-PBA-modified lysine 
residues from peptides in the brain, liver and plasma of GWI mice  
 For an acute post-exposure timepoint, I examined 3-PBA modified proteins in liver, 
brain and plasma of GWI mice euthanized at 1-day post-exposure.  I also examined a serum 
sample of a subject positive for 3-PBA in urine as a positive control. Figure 4.1A shows PER 
metabolite structures and detected ions that correspond with the presence of 3-PBA lysine 
residues after pronase digestion that was performed to release these adducts from peptides 
(Figure 4.1B). I also quantified 3-PBA released post-protein-hydrolysis which showed the 
presence of 3-PBA in the livers and brains of GWI mice at 1.5 months post-exposure (Figure 
4.1C and 4.1D). However, free 3-PBA was detected only in the livers but not in the brains of 
GWI mice. As expected, no 3-PBA was detected in control mice. Neither free nor protein-
conjugated 3-PBA was detected in the brains or livers of GWI mice at 3- or 7-months post-
exposure.  
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Table 7: Final concentration of 3-PBA elimination in the urine 
Figure 4.1: Metabolites of PER pesticide is detected as protein adducts in the brain and liver 
homogenates. (A) A schematic of PER metabolites. (B) Detection of precursor and product ion of 3-PBA 
lysine (343.2) and its product ions (197.06) in the brain and liver homogenates from a GWI mouse sample. (C 
and D) Using LC-MS and LC-MS/MS, I detected 3-PBA (m/z 213.055 at 2.3min) and its PRM product ion 
(m/z 213.1 > 93.033 at that same time) in the brain and liver (mean ± SE (n = 4 or 5/group). While only 
protein-conjugated 3-PBA recovered after hydrolysis was detected in the brain, free 3-PBA and protein-
conjugated 3-PBA were detected in the liver at 1.5 months post-exposure.(E-F) Peak plots show absence of 3-
PBA (m/z 213.055 at 3min) and its transition ion (m/z 93.033) ions in control mice (E)brain and (F)liver. These 
peak plots show presence of 3-PBA internal standard 219.1 at 3min and its transition ion (m/z 93.033) ions in 
control mice 
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code no. 
3-PBA conc. 
(mg/L) Sex 
SPT-C-1-001 ND male 
SPT-C-1-002 ND female 
SPT-C-1-004 ND Female 
SPT-C-1-012 ND Male 
SPT-C-1-013 ND Male 
SPT-C-1-003 0.02740 Male 
SPT-C-1-005 0.01080 female 
SPT-F-1-019 0.14520 Male 
SPT-F-1-024 0.05236 Male 
SPT-F-1-026 0.06011 male 
Note: These data were generated by collaborator (Dr. Hongsibsong) who gave permission to 
publish these data. 
4.3.2 3-PBA-albumin autoantibodies in plasma from GWI mice and in GWI veterans 
 Western blot analyses showed that while plasma from control mice did not have 
immunoreactivity to free albumin or 3-PBA-albumin, plasma from GWI mice showed a strong 
immunoreactivity with 3-PBA-albumin but not with free albumin (Figure 4.2A). We then 
examined if 3-PBA-human albumin-reactive autoantibodies were detectable in plasma from 
GW veterans. Plasma from 10 out of 12 GW veterans diagnosed with GWI showed 
immunoreactivity to 3-PBA-albumin, and 1 out of 10 healthy GW veterans had 
immunoreactivity to 3-PBA albumin (χ2 = 11.73, df = 1, p = 0.001, Figure 4.2 B). None of the 
plasma samples from GW veterans showed any immunoreactivity to albumin alone (Figure 4.2 
B).  There was a significant association between self-report of pesticide exposure and 3-PBA-
albumin autoantibody presence among veterans with GWI (χ2 = 9.46, df = 1, p = 0.03). Only 
one control GW veteran had 3-PBA-albumin autoantibodies and was exposed to pesticides.  
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Two additional controls who didn’t have autoantibodies did report pesticide exposure, where 
one subject had an exposure to fogged area whereas the other subject did report exposure to 
pesticide imbedded uniforms, creams and sprays. In another cohort from Thailand, I detected 3-
PBA- albumin autoantibodies in serum of 5 subjects who had positive 3-PBA urine levels, 
whereas 5 control serum samples with undetectable urinary 3-PBA levels did not show 
immunoreactivity to 3-PBA-albumin (Figure 4.2C).  
 
 
 
4.3.3 Peripheral T-cells and B-cells activated following 3-PBA-albumin treatment 
Figure 4.2: Chronic elevation of autoantibodies against 3-PBA-albumin in plasma of GWI mice, in 
veterans with GWI and in farm workers exposed to pyrethroids. Western Blot showed that control mice 
had no cross-reactivity to 3-PBA-albumin or albumin alone, but cross-reactivity in GWI mice plasma was 
observed for 3-PBA-albumin at 1.5-, 3- and 7-months post-exposure in GWI mice (n = 4 or 5/group). (B) 
Autoantibodies against 3-PBA-albumin were detected in 12 out of 14 veterans with GWI and 1 out of 10 
control GW veterans. (C) Immunoreactivity of plasma with 3-PBA-albumin was observed in 5 out of 5 
pyrethroid-exposed farm workers or ate pyrethroid tainted fruits and vegetables (as confirmed using 3-PBA 
measurements in urine), and a lack of immunoreactivity in controls in whom urine 3-PBA was undetected. 
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 Murine blood was cultured overnight to examine if 3-PBA-albumin as compared to 
albumin alone, 3-PBA alone and control treatments can activate B-cells, T-cells and monocytes.  
Antigen-responsive CD19+ CD27+ B-cells were significantly different between the four groups 
(F(3,12) =12.2, p = 0.001, Figure 4.3A), with the 3-PBA-albumin group being significantly 
elevated compared to all other groups (post-hoc p < 0.05). Group comparisons for CD3+ CD4+ 
T-helper cells showed significant differences between treatments (F(3,16) = 61.19, p = 0.001, 
Figure 4.3B) with post-hoc analyses showing increases in CD3+CD4+ T-helper cells by 3-
PBA-albumin treatment as compared to controls, 3-PBA and albumin alone (p < 0.05). There 
were no differences in CD3+CD8+ T-lymphocytes when treated with 3-PBA-albumin 
compared to all other treatments (p > 0.05). Total monocyte population gated by CD11b+ and 
CD115+ differed significantly between the groups (F(3,12) = 20.48, p = 0.001, Figure 4.3C), and 
post-hoc comparisons showed an increase in these cells in the 3-PBA-albumin group compared 
to others (p < 0.05). Consistently, IgG levels were increased by 3-PBA-albumin treatment 
compared to all other groups (F(3,12) = 221.8, p = 0.001 Figure 4.3D).  
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4.3.4 Activated peripheral immune cells and plasma proinflammatory cytokines are 
increased in the blood of GWI mice and veterans with GWI 
 An antigen-reactive B-cell population positive for CD45+CD19+ CD27+ was elevated 
in the blood of GWI compared to control mice (t-test(df= 6) = 5.7, p = 0.0012, Figure 4.4A). 
However, the CD19+ CD27- population did not differ between the two groups (p > 0.05) 
suggesting that while total B-cell population doesn’t change, antigen responsive B-cells 
Figure 4.3: 3-PBA-albumin treatment increased memory B-cell and T-helper cells in murine blood. Mean 
± SE (n = 4 per group). (A) After overnight incubation of murine blood with 3-PBA, albumin and 3-PBA-
albumin, antigen-responsive CD45+ CD19+ CD27+ B-cells are significantly elevated in 3-PBA-albumin 
compared to all other treatments. (B) T-helper cells, CD3+CD4+, were also elevated upon 3-PBA-albumin 
treatment. Comparisons between 3-PBA and controls and albumin and controls were not significant. (C) 
antigen responsive CD11B+ CD115+ cells are significantly elevated in 3-PBA-albumin compared to all other 
treatments (D) Quantification of IgG in blood by ELISA. ANOVA with post-hoc tukey *p < 0.05 
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proportionally increase. Higher levels of IgG were present in blood from GWI mice compared 
to controls (t-test(df= 5) = 4.5, p = 0.008). I analyzed CD4+ and CD8+ markers after gating on the 
blood lymphocyte population. This study revealed that CD4+ T-helper cell population was 
significantly higher in the lymphocytes of GWI mice compared to control (t-test(df= 7) = 2.7, p = 
0.024, Figure 4B). T-helper cells expressing CD3+CD4+ were also elevated in the blood of 
GWI mice (t-test(df= 6) = 5.3, p = 0.0017, Figure 4B). Although CD8+ lymphocytes didn’t differ 
between the two groups (p > 0.05), the ratios of CD4+ to CD8+ cells were elevated in GWI 
compared to control mice (t-test(df= 6) = 3.7, p = 0.0014, Figure 4.4B). In addition, at 7 months 
post-exposure, several proinflammatory cytokines, including IL-1β, IL-6, IFN-g and TNF-α and 
a chemokine CX3CL1 were elevated in the brain and plasma from this GWI mouse model 
(Figure 4.3C).  
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I also examined peripheral T- and B-cells in PBMCs from GWI and control GW veterans. 
The memory B-cell population, as defined by CD19+CD27+ cells, was significantly increased 
in GWI compared to healthy GW veterans (t-test(df = 20) = 5.01, p = 0.0014, Figure 4.5A). T-
helper cells expressing CD3+CD4+ are also elevated in GWI veterans (t-test(df = 28) = 8, p = 
0.001, Figure 4.5B). Although CD3+ CD8+ T-cells didn’t differ between the two groups (p > 
0.05), the ratios of CD4+ to CD8+ cells were elevated in GWI compared to control GW 
veterans (t-test(df= 20) = 3.7, p = 0.0014).  Compared to healthy GW veterans, plasma levels of 
proinflammatory cytokine IL-1β and CX3CL1 were higher in veterans with GWI (Figure 4.5C).  
Figure 4.4: Antigen-activated B- and T-cells are increased in blood of GWI mice at 7 months post-
exposure. Mean ± SE (n = 4/5 per group). (A) Increased staining of antigen-responsive CD19+ CD27+ B-cells 
were detected in GWI compared to control mice. (B) Panel B shows that CD3+CD4+ T-cells are increased in 
blood of GWI mice. However, CD8+ T-cells did not differ between the two groups. Ratios of CD4:C8 was 
significantly elevated in GWI mice.(C) Pro-inflammatory cytokines and chemokines are chronically elevated in 
plasma and brain in GWI mice. T-test *p < 0.05 
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4.3.5 Disruption of the BBB in GWI mice 
 Since MMP-9 is increased during inflammation, I examined MMP-9 levels in the brain 
homogenates from GWI and control mice. MMP-9 was significantly higher in the brains of 
GWI mice (t-test(df= 10) = 2.81, p = 0.018, Figure 6B). Assessment of BBB integrity examined 
using occludin showed a significant decrease in GWI compared to control mice (t-test(df= 10) = 
2.5, p = 0.029, Figure 4.6A). As increases in brain IgG levels are generally indicative of BBB 
impairment.  Levels of IgG were increased in the brains of GWI mice compared to controls (t-
test(df= 10) = 2.61, p = 0.026, Figure 4.6B).  
Figure 4.5: Memory B- and CD4 T-cells are increased in blood of veterans with GWI. Mean ± SE (n = 12 
per group). (A) Increased staining CD19+ and CD19+ CD27+ memory B-cells in blood of veterans with GWI 
compared to healthy GW control veterans. (B) CD3+CD4+ TH cells are increased in blood of veterans with 
GWI. However, CD8+ TH cells did not significantly differ between control and GWI veterans. However, there 
were no group differences for CD3+CD8+ TH cells.(C) Pro-inflammatory cytokines and chemokines are 
chronically elevated in plasma in GWI human. Kolmogorov–Smirnov test *p < 0.05 
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4.3.6 Infiltrating monocyte population in the blood and brain of GWI mice 
 Monocytes staining with CD11b+ CD115+ and Ly6C+ classified as proinflammatory 
and infiltrating were elevated in GWI blood compared to control mice (t-test(df= 11) = 3.7, p = 
0.0032, Figure 4.7A). Macrophages were detected using Cd11b+ CD206+ Ly6C+ positive 
stains were increased in the brains of GWI compared to control mice (t-test (df= 2.8) = 4.7, p = 
0.04, Figure 4.7B). The microglia population characterized by CD11b+, CX3CR1+, CD206- 
Ly6C- showed no differences between the two groups (Figure 4.7C). Infiltrating monocytes 
detected by CD11b+ CX3CR1- Ly6C+ were significantly increased in the brains of GWI mice 
compared to controls (t-test(df= 4) = 4.7, p = 0.01, Figure 4.7D). We also observed increased 
MHC-II protein levels in the brains of GWI mice compared to controls (t-test (df= 6) = 6.2, p = 
0.0007, Figure 7E).  
Figure 4.6: GWI mice showed evidence of BBB impairment. Mean ± SE (n = 6 per group). (A) Occludin 
was decreased in the brains of GWI mice whereas (B) MMP-9 and IgG were increased in GWI mice brain. T-
test *p < 0.05 
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4.3.7 Chemokines and their receptors that promote CNS and peripheral immune cross-
talk in are increased in GWI mice 
 Since plasma CX3CL1 levels were increased in GWI mice and in veterans with GWI, I 
examined its receptor CX3CR1 in the brain homogenates from GWI and control mice at 7 
months post-exposure. Levels of CX3CR1 were elevated in GWI mice compared to control 
mice (t-test(df= 5) = 3.1, p = 0.03, Figure 4.8A). There were no differences in the membrane 
fraction of the brain homogenates for CX3CL1 levels between GWI and control mice at 7 
Figure 4.7: Infiltrating monocytes are increased in blood and brains of GWI mice at 7-8 months post-
exposure. Mean ± SE (n = 12 per group) (A) Increases in blood monocyte gated by CD11B+ CD115+ and 
Ly6C+ in GWI mice were observed. (B) GWI mice brain showed increased macrophage population as detected 
by CD11b+CD 206+Ly6C+ but (C) no change in microglia population detected by CD11b+CX3CR1+ and 
CD206-. (D) Infiltrating monocytes converting to macrophage (CD11b+, CX3CR1- and Ly6C+) were also 
increased in the brains of GWI mice. (E) Increase in MHC-II in the brain of GWI mice was detected by 
Western Blot. T-test  *p < 0.05 
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months post-exposure (p = 0.86, Figure 4.8B).  Levels of CCR2 (t-test(df= 10) = 4.71, p = 0.0008, 
Figure 4.8C) and its ligand CCL2 (t-test(df= 10) = 3.9, p = 0.003, Figure 4.8D) were increased in 
the brains of GWI compared to control mice. Immunohistochemistry work showed astroglia 
activation in the cortex and hippocampus of GWI compared to control mice53. I examined the 
ratios of p- NFkB to NFkB in GWI mice to assess inflammation. There was a significant 
increase in p- NFkB / NFkB ratios (t-test (df = 5) = 2.2, p = 0.06, Figure 4.8A) Post-hoc analyses 
showed that the ratios of p- NFkB / NFkB were increased in GWI mice at this 7-months post-
exposure timepoint.  
 
 
 
 
Figure 4.8: CCR2 and its ligand CCL2 are chronically increased in the brains of PB+PER-exposed mice 
leading to inflammation. Mean as % control ± SEM (n = 6 per group). (A) Western Blot showing 
CX3CR1/actin and pNFκB/NFκB is increased in the brains of PB+PER-exposed mice. ( B) No change in 
CX3CL1 level as measured by ELISA. (C) Levels of CCL2 were also increased in PB+PER-exposed mice at 7-
months post-exposure. (D) CCR2 levels were increased in the brains of GWI mice. T-test *p < 0.05 
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4.3.8 Astrocyte and Microglia Responses in the GWI mice Brain 
Morphological changes to astroglia in the GWI brain at 7 months post exposure specially DG 
and cortex were observed. Robust activation of astroglia cells typified by an increase in cell 
density and expression of cell surface markers, such as, GFAP is evident in the GWI DG and 
cortex (Figure 4.9). The microglial cells show no change in number as well as in morphology in 
GWI brain at similar time point. 
 
 
Figure 4.9: Representative images of GFAP and IBA-1 staining in the DG regions. Sagittal sections of the 
mouse brain at 0.8 mm lateral to midline in the brainstem. 20x images of astroglia GFAP staining(pink) and 
IBA-1(green) in the DG showed a significant increase in GFAP within the DG was observed in GWI compared 
to controls. Quantitative analysis of GFAP and IBA-1 staining intensity indicated an increased area of GFAP 
immunoreactivity in the DG of GWI mice. Mean ± SEM (n = 4 per group). T-test * p ≤ 0.05 Green=IBA-1, 
Pink=GFAP, Blue=Dapi 
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4.4 Discussion: 
 Evidence suggests that overexposure to PB and pesticides, which included pyrethroids 
and organophosphates, was one of the etiological factors in GWI 1,2,276. Exposure to these 
compounds has been shown to induce chronic immune dysfunction 192,313,314. While clinical 
symptoms of GWI resemble those of autoimmune diseases, the exact mechanism by which GW 
chemicals caused immune activation remains unknown. In this translational study, we show that 
a common pyrethroid metabolite, 3-PBA, can haptenate albumin, which activates CD4+ T-
helper and antigen-responsive B-cells. These immune cells were elevated in PB+PER exposed 
mice and in veterans with GWI. We observed autoantibodies against 3-PBA-albumin in our 
PB+PER mouse model and in veterans with GWI at chronic post-exposure timepoints. In this 
PB+PER mouse model, we also show that brain macrophages thought to be derived from 
Figure 4.10: Increased GFAP in the cortex of GWI exposed mice. GFAP staining (Pink) and IBA-1(green ) 
visualized with confocal microscopy (20x image) show increased staining in the GFAP staining in the GWI 
mice. Quantification of relative intensities of IBA-1 and GFAP exposed vs. control mice. Mean ± SEM (n = 4 
per group).T-test  *p < 0.05. Scale Bar=100um Green=IBA-1, Pink=GFAP, Blue=Dapi. 
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peripheral blood monocytes were increased in the brains of PB+PER mice. These studies 
suggest that activation of autoimmune responses against endogenous proteins modified by 3-
PBA corresponds with activation of brain macrophages and neuroinflammation in PB+PER 
mice. The work described herein could aid in the development of sensitive and specific 
biomarkers for diagnosing GWI in order to provide appropriate care and treatment to veterans 
with GWI.   
 During the 1991 GW, a large proportion of veterans were using pyrethroid-based 
pesticides routinely 1,276. To date, accurate diagnosis of GWI remains an unmet need for ill GW 
veterans. One reason it is difficult to accurately diagnose GWI is because the diagnosis is based 
on self-report of symptoms and exposures. Since studies have shown that 3-PBA can form 
adducts with lysine residues on endogenous proteins 282,315,316, we performed this experiment 
and found a presence of 3-PBA-lysine residues in the brain, blood and liver of PB+PER mice 
acutely after GW chemical exposure.  We also examined 3-PBA recovered after protein 
hydrolysis and found it to be present at 1.5 months after exposure to PB and PER but not at 
later post-exposure timepoints. This suggests that 3-PBA-haptenated proteins are eventually 
eliminated. Small molecules which haptenate endogenous proteins can elicit adaptive immune 
responses, ultimately resulting in B-cell activation and autoantibody production 317,318. Since 
albumin is easily haptenated by drugs due to its abundance in blood and availability of lysine 
residues that can be covalently modified297, albumin was chosen for haptenation studies with 3-
PBA. Our observations of autoantibodies against 3-PBA-albumin in blood from PB+PER mice, 
veterans with GWI and pyrethroid-exposed subjects suggest that 3-PBA-albumin is capable of 
provoking autoimmune responses. These studies for the first time provide evidence of 
autoantibodies following pyrethroid exposure in veterans with GWI. The specificity of these 
autoantibodies to pyrethroid exposure is further supported by the observation of 3-PBA-
albumin autoantibodies in subjects with detectable urinary 3-PBA levels and observable 3-
PBA-lysine adducts in their serum. While it remains to be determined if autoantibodies against 
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3-PBA-albumin have a pathological role in GWI, a higher prevalence of these autoantibodies in 
GWI veterans compared to control GW veterans suggests that they could be useful biomarkers 
of GWI.  
 Our animal and human studies suggest that autoantibodies against 3-PBA-albumin 
persist for a long time, despite the fact that 3-PBA is not detected in the brain or the liver 
beyond 1.5 months post-exposure. Studies have shown that proteins haptenated by other 
chemicals can directly interact with APC, which then travel to the lymphatic system where they 
present these antigens to T- and B-cells 283. This may result in the production of autoantibodies 
against haptenated proteins 283,319,320. While the exact mechanism behind the persistence of 
autoantibodies against 3-PBA-albumin remains to be investigated, it may involve a similar 
mechanism which requires memory B-cell activation and subsequent autoantibody production 
by plasma B-cells 73,321. As mentioned above, we show that autoantibodies against 3-PBA-
albumin are generated in our PB+PER mouse model. Furthermore, results of our in vitro blood 
culture studies suggest that the adaptive immune system is engaged in promoting immune cell 
activation after 3-PBA-albumin treatment, which is characterized by an elevation of antigen-
presenting monocytes, CD3+CD4+ T-helper cells and antigen-responsive CD19+ CD27+ B-
cells. Interestingly, these cells did not react to 3-PBA or albumin alone, further strengthening 
the concept that chemical haptenation of albumin is required to elicit adaptive immune 
responses and that 3-PBA alone cannot promote immune activation. Increases of CD3+ CD4+ 
T-helper and CD19+CD27+ B-cells, together with the presence of autoantibodies against 3-
PBA-albumin in PB+PER mice and in GWI veterans, further support an autoimmune-type 
response in GWI. These studies provide support for an activation of the adaptive immune 
system in GWI and are consistent with those conducted by Vojdani and colleagues 107, showing 
an elevation of CD4+ T-helper cells and B-cells in the blood of veterans with GWI. Together, 
these findings suggest that 3-PBA-albumin can stimulate peripheral immune cell activation.  
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While most veterans deployed in the GW conflict self-report the use of PB, it is unlikely that 
PB alone is a major contributing factor in the overactive immune responses noted in veterans 
with GWI. Previous research has suggested that PB is able to suppress inflammation in rodent 
models 322, with exposure to PB alone resulting in decreased production of pro-inflammatory 
cytokines such as IL-6, IFN-y and TNF-a at chronic time points 323. However, we, along with 
others, have shown that these cytokine levels are upregulated in plasma from veterans with 
GWI 104,106. The mechanism of PB is well defined in the literature, acting as a reversible 
acetylcholinesterase (AchE) inhibitor 324, while offering prophylactic protection against nerve 
agents. PB use would likely result in an increase in acetylcholine (ACh) levels in the periphery 
324. Recent evidence suggests a role of ACh in stimulating anti-inflammatory responses in the 
periphery via a direct interaction with nicotinic receptors on peripheral immune cells 325,326. As 
such, one would expect a dampened immune response in GWI mice. However, since we 
observe activated immune responses and the presence of 3-PBA-albumin autoantibodies in 
plasma of both human and PB+PER exposed mice, it is possible that PB was unable to suppress 
immune cell activation that occurs in the presence of combined PB+PER exposure 
78. Additional research is needed to clarify if PB metabolites may also form haptenated proteins, 
which may promote synergistic interactions resulting in the observed adverse adaptive immune 
response. 
 
 Under normal physiological conditions, the BBB largely restricts entry of peripheral 
immune cells into the brain, which helps maintain the immune privilege status of the CNS327. 
However, peripheral immune cells have been shown to migrate into the brain parenchyma 
during inflammation resulting from the increases in proinflammatory cytokines and MMP9 
activity which weakens the BBB 287,327,328. We observed elevated proinflammatory cytokines, 
such as IL-1β and/or TNF-α, in the brains and blood of PB+PER mice 78. Similarly, other 
studies also support an elevation of proinflammatory cytokines in rodent models of GWI as 
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well as in plasma from veterans with GWI 78,103,104,329. As such, our observations of increases in 
these proinflammatory cytokines and in MMP9 and a loss of occludin in PB+PER mice 
suggests BBB disruptions. Studies on other autoimmune disorders show that autoantibodies 
against peripheral antigens can enter the brain when the BBB is compromised. Upon entering 
the brain, they may cross-react with brain proteins, as in the case of SLE where peripherally 
generated anti-DNA autoantibodies can cross-react with NMDA receptors 330,331. Hence, a 
similar mechanism could explain the CNS pathology of GWI, but this requires further 
investigation.  
 We also detected 3-PBA-lysine and 3-PBA recovered after protein hydrolysis in the 
brain. Hence, it is possible that a presence of 3-PBA-protein adducts in the brain could elicit an 
immune response. While the exact mechanism of how 3-PBA-proteins in the brains of PB+PER 
mice initiate an immune response is unknown, persistent activation of astroglia suggests that 
these cells are involved in modulating CNS immune responses following 3-PBA-protein adduct 
formation.  Alternatively, astroglia activation may be secondary to BBB damage as observed in 
this and other GWI rodent models 50,54,60,78. 
 Evidence of adaptive immune responses in GWI comes from our observations of 
increased CCL2 chemokines in the brains of PB+PER mice, which is also reported in other 
models of GWI 329,332. In other autoimmune conditions and in a pesticide-induced mouse model 
of Parkinson’s disease, release of CCL2 by astroglia is shown to promote an ingress of bone-
marrow-derived CCR2-expressing monocytes into the brain parenchymal space 188,290,333. We 
also observed increases in CX3CR1 in the brain homogenates of PB+PER mice. Ligation of 
this receptor by its ligand CX3CL1 promotes monocyte migration survival and promotes 
chronic inflammation 188,334. It is now well-documented that peripheral monocytes are a source 
of brain macrophages that are distinct from brain-resident microglia, which develop during 
embryogenesis 335–337. Within this population, tissue-infiltrating monocytes can be further 
characterized by their expression of Ly6C+; monocytes positive for this marker are able to 
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migrate into the brain parenchyma and convert into macrophages that are capable of 
participating in antigen-presentation 338,339. These studies collectively suggest an infiltration of 
monocytes into the CNS after GW pesticide exposure. These data suggest a cross-talk between 
astroglia and peripheral adaptive immune cells in promoting neuroinflammation, which is 
further supported by our studies showing activation of NFkB-mediated inflammatory signaling 
pathways that may be downstream of CCL2-CCR2- and CX3CR1-CX3CL1 ligation, among 
other pro-inflammatory receptor systems in the brain 292,340–342. These studies also suggest 
further examination of these co-stimulatory pathways for the pathogenesis of the CNS 
pathology of GWI.   
Conclusions: 
 These explorative studies provide strong evidence that PER metabolite 3-PBA can 
haptenate proteins and promote adaptive immune responses. We also observe autoantibodies 
against 3-PBA-haptenated proteins in PB+PER mice and in veterans with GWI. While the exact 
mechanisms associated with these aberrant autoimmune responses and their effects on the CNS 
pathology of GWI remain to be elucidated, the work presented herein suggests a cross-talk 
between the brain immune cells and peripheral adaptive immune cells, which may ultimately 
promote the entry of peripheral immune cells into the brain and promote neuroinflammatory 
responses. We anticipate that these studies will help guide future development of biomarkers 
and therapies for the CNS pathology of GWI. 
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Chapter 5: Discussion 
5.1 Summary: 
Approximately 30% of GW veterans have been suffering from GWI for nearly three 
decades.  To date, a significant number of GW veterans still do not have a proper diagnosis for 
their condition since there are no biomarkers for this multisymptomatic illness that can assist 
clinicians with objectively diagnosing GWI.   Furthermore, to identify veterans with GWI, 
currently available diagnostic methods rely on self-reports of symptoms (fatigue, pain, 
neurological-cognitive-mood, skin, respiratory, and gastrointestinal) and self-reports of 
exposure to the chemicals known to have contributed to development of GWI.  The problems 
for patients with GWI are not limited to the lack of objective biomarkers; the clinical 
presentation of GWI is complex and heterogenous and the pathogenesis is not understood and 
thus there are no effective therapies to target the underlying mechanisms.  While significant 
advances have been made in understanding the role of GW chemical exposure on the adverse 
clinical presentation of GWI, the exact pathology of GWI remains to be dissected fully so that 
appropriate biomarkers and treatments can be developed for GWI.  The research contained in 
this dissertation sought to identify and explore different GWI pathogenic mechanisms, and 
therefrom to validate a range of therapeutic targets for this currently untreatable illness. 
 
5.2 Field advances from this dissertation research 
Previous work from the Roskamp Institute GWI research team has identified 
abnormalities in peroxisome function characterized by the abnormal accumulation of ether 
phospholipids and VLCFA containing SM species in both the brain and blood of GWI rodent 
models 65,76,180.  The work described in Chapter 2 provided additional evidence for peroxisomal 
dysfunction in GWI where we showed that certain VLCFA were elevated in the blood of 
veterans with GWI and the same elevations can be seen in the brains of our GWI mouse model.  
My successful attempts to rescue this peroxisomal dysfunction by regulation of peroxisomal 
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lipid metabolism with OEA support its potential as a promising candidate for therapeutic 
intervention.  Treatment with OEA reduced the accumulation of peroxisome specific VLCFA in 
the brains of GWI mice and, furthermore, OEA treatment modified multiple major pathological 
hallmarks of GWI, including reduction of neuro-inflammation and astroglial pathology.  
Treatment with OEA also had beneficial effects on cognitive function as assessed by behavioral 
analyses.  
Although our study provides evidence that OEA treatment may have potential for 
treating GWI, further studies are still needed to fully explore the mechanism of action of OEA 
against GWI pathogenesis and its suitability as a treatment for GWI.  Although OEA is 
currently sold as a nutraceutical to aid in weight loss it may have potential side effects such as 
lipolysis at high doses343.  In addition, very little information is available on its 
pharmacodynamic and pharmacokinetic properties, and it is known to be rapidly hydrolyzed by 
FAAH and therefore formulation work is also needed to improve its bioavailability.  Therefore, 
further investigations of these parameters are required for optimal dosing strategies of OEA in 
order for it to be developed as a therapy for treating GWI.  The work described in Chapter 2 
provides sufficient support to further examine the translational potential of targeting 
peroxisomes with OEA.  Based on our work, the Department of Defense has funded a pilot 
clinical trial of OEA in GWI patients recruited through the Roskamp Institute Clinic.  This trial 
is due to commence in late 2019, and will examine if OEA corrects plasma lipid profiles, 
reduces inflammation and improves the overall health of affected GW veterans.  As such, my 
work is entirely consistent with the translational goals of the Roskamp Institute and may result 
in significant advances in treatment for the GWI patient population.   
Many previously published papers have identified mitochondrial dysfunction as a major 
hallmark of GWI and mitochondrial dysfunction has been shown to be a consistent feature 
across several animal models of the illness94,203.  Based on these findings, and the evidence for 
bioenergetic and mitochondrial function in our animal model 53, I investigated this second 
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avenue for therapeutic intervention (Chapter 3).  This study provided further information about 
underlying mitochondrial bioenergetic disturbance, as well as neuroinflammation, in a GWI 
mouse model.  My findings suggest that SirT1 may be a novel target for GWI treatment, which 
in turn inhibits activation of NFκB mediated pathways in a SirT1 deacetylation-mediated 
dependent manner. 
 First, I examined NAD+ and bHB levels in plasma from GW veterans which were 
significantly decreased in ill veterans compared to healthy controls. As previous metabolomics 
study did suggest decreased in mitochondrial metabolite related to bioenergetics in GWI mice  
and in veterans with GWI 54.  In small case-control study, I tested the levels of NAD+ and bHB 
and these metabolites to be lower in ill compared to control GW veterans.  Next, in a pilot 
animal study, I tested two treatments which are known to increase the levels of these 
metabolites: nicotinamide riboside (NR), which is the precursor for NAD+; and a ketogenic diet 
(KD), which increases bHB levels in the liver.  I observed that although both treatments work 
via different mechanisms they achieved similar outcomes relevant to GWI pathology.  For 
instance, both interventions were helpful in reducing inflammation and increasing 
mitochondrial bioenergetics. Chronic treatment of NR is safe and does not have any potentially 
harmful side effects 245.  It is currently used as a nutraceutical for vitamin deficiency.  The KD 
intervention has been used for decades to help control diabetes and epilepsy 270,344.  Thus, safe 
human use data is available for both of these potential GWI treatments, expediting their 
translational potential.  Our findings demonstrate that NR and KD treatments attenuate brain 
and systemic inflammation and induce mitochondrial biogenesis in the GWI mouse brain; since 
inflammation and mitochondrial dysfunction are involved in the pathophysiology of GWI, our 
study has potential clinical benefits if these findings are confirmed in human clinical studies.  
Based on recent findings from Abou-Donia and colleagues showing presence of 
autoantibodies against brain specific proteins in veterans with GWI and the fact that many of 
the clinical features of GWI are similar to those of patients with autoimmune diseases 345, I  
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examined if exposure to GW-related pesticides activate peripheral adaptive immune responses 
which may correspond with BBB disruption and CNS immune activation (Chapter 4). My work 
demonstrated for the first time that a 3-PBA-protein conjugate (a pyrethroid metabolite) is 
present in the brain, liver and plasma of our GWI mouse model at acute post-exposure 
timepoints.  Moreover, I also demonstrated the clinical relevance of this finding by detecting 
autoantibodies against 3-PBA-albumin in the plasma of GWI mice and of veterans with GWI. 
Although these studies need to be repeated in a larger cohort, if confirmed the presence of these 
autoantibodies can serve as future potential biomarkers not only for GWI but also for 
occupational exposure to pyrethroid or other types of pesticides that are capable of forming 
adducts with proteins.  The production of autoantibodies is a major pathological hallmark of 
autoimmune diseases with underlying adaptive immune dysfunction, such as multiple sclerosis 
and Traumatic brain injuries346,347.  These studies suggest that pesticide exposure associated 
with GWI may have resulted in the activation of adaptive immune responses, which possibly 
contributed to an autoimmune type phenotype in veterans with GWI and may have contributed 
to the activation of CNS immune cells and neuroinflammation. 
Although our work is focused on GWI, and the pesticide exposure to which the military 
was subjected during the 1991 GW, our findings have relevance for a much broader potential 
patient population as pyrethroids have been used in civilian settings for decades to 
control household and agricultural pests.  Most of the pyrethroid toxicity cases have arisen from 
occupational health exposure due to poor understanding of its toxicity and lack of knowledge 
about precautions that need to be taken 348. The use of organophosphate pesticides has decline 
in past decades but pyrethrin and pyrethroids use has increased during this period 
(Source:EPA.gov). Although these pesticides are used to protect crops, pesticide residue in food 
is potentially toxic to humans, particularly if they can accumulate in the body.  Exposure to 
these pesticides from contaminated food may have acute and chronic health problems 
depending on the quantity of exposure.  Professor Hammock and his team at the University of 
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California, Davis, have developed several assays to detect the presence of pyrethroids and their 
metabolites in human blood, urine and tissue and these appear to be useful in detecting acute 
exposure.  Our work could potentially complement these studies in civilian situations where we 
may assist by detecting chronic pyrethroid exposure.  As can be seen from the samples from the 
Thailand cohort (in Chapter 4), autoantibodies against 3-PBA-albumin were detected in 
subjects in whom 3-PBA urine levels were positive.  It is still unclear if these antibodies play a 
positive or negative role, nevertheless, their detection suggests that they might be objective 
biomarkers of pyrethroid exposure.  This proof of concept study has not only provided a 
foundation for developing biomarkers and appropriate therapies for targeting immunological 
aspects of GWI, but also provides a platform for further investigating pesticide-induced 
abnormal adaptive immune responses. 
The main objectives of this thesis are to find effective therapies against GWI that target 
underlying pathology of GWI. Along with finding possible therapies, these data provide an 
insight into possible mechanisms underlying cognitive impairments observed in soldiers with 
GWI. I hope that the work described in this thesis provides a groundwork for the development 
of objective biomarkers and therapies for GWI. In Chapters 2, I focused on targeting 
peroxisomal function as potential target for GWI. While chapter 3 dealt with mitochondrial 
function and biogenesis as potential target for GWI. Chapter 4 investigates the immunological 
dysfunction related with pesticide exposure in GWI human and mice. These studies suggest that 
pesticide exposure associated with GWI may have resulted in the activation of the peripheral 
and CNS adaptive immune responses, possibly contributing to autoimmune type phenotype in 
veterans with GWI. 
5.2 Limitations of the study: 
 While animal studies enable investigation of the pathobiological consequences of toxic 
exposures at any timepoint from exposure throughout the subsequent lifespan, they are limited 
by their inability to model all aspects of a disease, including the inherent heterogeneity of the 
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patient population and, in the case of GWI, the heterogeneity of GW agent exposure, for which 
we can only base our models on self-reporting surveys.  Furthermore, samples from human 
subjects are influenced by various factors that are not typically included in animal models, and 
this can particularly affect outcomes in immunological studies. For instance, cytokine 
measurements can be easily influenced by factors such as allergies or viral infections (G. 
Izaguirre. Molecular Mediators, Cytokines I: Lecture I).  Another potential confounding factor 
when comparing human and mouse data is that, while controlled standard laboratory diets allow 
researchers to minimize variables, it has been reported that the severity of disease in humans is 
heavily influenced by lifestyle and diet which further contributes to the heterogeneity of data in 
GWI research.  Similarly, while age- and gender-matched cloned lines of genetically 
manipulated rodents provides the opportunity to explore the influence of specific genetic risk 
factors, this is not representative of the large genetic variation that exists amongst humans and 
which can modulate disease etiology.  Nonetheless, this body of work in our PB+PER mouse 
model provides insights into the pathogenesis of GWI; if we wish we could now introduce 
additional variables (guided by data from our populations of GW veterans) into our laboratory 
model paradigms to see how they influence the pathogenic pathways that we have identified as 
contributing to GWI.   
One major limitation of Chapter 2 is that OEA affected lipid homeostasis in control 
mice treated with OEA, which corresponded with lowered anxiolytic response in the EPM test 
and higher immobility in the FST.  Despite that, we did not observe any adverse effect on 
memory or an increase in lipid peroxidation and inflammation in these mice.  However, given 
the role of OEA in lipid metabolism and reducing inflammation, increasing its level in the 
absence of underlying inflammation or metabolic dysfunction warrants further examination to 
anticipate any adverse events in patients where these are not the most prominent pathogenic 
features.  We do expect that additional pharmacokinetics and pharmacodynamics studies will 
help identify a safe and effective dose for chronic administration in veterans with GWI.  The 
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limitation of Chapter 3 is the small sample size and lack of neurobehavioral data.  This study 
needs to be repeated in a larger cohort of mice along with memory and anxiety evaluation.  One 
major experiment lacking in this study is analysis of mitochondrial metabolites which might 
give us more insight into bioenergetic disturbance following exposure to GW agents.  Similar 
limitations exist in Chapter 4, where our pilot human data needs to be replicated in a larger 
cohort to confirm a correlation between the pesticide exposure and presence of hapten 
antibodies. 
 Animal models are used in preclinical studies of drugs with the potential for human 
application in order to determine the safety, efficacy and reproducibility of a treatment 
paradigm.  An animal model is a simplified representation of a complex system.  Consequently, 
an animal model for a human disease like GWI is by no means an attempt to reproduce the 
human disease in all its complexity, but rather to model specific aspects of a disease.  When 
designed and conducted appropriately, animal models can provide valuable information 
regarding systems biology, pathology and target identification, and drive the development of 
new drugs.  There will be no single, all-encompassing model for GWI, owing to the mixed 
etiology and the heterogeneity of human populations.  The clinical presentation is very 
complicated, and includes features of a more subjective natures such as pain and fatigue, which 
increase the difficulty of replication in animal models.  If a single particular animal model is not 
a good representation of human physiology or disease, one possibility is to generate different 
models which attempt to recapitulate different aspects of the human pathology.  Because of 
these caveats, it would be foolish to rely solely on one GWI animal model to assess whether or 
not an intervention will have a favorable clinical outcome in human subjects.  As such, the 
OEA, NR and KD interventions should ideally be tested in several different animal models of 
GWI before moving to human studies.  That said, when dealing with widely used dietary 
supplements or repurposed drugs with a history of safe usage, the primary concern of Safety is 
 172 
largely addressed, and so moving straight into human testing presents less of a challenge; hence 
we are advancing to a human clinical trial with OEA in GWI patients. 
 
5.3 Future directions: 
Both clinical and animal studies now suggest an association between peroxisomal and 
mitochondrial dysfunction in GWI and therefore further evaluation of the enzymatic processes 
and proteins involved in their function is required.  This work would also benefit greatly by 
examining the influence of genetic factors involved in the transport and metabolism of these 
lipids as these could influence human response both to the toxic exposures and to the treatments 
targeting these systems.  Both NR and OEA are naturally occurring compounds, and chronic 
supplementation of these compounds has been shown to be well tolerated in humans 245,349.  
However, I do propose that additional pharmacokinetics and pharmacodynamics studies should 
be performed to identify a safe and effective dose for chronic administration of OEA and NR in 
veterans with GWI.  Furthermore, given the complexity of this illness, and the different 
pathogenic mechanisms which likely need to be targeted in tandem for greater overall health 
benefits to the sick veterans, preclinical testing of combinations of treatments is needed to 
maximize the translational potential.   
My major research highlights from Chapter 4 include: 1) the detection of 3-PBA in the 
livers and brains of our PB+PER GWI mouse model, and 2) the presence of autoantibodies 
against 3-PBA-albumin in GWI mice and GWI veterans at chronic post-exposure timepoints, 
where pesticide exposure was correlated with detection of autoantibody.  While the assessment 
of levels of these molecules is a good way to gain information about the association of such 
molecules in a disease state, this study should be replicated in a larger cohort, especially if the 
presence of these molecules is to be used as a biomarker.  Moreover, further research needs to 
be conducted focusing on the enzymes that metabolize PER, not only analyzing the expression 
level of these enzymes but also their enzymatic activity.  Additionally, the location of the 
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molecule could contribute to its role in the disease; therefore, studying certain organs/tissues 
(e.g. brain, adipose tissue, liver) and specific cell types may shed light on the toxic function of 
the molecule.  Finally, further studies should be conducted on protein modifications, 
investigating the reversible or irreversible chemical alterations of a protein after its 
haptenization, as these are believed to play a great role in the toxicological effect of pesticide 
such as permethrin. Future work must focus on identifying all the proteins that 3-PBA can bind, 
and its presence in different organs might help us to understand the mechanism behind immune 
activation led by 3-PBA. 
 
5.4 Conclusion:  
The work presented in this thesis describes novel and diverse approaches to treat GWI.  
It is my assessment that these approaches have good potential efficacy as therapeutic 
interventions, as they target the underling disease pathology.  This thesis also contributes to the 
existing cumulative knowledge of peroxisome and mitochondrial dysfunction in GWI.  
Furthermore, the findings of this thesis focus on the identification of biomarkers in GWI.  The 
diagnosis of this multisymptom illness relies heavily on self-report, supporting the need for an 
objective biomarker.  The human pilot study on fatty acid profiles suggested an increase in 
plasma VLCFA, a marker which could help in clinical diagnosis; however, more research is 
needed before we move to clinical trials.  The presence of autoantibodies in GWI indicated 
pesticide exposure in this cohort of veterans, and if replicated with additional positive and 
negative controls these autoantibodies could also serve as novel biomarkers for GWI.  
Collectively, these studies provide new targets for discovering treatments for GWI and 
additional information on biochemical and molecular abnormalities that persist long after the 
GW chemical exposure.  I anticipate that my work may provide useful insight into the persistent 
pathology of GWI and lead to the development of diagnostic markers and novel therapeutics for 
GWI and other toxic environmental exposures. 
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APPENDIX 
Chapter 2 
Table showing absolute concentration of human plasma free fatty acid and mice brain 
free fatty acid. 
 
Control SEM GWI case SEM  
FA19:0 2.246591909 0.12 1.943343 0.25  
FA20:0 12.19015685 0.34 10.5978 0.31  
FA24:4 1.264909042 0.22 1.265773 0.25  
FA24:5 0.994543005 0.11 1.367475 0.10  
FA24:6 0.570222951 0.11 0.775772 0.15  
FA16:0 655.8729547 3.2 628.3581 9.2  
FA16:1 40.54458228 4.3 55.59287 5.3  
FA18:0 594.1698374 5.5 515.779 3.5  
FA18:1 959.0170044 55.4 1247.565 66.4  
FA18:2 384.8887904 50.3 520.0629 70.3  
FA18:3 37.24441324 32.3 48.81775 45.3  
FA20:3 16.89213982 1.2 21.89752 2.2  
FA20:4 56.75493424 1.4 72.25026 2.4  
FA20:5 10.1522195 0.71 10.94809 0.51  
FA22:1 3.54638816 0.54 1.871912 0.74  
FA22:4 11.0888527 1.1 14.55546 1.51  
FA22:5n3 10.78242947 1.24 16.95872 1.4  
FA22:5n6 5.011327198 0.33 7.128399 0.36  
FA22:6 37.53091998 1.2 48.07908 1.42  
FA24:0 4.491940173 0.66 3.040707 0.56  
FA24:1 0.041859864 0.004 0.028608 0.004  
Phytanicacid 2.613029327 0.24 2.318204 0.42  
Pristanicacid 0.313721956 0.23 0.272232 0.33  
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control(uM/ug)  Control+OEA(uM/ug)  Control+OEA(uM/ug) GWI (uM/ug) GWI+OEA 
(uM/ug) 
FA19:0 4.739045128  0.006200183  0.006200183 0.004616551 0.004092696 
FA20:0 0.2942313  4.998083067  4.998083067 4.56812933 5.104133545 
FA24:4 0.372420263  0.358603938  0.358603938 0.325075834 0.253387323 
FA24:5 2.108312343  0.402495544  0.402495544 0.395023328 0.40196681 
FA24:6 402.6457587  2.033658105  2.033658105 2.130905512 2.185015291 
FA16:0 0.022877354  290.7922474  290.7922474 335.8799076 407.2470259 
FA16:1 33.4497406  0.026184025  0.026184025 0.024065568 0.02876678 
FA18:0 0.610180401  30.04084201  30.04084201 32.65348571 24.60366764 
FA18:1 0.136549656  0.698006756  0.698006756 0.610208317 0.680130617 
FA18:2 0.038091028  0.092237605  0.092237605 0.124736518 0.177761754 
FA18:3 11.82895541  0.030758311  0.030758311 0.034279802 0.041367123 
FA20:3 24.91360256  21.8625  21.8625 14.32595573 8.046601942 
FA20:4 0.007381428  25.08444386  25.08444386 25.83356742 25.70951979 
FA20:5 0.921089582  0.007018559  0.007018559 0.006623717 0.012687693 
FA22:1 20.41432927  0.899825131  0.899825131 0.847879617 0.479563529 
FA22:4 0.112785436  25.13103831  25.13103831 27.05969668 22.26494408 
FA22:5n3 0.074417373  0.116192749  0.116192749 0.122361611 0.125318276 
FA22:5n6 301.8505338  0.048868606  0.048868606 0.059545853 0.065376641 
FA22:6 0.003731431  466.6225681  466.6225681 392.3535188 331.1289641 
FA24:0 2.886255924  0.003218759  0.003218759 0.002928319 0.004022372 
FA24:1 1.234  2.336787565  2.336787565 2.094017094 2.215873016 
Pristanic 
acid 
5.148228713  12.3  12.3 8.63 5.22 
 
 
Chapter 3 
Table showing absolute concentration of mice brain acetyl carnitine. 
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Compo
und 
control(n
mol/g)) 
SEM GWI(n
mol/g)) 
SEM Control+N
R(nmol/g)) 
SEM GWI+NR
(nmol/g)) 
SEM 
2:0 2.68243
2764 
0.1200
61792 
3.1885
11339 
0.1116
09334 
2.3736135 0.2611
3185 
2.3933900
94 
0.1194
82704 
3:0 0.02929
0341 
0.0015
99855 
0.0286
01164 
0.0067
77546 
0.02592179
9 
0.0026
96983 
0.0172059
61 
0.0007
80862 
4:0 0.01134
0902 
0.0009
78062 
0.0102
41298 
0.0010
93692 
0.00861925
4 
0.0013
27254 
0.0076326
2 
0.0014
03251 
5:0 0.01829
7939 
0.0009
66713 
0.0292
39519 
0.0002
32218 
0.01850072
3 
0.0016
32812 
0.0183468
25 
0.0015
67656 
6:0 0.00051
4256 
0.0001
07788 
0.0003
7363 
9.5093
6E-05 
0.00029989
3 
5.0121
7E-05 
0.0001500
58 
1.8282
3E-05 
14:0 0.08869
4035 
0.0038
91811 
0.1647
16846 
0.0075
08173 
0.08284331
5 
0.0042
88409 
0.0906598
7 
0.0012
97559 
16:0 0.48974
0936 
0.0184
66255 
0.5169
14768 
0.0249
67277 
0.47607314
7 
0.0218
48491 
0.4750008
58 
0.0247
46998 
16:1 0.06340
9549 
0.0083
15284 
0.0772
07239 
0.0030
35203 
0.05569842
5 
0.0025
59204 
0.0473617
38 
0.0007
57277 
18:0 0.10608
664 
0.0077
01896 
0.1147
09485 
0.0078
00853 
0.09784207
7 
0.0057
03363 
0.1159791
7 
0.0066
78328 
18:1 0.27299
1139 
0.0175
24292 
0.2892
29948 
0.0077
06301 
0.24606878
5 
0.0124
16752 
0.2677009
55 
0.0101
83048 
18:2 0.01425
3615 
0.0015
19379 
0.0199
92729 
0.0028
07475 
0.01316730
5 
0.0012
40846 
0.0153770
21 
0.0008
28518 
18:3 0.01829
7939 
0.0009
66713 
0.0278
22853 
0.0007
00838 
0.01850072
3 
0.0016
32812 
0.0183468
25 
0.0015
67656 
20:0 0.00403
0584 
0.0003
83579 
0.0040
8381 
0.0002
70507 
0.00327326
5 
0.0001
55776 
0.0047054
51 
0.0003
14129 
20:1 0.02144
1479 
0.0023
97366 
0.0282
43446 
0.0019
76899 
0.01860665 0.0022
42977 
0.0227757
86 
0.0014
96857 
20:3 0.00819
5642 
0.0007
89612 
0.0087
06749 
0.0007
44218 
0.00659507
5 
0.0004
56569 
0.0066689
59 
0.0014
93714 
20:4 0.16860
708 
0.0167
85426 
0.3432
39399 
0.0144
65694 
0.17188695
8 
0.0242
35004 
0.1289337
8 
0.0098
94133 
22:0 0.01829
7939 
0.0009
66713 
0.0292
39519 
0.0002
32218 
0.01850072
3 
0.0016
32812 
0.0183468
25 
0.0015
67656 
22:6 0.02043
1722 
0.0034
83075 
0.0280
82093 
0.0038
59073 
0.02606569
1 
0.0043
09954 
0.0269573
7 
0.0022
77509 
24:0 0.01829
7939 
0.0009
66713 
0.0268
22853 
0.0005
70623 
0.01850072
3 
0.0016
32812 
0.0183468
25 
0.0015
67656 
26:0 ND ND ND ND ND ND ND ND 
free 12.9527
1273 
0.6629
96618 
21.730
94677 
1.5268
76128 
18.8428313
5 
1.3278
78073 
17.049092
19 
0.8574
52665 
Gamma
-
butyrob
etaine 
0.56649
947 
0.0137
36568 
0.8298
01321 
0.0112
98211 
0.79348191
6 
0.0486
24783 
0.7200753
71 
0.0064
11785 
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Carnitin
e/GBB 
22.9579
5725 
1.1169
10177 
35.274
28455 
3.4920
18453 
24.1343946
1 
3.1622
34116 
23.697162
06 
1.3059
37655 
